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The human immunodeficiency virus type I (HIV-1) is a retrovirus that damages the human 
immune system, which is suppressed by a cellular factor APOBEC3G in non-permissive cells. 
The viral infectivity factor (Vif) can induce a poly-ubiquitination degradation of APOBEC3G 
to counteract the immune response by forming an E3 ubiquitin complex composed of cellular 
proteins Elongin B (EloB), Elongin C (EloC), Cullin 5 and Ring-Box protein. In this project, 
we solved the first structure for the Vif SOCS-box and EloBC complex in solution by Nuclear 
Magnetic Resonance, which shows that the proline-rich motif in the SOCS-box binds to the 
EloB carboxyl terminus by backbone interaction, based on weak van der Waals forces. Based 
on the results from cell assays it shows that the residues on the Vif proline-rich motif play an 
important role in viral infectivity; the proline-rich motif induced structure of the C-terminal tail 
has been demonstrated to be critical for EloB to perform further biological function, by a 
mechanism which allows HIV-1 to evade the immune response. In addition, expression and 
purification on full-length Vif in the presence of EloBC and core binding factor β (CBFβ) has 
been performed. These studies showed that soluble Vif in the tetramer is achieved when it is 
expressed at a low temperature with a low IPTG concentration. Solubility tests indicate that this 
complex must be kept in high salt concentration in order to prevent self-association. 
Comparison with previous studies on Vif expression and purification. This protocol enables one 
to obtain purified Vif from E. coli and opens the way to solve the structure by X-ray 








The work in Chapter 3, 4, 5 and 6 are a part of the NMR project that was firstly done by 
Dr. Julien Bergeron (2010). In the work detailed in this thesis, Dr. Julien Bergeron performed 
the backbone assignments (unpublished). All the other NMR work performed by the author of 
this thesis are based on the backbone assignments. Dr. Julien Bergeron’s work have been cited 
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CHAPTER 1: INTRODUCTION 
 
1.1 Acquired Immunodeficiency Syndrome Introduction 
 
Acquired immunodeficiency syndrome (AIDS) is a chronic disease caused by human 
immunodeficiency virus type I or type II (HIV-I or HIV-II), causing suffers to experience a 
decreasing immune response capability so that they become more susceptible to opportunistic 
infections which threaten their lives. Since the first AIDS case was confirmed and reported 
(Control 1982), there are tens of millions of people dying of HIV/AIDS. By the end of 2010, 
approximately 33.3 million people lived with HIV/AIDS, 10% of whom were children below 
15 years old. More than 2 million people died of AIDS or relative complications and meanwhile 
around 3 million people are newly infected every year (WHO 2010). Recently, several groups 
made huge progress in HIV drug and vaccine development (Wu, Yang et al. 2010, Wu, Zhou et 
al. 2011, Archin, Liberty et al. 2012), HIV/AIDS, however, is still a global problem that 
threatens all human beings. 
 
 
1.2 The human immunodeficiency virus 
 
1.2.1 Viral genome and cycling 
 
HIV belongs to the lentivirus family, one of the classes in the retrovirus category (National 
Institutes of Health 2002). Its genome is composed of nine genes sorted into two classes with 
three reading frames (Kuiken, Leitner et al. 2008). Genes gag, pol and env encode structural 
proteins and enzymatic proteins including reverse transcriptase, protease and integrase (Feng, 
Broder et al. 1996, Freed 2001). HIV-1, compared to other primitive retroviruses, contains 
another six genes called accessory genes namely vif, tat, rev, vpr, vpu and nef that encode 
essential factors believed to engage in the regulation of viral replication and the antagonizing 
against host restriction factors, i.e. viral infection factor (Vif) (Sheehy, Gaddis et al. 2002, 
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Wiegand, Doehle et al. 2004), transcriptional transactivators (Tat) (Gatignol and Jeang 2000, 
Hetzer, Dormeyer et al. 2005, Hong, Lee et al. 2013), reverse transcriptase (Rev) (Dundr, Leno 
et al. 1995, Hope 1999), viral protein R (Vpr) (Goh, Manel et al. 2004, Tomasicchio, Avenant 
et al. 2013, Wang, Singh et al. 2013), viral protein U (Vpu) (Bour, Schubert et al. 1995, Neil, 
Zang et al. 2008, Gautam and Bhattacharya 2013, McNatt, Zang et al. 2013) and the negative 
factor (Nef) (Kirchhoff, Greenough et al. 1995, Blagoveshchenskaya, Thomas et al. 2002, 
Foster and Garcia 2008, Arhel and Kirchhoff 2009, Lenassi, Cagney et al. 2010) respectively 
(figure 1.1a). These functional proteins will be described in detail later. 
HIV-1 virions infect immune CD4+ T cells by recognizing cellular receptors CD4 and CC-
chemokine receptor 5 (CCR5) or CXCR4 on cell surfaces via glycoprotein 120 (gp120) on the 
viral particle surface (figure 1.1b), followed by penetrating through the cell membrane and 
uncoating in the cytoplasm (Chan and Kim 1998, Markosyan, Cohen et al. 2003, Dimitrov, 
Louis et al. 2005), where the viral ribonucleic acid (RNA) is reverse transcribed into 
deoxyribonucleic acid (DNA) (Isel, Lanchy et al. 1996). In the cell nucleus, a portion of the 
viral DNA is integrated into the host genome and is copied and transcribed; This is responsible 
for ongoing viral generation in infected cells, and the rest of the DNA forms a circular DNA 
called the long terminal repeat DNA (Pauza, Trivedi et al. 1994, Gillim-Ross, Cara et al. 2005). 
Generated viral mRNA that is exported into the cytoplasm encodes for structural proteins that 
package viral RNA and assemble near the cell membrane (Yeager, Wilson-Kubalek et al. 1998, 
Wilk, Gross et al. 2001, Briggs, Simon et al. 2004), forming new HIV particles. A mature 
retrovirus is finally released after budding from the cell membrane (Swanstrom and Wills 1997, 
Pornillos, Garrus et al. 2002). 
 
1.2.2 Accessory proteins and the mechanism for evading immune response 
 
HIV-1 develops several methods to suppress various immune defenses via six accessory 
proteins in the genome as mentioned above. Tat, a 14-kDa protein encoded by two exons, is 
critical for Tat-mediated viral transactivation. Basically, it forms an adenosine triphosphate 
(ATP)-dependent RNA-Tat complex with other cellular factors, which performs the 
transactivitation function, including promoter clearance and elongation (Brigati, Giacca et al. 
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2003, Bannwarth and Gatignol 2005, Hetzer, Dormeyer et al. 2005). Rev is a 116-residue 
nucleolar protein with four functional domains, termed the nuclear localization signal, RNA 
binding domain, oligomerization domain and nuclear export signal, generated by spliced 
mRNAs (Feinberg, Jarrett et al. 1986, Sodroski, Goh et al. 1986, Cochrane, Perkins et al. 1990). 
The nuclear export signal, a leucine-rich motif, is important for Rev function because of the 
interaction with its nuclear export receptor CRM1, a conserved nuclear receptor from yeast to 
humans that regulates the export of many proteins (Fischer, Huber et al. 1995, Meyer, Meinkoth 
et al. 1996, Nekhai and Jeang 2006). Besides CRM1, a set of cellular factors, such as some 
members of DEAD-box family, are recruited by Rev to function at different stages as well, 
which is already detailed in the literature (Reddy, Tang et al. 2000, Hofmann, Reichart et al. 
2001, Fang, Kubota et al. 2004, Yedavalli, Neuveut et al. 2004, Yu, Sanchez-Velar et al. 2005, 
Joyner, Keuper et al. 2013). 
Antigen-specific CD8-mediated cytotoxic T lymphocytes (CTL) are important immune 
response in the host immune system and are able to recognize and kill HIV-infected cells in less 
than 6 hours (Schmitz, Kuroda et al. 1999). HIV-1 Vpr, a small protein with only 96 amino acid 
residues conserved in most lentiviruses (Tristem, Purvis et al. 1998), is able to suppress the host 
immune activation by arresting cell cycling at G2/M phase, giving approximately 2 hours for 
replication (Levy, Refaeli et al. 1994, Ayyavoo, Muthumani et al. 2002). Heat stress response 
is another anti-HIV immunity mechanism to protect the host against infection by reducing the 
Vpr-dependent G2 arrest. Vpr, however, can counteract this effect by down-modulating the 
production of heat shock proteins (Iordanskiy, Zhao et al. 2004, Iordanskiy, Zhao et al. 2004, 
Benko, Liang et al. 2007, Wei, Guo et al. 2012).  
Tetherin, a factor that had unknown function before, is a membrane protein sitting at the 
cell surface. It is also named CD317, HM1.24 or BST-2, and it is found that Vpu-deleted HIV-
1 virions fail to be released in the presence of Tetherin, i.e. they ‘tether’ mature viral particles 
onto the cell surface. Tetherin usually keeps a low expression level whereas type I interferons 
will induce high expression in vivo (Homann, Smith et al. 2011). The depletion of Tetherin 
abolishes the requirements of Vpu (Neil, Zang et al. 2008, Van Damme, Goff et al. 2008). Later 
studies reveal that Vpu-dependent immune neutralization is species-specific (Goffinet, 
Allespach et al. 2009, McNatt, Zang et al. 2009). It reduces the level of Tetherin on the cell 
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surface by launching the degradation of Tetherin via β-TrCP-dependent lysosomal pathway and 
endosome-dependent proteasomal pathway (Douglas, Viswanathan et al. 2009, Mangeat, Gers-
Huber et al. 2009). Considering that the down-regulation of Tetherin is not always demanded 
for Vpu-dependent virion release (Dube, Roy et al. 2010, Goffinet, Homann et al. 2010), this 
antagonizing-Tetherin mechanism is not the only mechanism that Vpu mediates against the 
blockage of virion release, which means further research is required to clarify the Vpu-induced 
immunal evasion. Meanwhile, some groups now propose that the selection pressure on Vpu by 
Tetherin is critical for the function of Vpu, suggesting a competition between hosts and virus 
during the evolution (Sauter, Unterweger et al. 2012, Douglas, Bai et al. 2013). 
HIV-1 Nef protein is a 27 kDa myristoylated protein localized on cytoplasmic membranes, 
with multiple functions that are required for viral recycling in cells. Besides the function of 
Tetherin antagonizing Vpu (Jia, Serra-Moreno et al. 2009, Zhang, Wilson et al. 2009, Sauter 
and Kirchhoff 2011), Nef down-regulates the level of major histocompatibility class I on cell 
surface so that infected cells can escape the antiviral effect by cytotoxic T lymphocytes cells 
(Blagoveshchenskaya, Thomas et al. 2002, Kasper, Roeth et al. 2005). Similarly, removing 
cellular surface receptors such as CD4, CCR5 and CXCR4 by inducing endocytic or lysosome 
degradation can help viruses escape CD4+ helper T cells-driven immune responses and prevent 
signal transduction among infected cells (Aiken, Konner et al. 1994, Lundquist, Tobiume et al. 
2002, Michel, Allespach et al. 2005, Sloan, Donahue et al. 2010). Immunoglobulin class 
switching in B cells is critical in immunity against the virus. Nef is found to evade B cells and 
disrupt the immunoglobulin G and immunoglobulin A switching, which counteracts antibody 
response that neutralizes infected cells (Qiao, He et al. 2006). Another novel function of Nef is 
to remove a kinase called Lck in the Src family from membrane micro-domains and to disrupt 
the vesicular transport of Lck, thus tailoring T-cell activation and optimizing virus replication 
(Pan, Geist et al. 2013), which provides new insight on the wide mechanisms of Nef behaviour 
in cells. More detail on Nef function have been described comprehensively in several reviews 
(Roeth and Collins 2006, Foster and Garcia 2008, Arhel and Kirchhoff 2009). Sterile alpha 
motif and histidine/aspartic acid domain–containing protein 1 (SAMHD1) is another protein 
that affects HIV infection by controlling nucleic acid metabolism, which is antagonized by viral 
protein x (Vpx) from HIV-2 (Schaller, Goujon et al. 2012). The host intrinsic defense by cellular 
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factors and the corresponding viral evasions are summarized in table 1.1 and figure 1.2. 
 
Table 1.1, Host intrinsic defenses and mechanisms of viral evasion or antagonism 
 
Host defence Antiviral effect Viral factors for evasion 
APOBEC3G Induce lethal hypermutations Vif: Induce ubiquitination of 
APOBEC3G Interfere with elongation process 
Activate global immune responses 
Trim 5α Interfere with uncoating Viral variability 
Tetherin Block viral release Vpu, Nef: Induce degradation of 
Tetherin 
SAMHD1 Reduce dNTP required for cDNA 
production 
Vpx: Induce proteaseome degradation 
 
1.2.3 Viral protein structural studies 
 
HIV/AIDS studies appeal to many structural biologists’ interest as well as to cytology and 
virology biologists, mainly because of the requirement for the understanding of basic biology 
from a molecular viewpoint and for the development of new anti-HIV drugs. In the past dozen 
years, there have been intensive reports on HIV-1 viral particle structures and viral protein 
structures, compared to other viruses or protein families. Architectures on HIV-1 structural 
proteins such as Gag and envelope protein (Env), accessory proteins including Vpu, Vpr and 
Tat, and proteases like transcriptases and integrases have been reported. Some of these 






Figure 1.1: (A) The genome and viral proteins of HIV-1. Proteins (middle) translated from the viral 
genome (top) are assembled into virions. Genes that share the same open reading frame are shown 
in the different colours. LTR, long terminal repeat. The figure is reproduced from website: 
http://www.stanford.edu/group/virus/retro/2005gongishmail/HIV.html. (B) The summary of HIV-1 
life cycle. Reverse transcription and translation complete in the cytoplasm (red region) and DNA 
replication takes place in the nucleus (grey region). Relative inhibitors used in each replication step 
are highlighted in green boxes. Reproduced from reference: HIV-1 entry inhibitors: evading the 









Figure 1.2: The summary of host defense reactions and viral counteracting pathways. Host immune 
factors are highlighted in yellow and viral functional accessory proteins are highlighted in green. 
The blue region in the middle stands for nucleus. The competition between host and virus is 





Env spikes consist of a glycoprotein trimer, gp120, linked non-covalently to a 
transmembrane glycoprotein trimer gp41 on the viral surface. The heterodimer so-formed 
dominates a cascade of conformational changes that initiates fusion between cell membranes 
and viral particles (figure 1.3A) (Zhu, Liu et al. 2006, Liu, Bartesaghi et al. 2008). A cellular 
surface receptor CD4 engages an interaction with core gp120, followed by a second binding to 
CCR5 and CXCR4 in the recognition and fusion step (figure 1.3B) (Kwong, Wyatt et al. 1998, 
Rizzuto, Wyatt et al. 1998, Pancera, Majeed et al. 2010). Some groups reported that this 
interface can be targeted as an inhibiting site by CD4-like molecules to neutralize virus, and 
that some positive results have already been achieved with this approach (Wu, Yang et al. 2010, 
Wu, Zhou et al. 2011). Gag, also called viral capsid protein, is a structural protein that forms a 
HIV core shell in which replication enzymes and viral RNA are housed (Briggs, Grunewald et 
al. 2006). Recent studies reveal that the core capsid structure is assembled by hexameric and 
pentameric Gags as ring structures (figure 1.4) (Pornillos, Ganser-Pornillos et al. 2009, 
Pornillos, Ganser-Pornillos et al. 2011) and encouragingly the mature capsid structure was 
published this year, thus providing a comprehensive knowledge on the HIV-1 capsid (Zhao, 
Perilla et al. 2013). 
HIV-1 reverse transcriptase and integrase are both encoded by the pol gene. The structure 
of reverse transcriptase with an inhibitor or in the presence of DNA was reported twenty years 
ago (Kohlstaedt, Wang et al. 1992, Jacobo-Molina, Ding et al. 1993). A multi-domain structure 
of HIV-1 integrase was reported a dozen years ago (Chen, Krucinski et al. 2000) whereas useful 
and universal structural mechanism of integrase were achieved from other integrases in the 
retrovirus family quite recently because of solubility problem (Hare, Gupta et al. 2010, 
Maertens, Hare et al. 2010). HIV-1 reverse transcriptase is composed of a p51 subunit and a 
p66 subunit containing four folded sub-domains named Fingers, Palm, Thumb and Connection 
(figure 1.5A). The active site for the excision reaction is located in the p66 Palm subunit and 
mutates under pressure to acquire drug-resistance to enhance the ATP-regulated excision at the 
3ˊ-hydroxyl of the DNA template (Jacobo-Molina, Ding et al. 1993, Tu, Das et al. 2010). The 
HIV-1 integrase C-terminus forms a dimer whose catalytic core is exposed inside the dimer 
interface, serving to bind DNA, bending and orienting it during integration (figure 1.5B) 
(Eijkelenboom, Sprangers et al. 1999, Chen, Krucinski et al. 2000). The crystal structure of the 
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integrase from the prototype foamy virus indicates that the N-terminus of integrase functions 
to stabilize the tetramer by the N-terminal domain linking to the catalytic core domain although 
it does not bind directly to DNA (Hare, Gupta et al. 2010). 
Crystallographic studies on Rev present that Rev behaves as a dimer in solution. The 
arginine-rich motif is on the top of this V-shape structure to interact with adjacent RNA (figure 
1.6A). A secondary binding interface is found to adopt a helical hairpin that is critical in Rev 
multimerization by hydrophobic interaction, which later binds to host export factor Crm1 
(Daugherty, Liu et al. 2010, DiMattia, Watts et al. 2010). The arginine-rich motif forms a 
hydrophilic surface that binds to RNA in the Rev polymer. Tat is largely unfolded as shown by 
nuclear magnetic resonance (NMR) studies when not bound, because the strictly conserved core 
region is highly flexible in the solution (Bayer, Kraft et al. 1995). The crystal structure shows 
that Tat is complementary to the surface of host protein positive transcription elongation factor 
by its arginine-rich α-helix (figure 1.6B) (Tahirov, Babayeva et al. 2010). The structure of Vpu 
cytoplasmic domain was solved in micelles by solution NMR (Wittlich, Koenig et al. 2009). 
The dodecylphosphatidylcholine micelles closely mimic the actual condition in cells for 
transmembrane proteins. It shows that Vpu holds a high degree of flexibility as well as Tat and 
Vpr (Schuler, Wecker et al. 1999) and its helical regions are relevant to membrane attachment. 
More comprehensive details on HIV-1 protein structures can be found in a recent review 






Figure 1.3: The structures of HIV-1 glycoproteins. (A) The structure of HIV-1 gp120 monomer. The 
left surface indicated by a blue arrow is bound to the broadly neutralizing antibody b12. This 
structure is regenerated from the crystal structure, PDB accession: 2NY7. (B) The structure of HIV-
1 gp41 trimer (top view). A blue α helix and a red one forms a gp41 monomer. The α-helical trimer 
crosses the cellular membrane and binds to gp120. PDB ID: 1QR8 (Ji, Shu et al. 1999). (C) The 
gp120-CD4 interaction. The structure of HIV-1 gp120 in the complex with cellular surface 
glycoprotein CD4 and FAB antibody. Phe43 on the receptor forms a hydrophobic cavity inside the 
complex highlighted in red. (VL stands for light chain and VH stands for heavy chain). Reproduced 














Figure 1.4: The structures of HIV-1 gag. (A) The structure of hexameric HIV-1 capsid protein. (B) 
The structure of pentameric HIV-1 capsid protein. Each monomer is presented in a different colour. 
View from the top of the protein. Each subunit is coloured individually. Figures are adapted from: 












Figure 1.5: HIV-1 polymerase proteins. (A) The structure of HIV-1 reverse transcriptase in the 
process of DNA genesis. The active site is indicated in red and four functional domains are 
highlighted in different colours. (B) The general view of the prototype foamy virus integrase 
structure. The N-terminus (coloured in grey) interacts with the C-terminus from the other subunit. 
Two C-terminus forms the catalytic core domain. DNA is embedded in the middle of the dimer. 
Figures are adapted from: The structural biology of HIV‑1: mechanistic and therapeutic insights 






Figure 1.6: HIV-1 accessory protein structures. (A) The dimer of HIV-1 Rev protein. Each monomer 
is coloured according to chain. The side-chains of three leucines on the interface are drawn in sticks 
in green. The positions of arginines 38, 39, 42 and 43 is indicated in blue. Reproduced from crystal 
structure 2X7L. (B) The structure of Tat (the unstructured peptide in pink) observed in crystal 




1.3 Cellular ubiquitination pathway 
 
Vif, an accessory protein that helps HIV survive in the non-permissive cells, functions by 
inducing ubiquitination on APOBEC3F and APOBEC3G. Before the review on Vif-
APOBEC3G interaction, the general mechanism of ubiquitination pathway will be introduced 
in this section first. 
 
1.3.1 Overview of ubiquitination mechanism 
 
Ubiquitin (Ub), originally known as ubiquitous immunopoietic polypeptide, is a 76-amino-
acid-residue protein covalently attaching to a large range of proteins in cells. The function of 
ubiquitin, termed ubiquitination, is referred to as a post-translational modification, resulting in 
protein turn-over and degradation. It is demonstrated that the linkage of ubiquitin to the target 
protein is via several lysine linkage types (Peng, Schwartz et al. 2003, Xu and Peng 2008). 
The ubiquitination process consists of three major steps (figure 1.7). In the first step, an 
E1 ubiquitin-activating enzyme binds to a free ubiquitin using the energy released by ATP. Then 
the ubiquitin on E1 is transferred to an E2 ubiquitin-conjugating enzyme. In the third step, the 
E2 domain binds to an ubiquitin and is recognized by E3 ubiquitin-ligase enzyme itself. Binding 
to the target protein helps to transfer the ubiquitin from E2 to the substrate via two domains, 
HECT or RING domain (Deshaies and Joazeiro 2009, Hochstrasser 2009, Rotin and Kumar 
2009). One of the members in Ring family is known as the Cullin-Ring enzyme, where 
structural studies showed that it is divided into two subunits. The E3 core is usually composed 
of Ring-finger protein (Rbx), Cullin protein (Cul), a substrate-recognition portion and other 
proteins, some structures of which have been published (Zheng, Schulman et al. 2002, Duda, 
Borg et al. 2008). As for the Vif-dependent pathway in HIV-1 infected cells, the E3 core 
complex is composed of proteins Cullin 5 (Cul5), elongin B (EloB), elongin C (EloC) and Rbx 











Figure 1.7: Ubiquitination pathway. The ubiquitin molecule is passed onto the substrate by several 
Elongin molecules. In the first step E1 recruits ubiquitin through its Cys residues, which is 
supplemented by ATP. The ubiquitin is then passed onto E2 that binds to E3 complex. In the final 
step the ubiquitin binds to the substrate followed by E2 and E3 dissociate. This cycle repeats several 
times until the substrate is labeled completely and transferred to the degradation pathway. 





1.3.2 The structural study on Elongin B and Elongin C 
 
Elongin BC dimer (EloBC) was originally identified in the Elongin ABC heterotrimer 
complex in 1995 (Aso, Lane et al. 1995). Later it was found that the suppressors of cytokine 
signaling (SOCS) factors also participate in protein degradation by interacting with EloBC, 
which reveals that the EloBC protein degradation pathway is connected to other transduction 
pathways (Zhang, Farley et al. 1999). In the ligase complex EloC is responsible for selectively 
recruiting the Cullin/Rbx complex in comparison to an EloC-like adaptor Skp1 protein that 
recruits other factors to form the complex (Yan, Kamura et al. 2004). 
Structural studies reveal that EloB and EloC form a heterodimer via their hydrophilic β-
sheet domains and the C-terminal tail on EloC interacts with a conserved domain on other 
proteins, namely the BC-box because of its binding to EloBC (Bullock, Debreczeni et al. 2006, 
Bullock, Rodriguez et al. 2007, Stanley, Ehrlich et al. 2008). NMR perturbation shows that both 
EloB and EloC experience a folding process during the binding to other proteins and EloC is 
partly unfolded before binding (figure 1.8) (Babon, Sabo et al. 2008, Knauth, Cartwright et al. 
2009, Bergeron, Huthoff et al. 2010). It is of note that there are no reports of producing soluble 
EloB or EloC individually from E. coli. 
 
 
Figure 1.8: The structure of EloBC heterodimer. The direction of the partial flexible EloB C-terminal 





1.4 APOBEC3 Family and the Vif-induced degradation of APOBEC3G 
 
1.4.1 Overview of APOBEC3 family 
 
The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3, A3) 
family of cytidine to uridine-editing enzymes contain seven members named from A to H 
(LaRue, Andresdottir et al. 2009) that are constitutively present in cells exhibiting physiological 
functions such as triggering deamination pathways in antibody gene diversification processes 
and anti-virus defence (Petersen-Mahrt, Harris et al. 2002, Harris, Sheehy et al. 2003, 
Conticello, Thomas et al. 2005, Pham, Bransteitter et al. 2005, Rosenberg and Papavasiliou 
2007, Kohli, Maul et al. 2010). All of these genes are located on choromosome 22 (Jarmuz, 
Chester et al. 2002). APOBEC3G (A3G) is a cellular factor with 384 amino acid residues 
translated from the a3g gene. It is the one that is known to play the most important role in viral 
suppression, especially in the anti-human immunodeficiency virus type 1 (HIV-1) processes, 
among the APOBEC3 family members, which have recently been comprehensively described 
in several reviews (Albin and Harris 2010, Kirchhoff 2010, Wissing, Galloway et al. 2010, 
Imahashi, Nakashima et al. 2012). 
 
1.4.2 Functional and structural studies on APOBEC3G 
 
The function of APOBEC3G to inhibit HIV was first identified in 2002 by Michael 
Malim’s group when this factor was named CEM15 at the time. They tested the expression level 
of CEM15 in permissive and non-permissive cells during the infection with or without Vif. It 
was found that HIV was suppressed by A3G in the absence of Vif, whereas this inhibition 
activity of A3G was overcome by Vif (Madani and Kabat 1998, Simon, Gaddis et al. 1998, 
Sheehy, Gaddis et al. 2002). A later study, however, showed that even Vif-deficiency HIV can 
still survive in the APOBEC3G-expressing cells, indicating that other mechanisms may exist 
to counteract the function of APOBEC3G (Hache, Shindo et al. 2008). 
APOBEC3G suppresses Vif-deficiency HIV-1 in non-permissive cells by being packaged 
in mature viral particles into next generation cells. The reverse transcription complexes of HIV-
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1 are not affected by A3G packaging, which means this mechanism is independent of HIV 
reverse transcription. After the virus has fused and decoated in target cells, A3G induces 
numerous mutations on retroviruses, especially cytidine to uridine mutations in the single-
strand viral DNA by deamination mechanism in host cells (Harris, Bishop et al. 2003, Lecossier, 
Bouchonnet et al. 2003, Mangeat, Turelli et al. 2003). The amount of A3G that is delivered into 
peripheral blood mononuclear cells is around seven molecules, suggesting that only a few A3G 
molecules are required for inhibiting HIV (Xu, Chertova et al. 2007). In another investigation, 
it was shown that that single packaged A3G molecule can induce the mutation as well by 
establishing low-expression cell lines (Browne, Allers et al. 2009). This molecular mechanism 
takes place by directly attacking position 4 of the pyrimidine ring in cytidine where zinc is 
required to bind the pyrimidine ring, inducing a substitution of the 4ˊ amino-group with a 
carbonyl-group (figure 1.9A) (Neuberger, Harris et al. 2003). 
Besides viral DNA degradation, APOBEC3G, as well as APOBEC3F, is able to suppress 
the virus by impeding viral DNA reverse transcription, specifically, by inhibiting reverse 
transcriptase-catalyzed DNA elongation reactions in target cells in the absence of 
hypermutation (Holmes, Koning et al. 2007, Iwatani, Chan et al. 2007, Bishop, Verma et al. 
2008). Recently a novel study on APOBEC3G showed that the expression of APOBEC3G was 
not only acting as a viral defense, but also as an activator of the immune system (Casartelli, 
Guivel-Benhassine et al. 2010). In the present of APOBEC3G, CD8+ cytotoxic T lymphocytes 
were significantly activated. The function of APOBEC3G is considered much more complex 
than expected because it is involved in the host global immune system rather than just the 
stimulation of mutations. 
Since the first time that APOBEC3G (CEM15) was found to inhibit HIV-1 in the absence 
of Vif (Sheehy, Gaddis et al. 2002), the structure solution of APOBEC3G and its related 
complex naturally became a critical target due to the possibility for treating HIV/AIDS. In 2008 
the C-terminal 187-amino-acid-residue structure was solved both in solution by NMR by 
Chen’s group (Chen, Harjes et al. 2008) and by X-ray crystallography Holden’s group 
respectively (Holden, Prochnow et al. 2008). 
The NMR solution structure suggests that the C-terminus of A3G (198-384) containing the 
deamination activity is composed of five α-helices and five β-strands (figure 1.9B) (Chen, 
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Harjes et al. 2008). The crystal structure is composed of six α-helices, one of which is not 
defined at the N-terminus in the NMR structure, and five β-strands. Notably, the β2 strand in 
the crystal structure is an intact β strand whereas in the solution structure it is short. This 
difference may be caused by the mutation in the NMR structure, implying that five β-sheets are 
a common structure in the APOBEC family (Holden, Prochnow et al. 2008). Alignment of 
APOBEC2 and APOBEC3G crystal structure shows that the core structures of the APOBEC 
family is highly conserved. However, APOBEC3G has a longer active centre loops. For 
example, loop 3 in the crystal structure is a deaminase domain (figure 1.9C), where mutation at 
R215 will abolish the deamination activity because R215 is responsible for an interaction with 
R313 and W285 by hydrogen bonds (figure 1.9D). Besides, R256 and R264 in the loop form a 
strong salt bridge that stabilizes the loop. The single-strand DNA (ssDNA) acts as a substrate 
and is embedded in the groove on the surface of A3G starting from loop1 to loop3, where the 
target base of the ssDNA is located in the active site so that the Zn2+-induced deamination can 
take place. These newly discovered features revealed by structural biological methods explain 
the deamination mechanism and provide a knowledge that may be used in later drug design. 
 
1.4.3 The Vif-induced degradation on APOBEC3G 
 
Because the behaviour of HIV is different in human T cells in the absence or in the presence 
of Vif, these cells are divided into two groups as ‘permissive cells’ or ‘non-permissive cells’ 
(Fisher, Ensoli et al. 1987, Madani and Kabat 1998, Simon, Gaddis et al. 1998). The difference 
is now widely known as a restrictive capacity to overcome the function of APOBEC3G which 
has been detailed above. Vif counteracts the anti-viral defence by inducing degradation of some 
members of APOBEC3 family, including A3DE (Dang, Wang et al. 2006), A3F (Wiegand, 
Doehle et al. 2004, Zheng, Irwin et al. 2004, Albin, Anderson et al. 2013), A3G (Yu, Yu et al. 
2003, Mehle, Strack et al. 2004, Feng, Love et al. 2013) and some A3H proteins which 
originated in west and central Africa (OhAinle, Kerns et al. 2008, Tan, Sarkis et al. 2009, Zhao, 
Ishida et al. 2012). The mechanism is to neutralize those anti-virus cellular factors by a 




















Figure 1.9: The deamination mechanism and APOBEC3G structures. (A) The proposed mechanism 
for cytidine deaminases action by APOBEC3G. Enz stands for enzyme. (B) The alignment of the 
carboxyl terminal solution structure 2JYW (green) and the crystal structure 3E1U (blue). The 
number of β-strands are presented on the solution structure. The N-terminus and C-terminus are 
indicated. (C) The crystal structure of C-terminal A3G. The secondary structures are colored 
differently. The functional domain of loop 1 and loop 2 are highlighted in black. Some α-helix are 
numbered according to the original paper (Holden, Prochnow et al. 2008). (D) Zoom in on the active 
domain of C-terminal A3G. The side-chains from three critical residues are highlighted in red. The 
water molecule coloured in blue in the middle are connecting to R313 and W285 via hydrogen 





recruited to start the degradation (Conticello, Harris et al. 2003, Marin, Rose et al. 2003, Sheehy, 
Gaddis et al. 2003, Yu, Yu et al. 2003). Co-expression of Vif with A3G improves the 
degradation rate of the two polyubiquitinated components while Vif is only monoubiquitinated 
in the absence of A3G (Mehle, Strack et al. 2004). However, other studies argue that the 
correlation between the degradation of APOBEC3G and the rescue of viral infectivity is not 
direct as expected before and these two functions of Vif are separable (Kao, Goila-Gaur et al. 
2007). 
In the Vif-induced ubiquitination pathway, several specific cellular factors are recruited to 
form a ligase complex composed of EloB, EloC, Cul5 and Rbx, (Yu, Xiao et al. 2004, Luo, 
Xiao et al. 2005, Duda, Borg et al. 2008, Mahrour, Redwine et al. 2008) in the presence of Vif 
(figure 1.10A). The core binding factor β (CBFβ), a newly discovered chaperone, is crucial for 
the folding and stabilizing of Vif (Jager, Kim et al. 2012, Zhou, Evans et al. 2012, Kim, Kwon 
et al. 2013), the Vif-APOBEC3G interaction, (Zhang, Du et al. 2012, Du, Zhao et al. 2013) and 
regulation of host gene expression (Kim, Kwon et al. 2013). The formation of the E3 ligase 
complex results in ubiquitination of the target proteins and neutralization of the anti-viral 
responses. The Vif sequence and its functional domains are presented in figure 1.10B. In detail, 
the N-terminus of Vif has been shown to bind to members of the APOBEC3 family (Russell 
and Pathak 2007, He, Zhang et al. 2008). Recent work from John Gross’s group shows that the 
N-terminal residues 1-140 also interact with CBFβ (Kim, Kwon et al. 2013). Vif can selectively 
bind to Cul5 through a zinc-binding motif, H108x5Cx17-18Cx5H139 (HCCH motif), a region in the 
middle of the sequence and upstream of the SOCS binding domain (SOCS-box). Vif without 
the zinc-binding motif from the non-primate lentivirus has a weaker interaction with the E3 
ligase (Luo, Xiao et al. 2005, Mehle, Thomas et al. 2006).  
The SOCS-box of Vif has been known to bind to the EloB-EloC heterodimer along with 
Cul5. The SOCS-box is C-terminal to the zinc-binding HCCH motif and contains a conserved 
SLQYLA motif (residues 144-149) called ‘BC-box’ because of its interaction with EloBC (Yu, 
Xiao et al. 2004, Kobayashi, Takaori-Kondo et al. 2005). Mutation of this motif has been 
demonstrated to result in a functional loss of Vif, which indicates that this domain plays a 
critical role in Vif (Mehle, Goncalves et al. 2004, Mehle, Strack et al. 2004, Yu, Xiao et al. 
2004, Kobayashi, Takaori-Kondo et al. 2005). The SOCS-box also has a critical proline-rich 
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motif (161PPLPS165, PPLPS motif) (Donahue, Vetter et al. 2008) downstream of the BC-box, 
whose biological role is poorly understood regardless of its possible function in forming 
homomultimers (Yang, Gao et al. 2003, Techtmann, Ghirlando et al. 2012). The proline-rich 
motif is found to interact with the EloB C-terminal tail to perform an unknown biological 
function (Bergeron, Huthoff et al. 2010). Mehle’s group found that the binding to EloC was 
regulated by phosphorylation on the Serine-144 site in the SOCS-box domain, implying that 
this Vif-induced ubiquitination may be relative to other signal regulation pathway (Mehle, 
Goncalves et al. 2004). 
Recently there were two reports that a cellular factor named core binding factor β (CBFβ) 
which usually functions in T-cell differentiation is hijacked by Vif in the ubiquitination pathway, 
resulting in APOBEC3G degradation and improved viral infectivity (Jager, Kim et al. 2012, 
Zhang, Du et al. 2012). It is of note that this factor is able to help Vif fold and become soluble 
when CBFβ and Vif are co-expressed in Escherichia coli (E. coli), which significantly 
highlights that in the structural studies on Vif there is no report on Vif structure except an α-
helical BC-box structure (Stanley, Ehrlich et al. 2008). Once soluble Vif can be obtained by 
protein engineering methods, further efforts can use X-ray crystallography or cryo-electron 
microscopy to solve the structure. The general view of Vif-induced APOBEC3G degradation is 
shown in figure 1.11. 
 
1.4.4 APOBEC3G-induced HIV-1 evolution and adaption 
 
APOBEC3G suppresses HIV-1 by triggering mutations in the DNA during transcription. In 
the old days, scientists focused more on the interaction mechanisms of the APOBEC3G-Vif 
complex because of the potential clinical implications, and ignored the role that APOBEC3G 
plays in HIV-1 mutation and evolution. A dozen years ago a sequence analysis of HIV-1 from 
infected people revealed that the subsets of sequences were dominated by G-to-A 
hypermutation (Janini, Rogers et al. 2001), which implies an important biological role of 
APOBEC3G besides its anti-virus function (Malim and Emerman 2008), i.e. the APOBEC3G 
deamination capability may facilitate HIV to mutate and evolve, a mechanism by which viruses 









Figure 1.10: The ligase complex and Vif sequence. (A) The Vif-induced ubiquitination complex. 
The complex composed of Rbx, Cul5, EloB, EloC and Vif is named E3 ligase complex. (B) The Vif 












Figure 1.11: The pathway of Vif-induced A3G degradation. Adapted from reference: Immune 





This hypermutation happens more frequently in a dinucleotide context, especially in the 5ˊ-
GG-3ˊ context which amounts for 95% hypermutations and correlates with higher CD4 counts 
(Kieffer, Kwon et al. 2005, Gandhi, Siliciano et al. 2008, Land, Ball et al. 2008). This possibly 
explains that APOBEC3G may help HIV form A-rich genomes (Berkhout and van Hemert 
1994), as it has been concluded in the review (Hache, Mansky et al. 2006). Although it is still 
unclear how the APOBEC3 family proteins stimulate pressure on sequence selection during 
evolution, a study using a newly-developed mathematical model with 3,499 HIV env gene 
sequences from 102 subjects demonstrated that APOBEC3G or APOBEC3F contributed to the 
sequence diversity (Keele, Giorgi et al. 2008). 
Importantly, the understanding of the viral evolution and adaption attributed from 
APOBEC3 family enables us to re-consider the drug resistance that is thought to be related to 
APOBEC3 proteins. In the clinic, there have been many drug-resistance-related mutations 
reported in the past decades. One of the resistances to the thymidine analogue zidovudine, a 
component used for blocking the reverse transcription in a highly active antiretroviral therapy 
(HAART), was resulted from a G-to-A mutation taking place on an APOBEC3F hotspot, after 
which an aspartic acid was replaced by an asparagine (Mitsuya, Weinhold et al. 1985, Larder 
and Kemp 1989, Hache, Mansky et al. 2006). The effect of Nelfinavir, another typical drug that 
inhibits HIV protease (Patick, Mo et al. 1996), was partially weakened because of amino acid 
replacement that is obtained by a simple G-to-A DNA mutation as well (Pazhanisamy, Stuver 
et al. 1996, Hache, Mansky et al. 2006). Meanwhile, the G-to-A hypermutation virus was 
reported in 2001, indicating that Vif does not always overcome the function of APOBEC3G, 
(Janini, Rogers et al. 2001). However, Berkhout argued that even in APOBEC3G-negative cells 
large amounts of G-to-A hypermutation were also detected (Berkhout, Das et al. 2001, Berkhout 
and de Ronde 2004). 
Some later studies, including in vitro experiments and calculation models, demonstrated 
that APOBEC3G can facilitate HIV adaption. The HIV-1 provirus mutant with lamivudine-
resistance appeared in the presence of APOBEC3G before exposure to a drug. This drug-
resistance ability was then acquired by recombination with the mutated provirus (Mulder, 
Harari et al. 2008). Jern, et al. developed a computational model to calculate the probabilities 
of G-to-A mutation targeted by APOBEC3G regarding the ratio of nonsynonymous to 
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synonymous sequence changes which leaves a footprint during virus generations (Jern, Russell 
et al. 2009). The result revealed that APOBEC3G-targeted HIV-1 genomes experienced 
mutations at a higher ratio compared with the random control, and that mutants induced by 
APOBEC3G did acquire the drug-resistance, although it happened at a lower rate, suggesting 
that APOBEC3G plays a positive role in viral survival and evolution. Another investigation 
using sequence analysis showed that APOBEC family proteins help HIV-1 escape early 
immune response by mutating nucleotides on CTL epitope sites (Wood, Bhattacharya et al. 
2009). The CTL is a component that suppresses HIV in the early immune response. 
The discovery that APOBEC3G has a two-sided function has stimulated work producing 
some encouraging results which are disclosing the secret picture of APOBEC3G-Vif interaction. 
It is worth mentioning that in Berkhout’s case (Berkhout and de Ronde 2004), perhaps it is other 
cellular factors that lead to the G-to-A hypermutation. On the other hand, there are still lots of 
questions remaining to be answered. For example, how important is APOBEC3G in viral 
evolution to help the virus escape immune response and acquire drug-resistance? No doubt 
APOBEC3G, as a critical anti-virus factor in host cells, can inhibit HIV-1, so what is the balance 
between the two opposite functions? Besides APOBEC3G and APOBEC3F, do other 
APOBEC3 family proteins facilitate the evolution of HIV-1? More efforts are required to 
uncover the complicated mechanisms. 
 
 
1.5 HIV drug development 
 
In order to suppress HIV-1 levels in plasma, many tools, drugs and treatment strategies 
have been tried in the past two decades. The most successful treatment is HAART that combines 
several virus inhibitors working in various steps of viral replication in order to prevent viral 
mutations that may easily help the viruses escape the effects of one drug.  
HAART, however, is not very beneficial due to its high cost and unknown long-term side 
effects, and most importantly, HAART fails to cure the HIV infection or AIDS because it has 
no effect on latent integrated provirus. That means these slowly-replicating viruses form stable 
reservoirs in resting memory CD4+ T cells that will break out sometime later, causing more 
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severe symptom (Siliciano, Kajdas et al. 2003, Richman, Margolis et al. 2009, Yang, Xing et 
al. 2009). Therefore, in order to cure the disease, another therapeutic strategy is required to 
clear provirus in resting T cells and make up for the disadvantages of HAART (Trono, Van Lint 
et al. 2010, Deeks 2012). This strategy now is a leading field in HIV vaccine and drug 
development. 
A report in 2009 from Robert Siliciano’s group shed the first light on the discovery of 
chemical molecules that were able to provoke the ‘hiding’ provirus (Yang, Xing et al. 2009). 
They established a primary Bcl2-transduced cell strain as a model system and used it to screen 
chemical-molecule libraries. A small molecule, 5-hydroxynaphthalene-1,4-dione, unlike other 
activators, is found to be able to reactivate latent viruses in resting CD4+ T cells through ROS 
and NF-κB pathways without activating the global T cell response. This is a huge advantage 
because activated T cells will be infected by viruses again which decreases the treatment effects. 
Recently a group of quinolin-8-ol derivatives have been identified based on initial hits by the 
same group, which expends the possible drug candidates in the pool (Xing, Bhat et al. 2012). 
A more encouraging and promising study reported in Nature recently demonstrates that this 
clean-latent-virus strategy can be applied in clinical study and impact HIV-1 latency in vivo 
(Archin, Liberty et al. 2012). They chose eight patients who were treated with HAART and in 
whose body the viruses were suppressed completely. Those patients were given a type of 
histone deacetylase inhibitor called suberoylanilide hydroxamic acid, known as a vorinostat 
that has been identified to disrupt HIV-1 latency in vitro (Archin, Espeseth et al. 2009, Archin, 
Keedy et al. 2009, Contreras, Schweneker et al. 2009). In that study, a single dose of vorinostat 
improved the level of an acetylating biomarker and HIV-1 RNA expression in the resting T cells 
of each individual, showing that these reactivated cells can be recognized by the immune 
systems. This proof-of-concept study indicates that stimulated HIV-1 reservoirs can be 
therapeutically targeted and then removed by novel drugs and feasible strategies in the future. 
Besides the drug development, recently the development of broadly neutralizing antibodies has 
also achieved a huge success (Wu, Yang et al. 2010, Wu, Zhou et al. 2011), which has been 
highlighted in several latest reviews (Haynes and McElrath 2013, Mascola and Haynes 2013, 





1.6 Aim of this thesis 
 
Due to problems with over-expressing, purifying and crystallizing the full-length folded 
soluble Vif and APOBEC3G (Barraud, Paillart et al. 2008, Engelman and Cherepanov 2012), 
it is still unclear from a structural biological viewpoint how Vif recruits cellular factors and 
interacts with APOBEC3G to stimulate degradation. Most reports until now have been on the 
properties of Vif despite only a structural study on the α-helical BC-box domain (Stanley, 
Ehrlich et al. 2008). Therefore, the purpose of this project is to elucidate Vif structure and 
function by biophysical methods including NMR, crystallography, mass spectrometry (MS), 
isothermal titration calorimetry (ITC), and cellular biological assays. 
The Vif SOCS-EloBC structure is reported first. Following our previous research (Bergeron, 
Huthoff et al. 2010), more NMR data allows us to solve the 36 kDa complex structure, revealing 
the interface between the proline-rich motif of Vif and EloB carboxyl terminus. Moreover, 
biophysical and biological assays characterize the role of residues on the proline-rich motif. 
The results suggest that it is a weak interaction between the proline-rich motif and EloB subunit 
involving van der Waals forces. 
In the second part, we are more interested in purifying and crystallizing the full-length Vif 
after CBFβ was reported to function in the Vif-induced degradation pathway (Jager, Kim et al. 
2012, Zhang, Du et al. 2012). The complete protocol of protein production is presented, and 
solubility tests through different methods are discussed to explain the conditions used for 
purification. Interestingly, the behaviour of two CBFβ isoforms are different during the sample 
preparation, indicating that the carboxyl terminus of the shorter isoform participates in helping 





CHAPTER 2: MATERIAL AND METHODS 
 
2.1 Molecular cloning 
 
The plasmids for Vif SOCS-box peptide and EloBC were made by Dr. Julien Bergeron 
(Bergeron, Huthoff et al. 2010). CBFβ isoform I and II cDNAs were synthesized by Genscript 
and BlueHeron respectively. Vector pRSFDuet was purchased from Novagen. 
Polymerase chain reactions (PCR) were performed using the Phusion® DNA polymerase 
kit (Finnzyme) in a 50 μl containing 1 unit of polymerase, 10 mM dNTPs (each), 10-50 ng 
DNA template and 10-50 pmol of 5ˊ or 3ˊ primer in ‘High Fidelity’ reaction buffer. Sequences 
of primers used for different constructs are listed in appendix I. A general program used for 
PCR is described in table 2.1. 
 
Table 2.1, PCR program used for molecular cloning 
 
Step Temperature Time 
1 95 ℃ 2 minutes 
2 95 ℃ 30 seconds 
3 55 ℃ 30 seconds 
4 68 ℃ 1 minute 
5 Repeat step 2-4 30 cycles 
6 68 ℃ 10 minutes 
7 4 ℃ hold 
 
Plasmids, PCR products and vectors were digested by restriction endonucleases from New 
England Biolabs (NEB). Reactions were carried out in a 40 μl volume containing 4 μl enzyme 
buffer depending on the endonucleases, 4 μl 10% bovine serum albumin (BSA), 1000 ng DNA, 




Plasmids and PCR products or restriction digests were analyzed and separated by mixing 
5 μl of sample with 1 μl of 6* loading buffer (Abgene) on a 1-1.2% agarose gel containing 
Tris/Borate/EDTA buffer (Fisher) and 0.5 μg/ml ethidium bromide. Ladders from NEB were 
used to estimate the size of the DNA of interest. Gels were run at 100 V, and visualized under 
the ultraviolet trans-illuminator (Biorad). 
The products of PCR reactions or digested DNA separated on agarose gel were purified via 
a QIAquick® purification kit (QIAGEN), according to the manufacturer’s instructions. The 
DNA was re-suspended in around 50 μl H2O. 
In order to insert DNA fragments into expression vectors, 2 μl digested vector and 6-10 
times the amount of DNA fragments were mixed in a total reaction volume of 20 μl containing 
T4 ligase buffer and 1 μl T4 DNA ligase (NEB). The transforming reaction mix was incubated 
at 4 ℃ overnight. 10 μl of ligation reaction was transformed into 80 μl volume of XL-blue 
competent cells. The solution mix was incubated on ice for 45 min, followed by a heat shock at 
42 ℃ for 1 min. After recovering in 250 μl Luria-Bertani broth (LB) at 37 ℃ for 45 min, 
transformed cells were plated on LB-agarose plates containing appropriate antibiotics. After 18 
hours, colonies were picked and grown at 37 ℃ for 12 hours in 5 ml LB plus antibiotics. 
Plasmids were extracted using the QIAprep® spin miniprep kit (QIAGEN). Final constructs 
were confirmed by PCR reactions or by digest tests, as well as by sequencing (MWG-biotech). 
 
 
2.2 Bioinformatic analysis 
 
Nucleotide blast was performed on the BLAST server (blast.ncbi.nlm.nih.gov/Blast.cgi) 
on the National Center for Biotechnology Information website to validate the cDNA sequences 
from molecular cloning. Protein sequence alignment and relative conservation analysis were 
performed using Clustal-W with default settings (Larkin, Blackshields et al. 2007). 
Secondary structures were predicted by PsiPred (Jones 1999). The prediction of flexibility 
was carried out using Random Coil Index (RCI) from the backbone assignments (Cα CO, Cβ, 
N, Hα, NH) and employing an RCI web server (Berjanskii and Wishart 2005). Torsion angles 
were predicted by TALOS+ from backbone assignments (Shen, Delaglio et al. 2009, Wassenaar, 
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van Dijk et al. 2012). 
The characteristics of residual sequences, including pI, positive/negative charges and Scan 
Mass Spectrometry results were acquired from Protein Calculator provided by Scripps Institute 
(www.scripps.edu/~cdputnam/protcalc.html). Hydrophobic statistics, molecular weight and 
amino acid abundance of sequences were analyzed by a self-written script that is attached and 
explained in appendix II. Extinction coefficient values, grand average of hydropathicity and 




2.3 Protein expression and purification 
 
2.3.1 Protein expression 
 
Vif SOCS-box and EloBC were expressed as described previously (Bergeron, Huthoff et 
al. 2010). For the Vif/EloBC/CBFβ tetramer, plasmids pETDuet with EloBC constructs and 
pRSFDuet with Vif/CBFβ constructs were co-transformed into BL21 (DE3) pLysS competent 
cells, followed by plating cells on LB-agarose dishes containing 50 ng/ml Kanamycin and 
100 ng/ml ampicillin and grown at 37 ℃ overnight. One colony was picked and grown in 3 ml 
LB with appropriate antibiotics at 37 ℃ for 12 hours. One volume of bacteria was mixed with 
one-volume of sterilized 50%-glycerol LB media to produce a glycerol stock which was stored 
at -80 ℃. All bacteria used for protein expression and purification later were from the glycerol 
stocks.  
Cells from -80 ℃ were grown in 3 ml LB at 37 ℃ for 12 hours. 10 μl of recovered 
bacteria was included to fresh 5 ml LB containing 0.1 mM ZnCl2 and grown at 37 ℃ for 
another 12 hours. Next day the overnight culture was added into 800 ml LB containing 0.1 mM 
ZnCl2 and appropriate antibiotics. Expression was induced by isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 0.2 mM when OD600 reached 0.8, the 
temperature was decreased to room temperature. Proteins were then expressed at 16 ℃ for an 
additional 20 hours. Cells were collected by 6,000 rpm centrifugation at 4 ℃ for 20 min. 
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Pellets were stored at -20 ℃. Cell lysis after induction was not usually taken for SDS-PAGE 
gel analysis because the amount of protein in each cell was very low due to the induction 
temperature and IPTG concentration. All the media described above contained 50 ng/ml 
kanamycin and 100 ng/ml ampicillin. 
 
2.3.2 Protein solubility test 
 
1 ml of cells recovered from glycerol stock were added to 100 ml LB media containing 
0.1 mM ZnCl2, 50 ng/ml kanamycin and 100 ng/ml ampicillin. Proteins were induced for 
4 hours with 0.5 mM IPTG at 37 ℃ or low temperature as described above. After induction 
the media was distributed into 10 aliquots of 10 ml each. Bacteria pellets were spun down at 
4,500 rpm for 20 min and re-suspended in 500 μl of different buffers with pH and salt gradient. 
Samples were sonicated at 30% amplitude using a Sonifier®250 (Branson) for 2 min with a 
pulse program of 5-sec on/10-sec off. Cell lysis was centrifuged at 17,000 rpm for 30 min. 20 μl 
of cell lysis and supernatant were added to 2* gel loading buffer. 10 μl of each sample was run 
on a 15% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) or Tricine 
gel, displayed with Coomassie blue. 1 μl of each sample was used for western blot with Vif 
antibody. 
 
2.3.3 Nickel-nitrilotriacetic acid affinity purification 
 
The purification of Vif SOCS-box and EloBC has been described before (Bergeron, 
Huthoff et al. 2010). Pellets for the Vif/EloBC/CBFβ tetramer were resuspended in Vif re-
suspending buffer (20 mM phosphate pH 7.0, 100 mM NaCl, 20 mM imidazole, 10% glycerol, 
8 mM 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate (CHAPS), 
Roche protease inhibitor cocktail, 0.05% sodium azide) and sonicated by Sonifier®250 for 10 
min with a pulse program of 5-sec on/10-sec off. The cell lysis was centrifuged at 17,000 rpm 
at 4 ℃for 1 hour. The supernatant was loaded onto the equilibrated Ni-NTA agarose beads 
(QUIAGEN) and the flow-through was then re-loaded onto the column, which was 
subsequently washed with approximately 200 ml of washing buffer (20 mM phosphate pH 7.0, 
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250 mM NaCl, 40 mM imidazole, 0.05% sodium azide). Proteins were eluted into elution buffer 
(20 mM phosphate pH 7.0, 250 mM NaCl, 200 mM imidazole, 8 mM CHAPS, Roche protease 
inhibitor cocktail, 0.05% sodium azide) and stored at 4 ℃. The entire process of purification 
was conducted in the cold room. 
 
2.3.4 SDS-PAGE analysis 
 
15% SDS-PAGE was used to analyze protein samples. Running gels (375 mM Tris-HCl 
pH 8.8, 0.1% ammonium persulphate, 0.1% SDS, 0.004% N,N,Nˊ,Nˊ- 
Tetramethylethylenediamine (TEMED), 15% acrylamide) was cast in ATTO (Japan) system 
and covered with butanol until the gel had polymerized. The butanol was discarded after 30 min 
and the spacer gel (125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% ammonium persulphate, 0.004% 
TEMED, 4% acrylamide) was loaded on the running gel. Between 3 μl and 20 μl of the samples 
were loaded onto the gel depending on samples, and run at 120 V for 2 hours in running buffer 
(27.6 mM Tris, 0.2 M glycine, 0.1% SDS). 
 
2.3.5 Tricine gel analysis 
 
Tricine is an organic compound made from tris and glycine where the word ‘Tricine’ 
derives from. The Tricine gel system is a modification of traditional SDS-PAGE for low 
molecular weight proteins. In solution Tricine is more negatively charged than glycine, making 
the small-molecule highly charged and thereby move faster in the gel. This allows small 
proteins whose molecular weight (MW) is between 1 kDa to 100 kDa to be separated (Schagger 
and von Jagow 1987, Lesse, Campagnari et al. 1990). 
Tricine gel was used to analyze the tetramer sample owing to the slight difference in protein 
MW between Vif and CBFβ. The running gel contained 15% acrylamide, 1.0 M Tris-HCl pH 
8.45, 0.1% SDS, 10% glycerol, 0.033% ammonium persulphate and 0.004% TEMED. The 
spacer gel contained 4% acrylamide, 0.6 M Tris-HCl pH 8.45, 0.06% SDS, 0.033% ammonium 
persulphate and 0.004% TEMED. Running buffer covering the top of the gel contained 0.1 M 
Tris, 0.1 M Tricine pH 8.25, and 0.1% SDS. Running buffer in the bath was made from 0.2 M 
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Tris pH 8.9. The gel was run at 100 V for 5 hours and stained overnight.  
 
2.3.6 Protein preparation for Nuclear Magnetic Resonance Spectroscopy 
 
Bacteria containing the Vif SOCS-box construct and the EloBC construct were recovered 
in 5 ml LB media overnight. Cells were collected by 4,000 rpm centrifugation for 10 min and 
the media was discarded. Pellets were re-suspended in 100 ml M9 minimal media (6 g/L 
Na2HPO4, 3 g/L KH2PO4, 0.5 g/L NaCl, 0.1 mM CaCl2, 2 mM MgSO4, 1 g/L 15NH4Cl, 4 g 
glucose) containing 15N or 13C according to experiment requirements and grown overnight. The 
small culture was transferred to 900 ml minimal media containing 15N or 13C on the next day. 
Proteins were induced by IPTG to a final concentration of 1.0 mM at OD600 0.8 for four hours. 
Cells were collected as described above. For deuterated samples, recovered bacteria were 
grown in 5 ml minimal media culture overnight. The culture was then grown in a small volume 
of 30% and 70% D2O minimal media before 1L of 100% deuterated minimal media was used 
to express proteins. 
1-13C glutamine and 1-13C proline-labeled proteins were obtained in 100% deuterated M9 
minimal media containing 15NH4Cl and non-labeled glucose. 0.2 g of each labeled amino acid 
were re-suspended in 10 ml minimal media and added to the cell culture just before induction. 
All labeled proteins were purified as described above. 
 
 
2.4 Biophysical assays 
 
2.4.1 Analytical gel filtration study 
 
Size exclusion column purification of SOCS-box and EloBC have been detailed in 
Dr. Julien Bergeron’s paper (Bergeron, Huthoff et al. 2010). As for the SOCS-EloBC complex, 
1 volume of labeled component was mixed with 1.2 volume of unlabeled component and 
concentrated to 1 ml. Sizing exclusion column GE Superdex 75 10/300 GL was equilibrated 
with NMR buffer (10% D2O, 50 mM sodium-phosphate buffer pH 6.7, 0.05% sodium azide) 
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before using. A final sample of the 1:1 complex sample was collected usually from fraction 21 
to 25. Protein concentration was measured by UV at 280 nm wavelength on NanoDrop VD-
1000 spectrophotometer. 
As for the Vif-EloBC-CBFβ tetramer, the whole gel filtration system was sitting in a cold 
cabinet at 4 ℃. Size exclusion column Superdex 200 10/300 GL was equilibrated with 30 ml 
Vif final buffer (10 mM phosphate buffer pH 7.0, 250 mM sodium chloride, 0.02% sodium 
azide, 8 mM CHAPS) before the experiment. Protein samples from a Ni-NTA column were 
concentrated to 2 ml. In each run 1 ml samples was loaded onto the column. The running speed 
was set at 0.5 ml/min per fraction. 
In order to calibrate the system and to obtain a guide on the behaviour of various molecules 
with different MW, a group of standard components were diluted in 1 ml of the final buffer and 
tested on the Superdex 200 gel filtration column at 4 ℃. Each component and its MW is listed 
in table 2.2. Target samples of the tetramer usually came out at approximately 14-ml washing 
volume, or around fraction 24. 
 
Table 2.2, Protein ladder for gel filtration analysis 
 
Name Molecular weight / Da Peak position / ml 
Thyroglobulin, bovine 669,000 7.6 
Apoferritin, horse spleen 443,000 11.3 
β-Amylase, sweet potato 200,000 12.4 
Albumin, bovine serum 67,000 14.4 
Carbonic Anhydrase, bovine erythrocytes 29,000 16.5 
lysosome 11,000 19.1 
Aprotinin, Bovine lung 6,500 22.2 
 
2.4.2 Dynamic light scattering 
 
Protein samples and standard control BSA were diluted to approximately 0.2 mg/ml (by 
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BioRad) in the final buffer. The sample room of the machine was cooled down to 10 ℃ for 
15 min before use. A 12 μl sample was added into 12-μl Quartz cuvette after a hard spin at 
13,000 rpm at 4 ℃  for 10 min. The molecular diameter was detected and converted to 
molecular weight by the Dynapro 99 manufactured by PROTEINSOLUTION. 
 
2.4.3 Differential condition scanning 
 
Differential condition scanning is also called thermal shift assay (TSA). 13 μl of test buffer 
was placed into 96-well PCR plates, followed by adding 1.5 μl protein samples (1 mg/ml by 
BioRad) into each condition. The original Dye SYPRO® Orange protein gel stain from Life 
TechnologiesTM was diluted at 1:31 ratio before loading 0.5 μl diluted dye into conditions. All 
processes were performed on ice. The sealed PCR plate was put in Stratagene MX3005P qPCR 
machine and incubated at 25 ℃ for 10 min, followed by a gradient temperature rising to 95 ℃ 
at 1 ℃/min. 
 
2.4.4 Analytical ultracentrifugation 
 
The Vif tetramer was concentrated to approximately 1 mg/ml measured by NanoDrop and 
diluted into 0.7 mg/ml and 0.5 mg/ml to obtain three concentrations. Each sample was run in a 
Beckman Coulter XL-A centrifuge. The experiments and analysis were performed by 
Dr. Rebecca Beavil at the Randall Division. 
 
2.4.5 Isothermal titration calorimetry 
 
Protein samples are purified from a sizing column and dialysed into a binding buffer, and 
concentrated to the required concentrations. 300 μl of 0.02 mM SOCS-box or mutants were 
placed in the chamber of MicroCal® ITC200 calorimeter and 2 μl aliquots of 0.2 mM EloBC 
was injected at 4 min intervals. The data were plotted using a single binding site model by the 
ITC software ITC200 with the Origin software provided with the calorimeter. The concentration 
of SOCS-box was measured by NanoDrop spectrophotometer and that of EloBC was measured 
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by the BioRad® PROTEIN ASSAY Dye Reagent Concentrate. 
 
2.4.6 Mass spectrometry 
 
In order to prepare the sample for Time-of-Flight mass spectrometry (ToF-MS), purified 
protein was mixed with loading buffer and run on a large SDS-PAGE. Bands stained by 
Coomassie blue ware cut and kept in water. The experiments and analysis were performed by 
Dr. Steve Lynham at the Proteomics Facility, Kings College London, Denmark Hill Campus. 
 
 
2.5 Nuclear magnetic resonance (NMR) theory 
 
2.5.1 NMR mathematical and physical principles 
 
NMR was first described by the American-Hungarian physicist Isidor Rabi who was 
awarded the Nobel prize for the discovery (Rabi, Millman et al. 1939) in molecular beam 
experiments. The overall spin of a nucleus is defined by a scalar quantity called the spin 
quantum number. All isotopes containing an odd number of nuclides have a non-zero spin 
whereas an isotope with an even number of nuclides has spin 0. Isotopes which are widely used 
for protein NMR are listed in table 2.3 below. 
A non-zero spin is defined by a non-zero magnetic moment μ according to equation (1): 
S                                    (2.1) 
where γ is the gyromagnetic ratio and S is the angular momentum. This means each moment is 
quantized. It is the magnetic moment that determines whether a spin system can be observed 
by NMR. In an external magnetic field, a spin system usually has two states, either parallel or 
anti-parallel with respect to the field. If the z axis is chosen for B0, the energy E is given by 
equation (2): 
0E mB                                  (2.2) 
Obviously, as for m=1/2 illustrated in figure 2.1, it is easy to calculate that the energy difference 
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between two states, namely 
0E B                                   (2.3) 
The populations of parallel and anti-parallel spins have a Boltzmann distribution, in which 
case the population rate of up-state β spin Nβ to the down-state α spin Nα is: 
// E kTN N e 
                            (2.4) 
where T is the absolute temperature in Kelvin and k is a constant whose unit is J/K. 
 











In NMR, relaxation is an important term that describes the process of a spin returning the 
equilibrium state from a non-equilibrium state. There are two main relaxation processes 
characterized by the relaxation time constant T1 and the relaxation time constant T2. T1, the 
spin-lattice relaxation time, is the decay constant with which the excited z component vector, 
Mz, reverts backs to its thermal equilibrium state M0. It is defined by the equation (5): 
1/
0 0( ) [ (0) ]
t T
z zM t M M M e
                        (2.5) 
T2 is called the spin-spin relaxation time, or transverse relaxation time and corresponds to a 
dephasing of magnetization between spins. This decay constant is defined by the equation (6): 
2/( ) (0) t Txy xyM t M e
                           (2.6) 
In most situations, T1 is larger than T2, but not in principle (Levitt 2008). 
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In 1948, Nicolaas Bloembergen, et al. presented a theory which accurately explained many 
experiments, taking into account the effect of the tumbling motion of a large molecular 
(Bloembergen, Purcell et al. 1948). In solution, molecules tumble at a certain rate determined 
by temperature, viscosity of solution and molecule weight. This motion is termed the correlation 
function G: 
/( ) (0) ctG t G e                               (2.7) 
Both T1 and T2 decay constants are related to the overall correlation time τc (figure 2.2). 
 
2.5.2 NMR spectroscopy 
 
In NMR, active nuclei will have an absorption at a frequency characteristic of each isotope 
which is termed the ’resonance frequency’. The energy of absorption and the signal acquired 
later are in proportion to the magnitude of external magnetic field, which means that higher 
field NMR spectrometers, such as 700 megaHz (MHz), 800 MHz or even 1 GHz are much more 
suitable for large biological macromolecules. 
Signals are acquired from NMR detectors in the form of a radiofrequency pulse with ranges 
of frequency centred on the Lamor frequency, followed by a signal decay (known as free 
induction decay, FID). This time-domain signal must be converted to a frequency-domain 
formula by Fourier transform: 
2( ) ( ) itvf v g t e dt                            (2.8) 
where v represents a particular frequency and t is the time of FID. 
The chemical shift δ is a measured unit which is related to the resonance frequency, used 
for describing the dependence of energy levels in a molecule (Kemp 1987, Balci 2005). 
Different types of isotopes, e.g. 1H, 13C and 15N that are widely used in protein research, usually 
behave differently depending on many factors, such as coupling, binding partner, proton 
distance and of course, the local magnetic field which means in practice every single atom has 










Figure 2.2: The relationship between correlation time (τ) and two relaxation time T1 and T2. ω0 is 
the Larmor frequency.  
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                               (2.9) 
where ω is called Larmor frequency of a spin and ω0 is the resonance frequency of a reference 
substance, usually tetramethylsaline (TMS) (Keeler 2005). 
 
Some important information is acquired from the scalar coupling or J-coupling between 
NMR active nuclei rising from the interaction between different spin states, which leads to a 
splitting of the NMR signals (Keeler 2005). For instance, for 1/2 spin systems, coupling to an 
equal nuclei will be split into n+1 multiple signals whose intensity follows Pascal’s triangle 
(table 2.4): 
 
Table 2.4, Pascal’s triangle for a J-coupling system 
 








This splitting pattern is dependent on the nature of atoms as well as the connecting bond. 
Furthermore, magnetization on a spin, typically 1H, can be transferred to its neighbouring spin, 
usually 13C and 15N, via their covalent bonds by the use of precisely-designed pulse sequences 
of radio-frequency pulses. This is called correlation spectroscopy (COSY), a kind of two-
dimensional (2D) NMR spectroscopy. The intensities of chemical shifts in a 2D spectrum can 











Figure 2.3: 3D NMR spectra cartoons. (A) In a particular plane, some peaks (small circles) from 
neighbouring spin system can be seen in the spin strip. The intensity of the peaks can be used to 
calculate the distance between the two spins. (B) In a HNCACB spectrum, Cα and Cβ peaks from 
current (blue and green) and previous residues that usually give peaks with low intensity (yellow) 
are visible in one strip, which enables one to assign all peaks in order. The intensity of peaks 
corresponding to current residues are usually stronger because of the energy transfer distance. Some 




There are several merits to 2D or 3D NMR. First, more dimensions help to better separate 
peaks for a many-spin system, especially for high molecular-weight molecules, therefore peaks 
will not overlap each other, which means it is much easier to conduct assignment. Besides, 
heteronuclear NMR allows one to analyse the interaction among different types of isotopes. 
Finally, multi-dimensional NMR, specifically, the nuclear Overhauser effect (NOE) 
spectroscopy (NOESY), can provide more information on side-chains and distance restraints 
for structural studies (figure 2.3A). 
 
2.5.3 Fundamentals of spectral assignment 
 
NMR signals are detected and acquired by special probes in the spectrometers. As 
described briefly above, peaks in ‘chemical shift’ units are converted from resonance frequency 
and are displayed on the control interface. For a particular protein structure, each isotope in the 
protein, such as 1H, 13C and 15N, has its own resonance frequency determined by the intrinsic 
non-zero spin and the other spin systems around it, which means a peak with unique 1H, 13C 
and 15N chemical shift on a spectrum always comes from the same residue. Based on this idea, 
a general backbone assignment protocol is used to start identifying amino acid residues to which 
peaks are corresponding. 
1H-15N heteronuclear single quantum coherence spectrometry (HSQC) is usually regarded 
as the starting spectrum or standard spectrum (Cavanagh 2007). 3D 13C spectra, including 
HNCACO, HNCACB and CBCACONH are used for the backbone assignment (figure 2.3B) 
because sequential backbone carbons, i.e. Cα and Cβ, can be identified by following the carbon 
chemical shifts in a strip where peaks from previous and current amino acids appear. 
CC(CO)NH (Bax and Ikura 1991, Grzesiek and Bax 1993), total correlation spectrometry 
(TOCSY) (Bax, Clore et al. 1990) and NOESY (Marion, Driscoll et al. 1989) are usually 
applied for side-chain assignments. 
In this project, the side-chain assignments for the Vif SOCS-box monomer was based on 
NOESY and TOCSY spectra together with Dr. Julien Bergeron’s backbone assignment 
(unpublished). HNCO, HCCH-COSY, HCCH-TOCSY, 15N-edited NOESY-HSQC, 13C-edited 
NOESY-HSQC spectra were recorded in order to assign SOCS-box sequence in complex. 
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HNCO, HNCACO, CBCACONH, HNCA, HNCACB, HCCH-TOCSY, 1H-15N TROSY-HSQC 
and 13C-edited NOESY-HSQC spectra were taken into account for EloBC assignments. Jeffrey 




2.6 NMR spectroscopy experiments 
 
2.6.1 NMR acquisition and processing 
 
All NMR samples were prepared as stated above. Sigma NMR tubes with the required 
550 μl sample volume were used for each experiment. All the experimental details are listed in 
table 2.5. TOPSPIN_3.0 was used for acquisition on a Bruker machine. Software VNMR was 
used for acquisition on a Varian machine. Raw data from NMR spectrometers was processed 
and transformed by NMRPipe (Delaglio, Grzesiek et al. 1995). Assignment, NOESY distance 
restraint calculations, dihedral constraint calculation and paramagnetic relaxation enhancement 
measurements were executed by using the CcpNmr suite (Fogh, Boucher et al. 2005, Vranken, 
Boucher et al. 2005). 
 
2.6.2 NMR titration 
 
15N-labelled SOCS-box NMR sample was prepared as usual with a final concentration of 
0.2 mM in 500 μl phosphate buffer. Unlabelled EloBC sample was concentrated to 0.5 mM and 
added to SOCS-box sample with a gradient ratio (EloBC : SOCS) 0.25:1, 0.5:1, 0.75:1, 1:1 and 
1.2:1. The pulse-program was copied to each experiment to keep all parameters the same. As 
for the perturbation studies, each EloBC mutant sample was prepared in the same way as wild 
type and divided into two aliquots. Purified SOCS-box peptide was added to one aliquot at a 




Table 2.5 Summary of NMR spectroscopy experiments (Up to April 30, 2013) 
 
Date Location/Lab Protein Name [conc] / mM T / ℃ Labelling Spectrum Spectrometer 
30/10/2010 NMRCa, Mill Hill SOCS -EloBCb 0.16 25 15N SOCS 3D-NOESY Bruker 700 MHz 
27/11/2010 NMRC, Mill Hill SOCS -EloBC 0.2 25 15N both 3D-NOESY Bruker 700 MHz 
13/12/2010 NMRC, Mill Hill SOCS -EloBC 0.2 25 15N SOCS 3D-NOESY Varian 800 MHz 
17/01/2011 Wolfson Wing, KCL SOCS -EloBC 0.4 25 13C, 15N SOCS COSY, TOCSY, C/H-CCONHc Bruker 700 MHz 
20/01/2011 NMRC, Mill Hill SOCS and EloBC 0.16 4d 15N SOCS Titration, T gradient, 3D-NOESY Bruker 700 MHz 
01/02/2011 Wolfson Wing, KCL SOCS -EloBC 0.4 - 13C, 15N SOCSe T gradient, 25, 30, 37 Bruker 700 MHz 
10/02/2011 NMRC, Mill Hill SOCS monomer 0.5 25 13C, 15N SOCS 13C-HSQC, 15N-TOCSY, NOESY Varian 800 MHz 
08/03/2011 Wolfson Wing, KCL SOCS -EloBC 0.2 30 15N EloBC HNHA Bruker 700 MHz 
31/03/2011 NMRC, Mill Hill SOCS -EloBC 0.2 25 13C, 15N SOCS 13C-NOESY, HNCO Bruker 700 MHz 
05/05/2011 Wolfson Wing, KCL SOCS -EloBC 0.4 30 15N both HSQC in 20/50 mM buffer Bruker 700 MHz 
22/05/2011 Wolfson Wing, KCL SOCS -EloBC 0.25 30 13C, 15N EloBC 13C-TOCSY, NOESY Bruker 700 MHz 
14/06/2011 Wolfson Wing, KCL SOCS -EloBC 0.27 37 15N SOCS `15N-HSQC for RDC Bruker 700 MHz 
23/06/2011 NMRC, Mill Hill 
SOCS -EloBC 0.1 37 15N SOCS 15N-HSQC for RDC 
Varian 800 MHz 
SOCS -EloBC 0.4 25 15N both 15N-NOESY 
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21/07/2011 NMRC, Mill Hill SOCS -EloBC 0.4 25 15N both 15N-TOCSY, 150 ms NOESY Bruker 700 MHz 
19/01/2012 NMRC, Mill Hill SOCS -EloBC 0.37 30 L, Q on EloBCf Trosy-13C-HNCO Varian 800 MHz 
14/02/2012 NMRC, Mill Hill SOCS -EloBC 0.2 30 L, Q on EloBC Trosy-13C-HNCO Bruker 700 MHz 
15/02/2012 Wolfson Wing, KCL SOCS -EloBC 0.2 25 15N EloBCg 15N-HSQC for RDC Bruker 700 MHz 
10/05/2012 NMRC, Mill Hill MIII-EloBCh 0.1 30 15N SOCS 15N-TOCSY, NOESY Varian 800 MHz 
11/05/2012 Wolfson Wing, KCL SOCS MIIIi 0.21 30 15N SOCS 15N-TOCSY, HNHA Bruker 700 MHz 
19/07/2012 NMRC, Mill Hill HIV2 SOCS 0.02 25 13C, 15N HNCA Bruker 700 MHz 
30/08/2012 NMRC, Mill Hill HIV2 SOCS 0.04 25 13C, 15N HNCA Varian 800 MHz 
17/10/2012 Wolfson Wing, KCL SOCS *-EloBC 0.055 25 15N EloBC 15N-HSQC for paramagnetic Bruker 700 MHz 
30/10/2012 NMRC, Mill Hill HIV2 SOCS 0.1 25 15N 15N-NOESY Bruker 700 MHz 
08/11/2012 NMRC, Mill Hill HIV2 SOCS 0.05 25 13C, 15N HNCOCA Bruker 700 MHz 
20/12/2012 NMRC, Mill Hill SOCS 0.2 25 13C, 15N 13C-TOCSYj Varian 800 MHz 
15/01/2013 NMRC, Mill Hill SOCS 0.2 25 13C, 15N HCCCONHk Bruker 700 MHz 
17/01/2013 Wolfson Wing, KCL SOCS -EloBCMl 0.05 25 15N EloBC 15N-HSQC for binding test Bruker 700 MHz 
25/01/2013 Wolfson Wing, KCL SOCSk 0.2 25 13C, 15N HCCCONH Bruker 700 MHz 
28/01/2013 Wolfson Wing, KCL SOCS -EloBCM 0.2 25 15N EloBC 15N-HSQC for binding test Bruker 700 MHz 
28/02/2013 NMRC, Mill Hill HIV2 SOCS 0.05 25 13C, 15N HNCACB Bruker 700 MHz 
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14/03/2013 Wolfson Wing, KCL 
SOCS -EloBCm 0.19 25 15N EloBC 15N-HSQC for binding test 
Bruker 700 MHz 
SOCS -EloBC 0.15 25 13C, 15N EloBC 13C, 15N-inter-NOESY 
11/04/2013 NMRC, Mill Hill SOCS -EloBCn 0.1 25 13C, 15N EloBC 13C-inter-NOESY Varian 800 MHz 
a. NMRC is the abbreviation of National Medical Research Centre. KCL is the abbreviation of Kings College London 
b. ‘SOCS -EloBC’ stands for the complex of SOCS and EloBC. ‘SOCS and EloBC’ stands for two subunits separately according to experiments. 
c. Two spectra, CC(CO)NH and H(CCO)NH. 
d. NOESY was run at 4 ℃. 
e. The sample is the same one run on 17/01/2011. 
f. 13CO-labeled proline and glutamine. Selectively-labeled EloBC in complex, 100% deuterated. 
g. The same aliquot from sample 14/02/2012. 
h. SOCS mutation III: P164S 
i. The same aliquot from sample 11/05/2012 
j. With two different mixing time: 8 ms and 17 ms. 
k. The sample is the same one run on 20/12/2012. But the spectrum failed. 
l. Three mutants: 101A, 102A and 103A. 
m. Free EloB104 mutant was run first. Then SOCS -EloB104 complex. 
n. 3/14 sample was changed to 100% D2O buffer by using a sizing column and the experiment repeat using the same pulse-program on Varian. 
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Table 2.5 Summary of 3D spectra parameters (Continue) 
 
Date Spectrum Protein Name Pulse-program Mixing time Running time 
27/11/2010 3D-NOESY SOCS -EloBC mh_wgnoesyhsqc_n15 90 ms 70 hrs 




hcchcogp3d 60 ms 22 hrs 
TOCSY hcchdigp3d 60 ms 22 hrs 
C -CCONH hccconhgpwg3d3  66 hrs 
H-CCONH hccconhgpwg3d2  40 hrs 




/ 70 ms 44 hrs 
15N-NOESY / 90 ms 46 hrs 




mh_c13noesy_tf_4 90 ms 69 hrs 




hcchdigp3d ?b 25 hrs 
13C- NOESY hesyhsqcetgp3d 120 ms 47 hrs 
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dipsihsqcf3gpso3d 60 ms 33 hrs 
15N-NOESY noesyhsqcf3gp193d 150 ms 58 hrs 




/ 40 ms 34 hrs 




dipsihsqcf3gpsi3d ?b 47 hrs 
HNHA hnhagp3d  45 hrs 
19/07/2012 HNCA HIV2 SOCS hncagpwg3d  63 hrs 
30/08/2012 HNCA HIV2 SOCS /  60 hrs 
30/10/2012 15N-NOESY HIV2 SOCS mh_wgnoesyhsqc_n15 90 ms 46 hrs 
08/11/2012 HNCOCA HIV2 SOCS hncacogpwg3d  91 hrs 
20/12/2012 13C-TOCSY SOCS 
/ 8 ms 27 hrs 
/ 17 ms 43 hrs 
15/01/2013 HCCCONH SOCS hccconhgpwg3d3  20 hrs 
25/01/2013 HCCCONH SOCS hccconhgp3d2  72 hrs 




13C-inter-NOESY SOCS -EloBC 
SOCS -EloBC 
noesyhsqcgpwgx13d 100 ms 66 hrs 
15N-inter-NOESY Noesyhsqcf3gpwgx13d 100 ms 46 hrs 
11/04/2013 13C-inter-NOESY SOCS -EloBC / 125 ms 85 hrs 
a. The pulse-programs from Varian machines are not listed here. All parameters were recorded in procpar file in each experiment. 
b. The mixing time was not found in the log files (acqu or pulse-program files). 
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2.6.3 Paramagnetic relaxation enhancement studies 
 
Gly-143, Asn-158 and Arg-167 of the SOCS-box peptide were mutated to Cys respectively 
in order to insert a Cys point-mutation for use in paramagnetic labelling. These three residues 
are selected for the reason that they are known to be outside two functional regions, the BC-
box and the PPLPS motif, and have less biological functions. All mutants had been checked by 
ITC to verify that the mutation did not interfere with the binding affinity of SOCS-EloBC. The 
mutant protein was mixed with an approximately 5-fold excess of dithiothreitol (DTT) for two 
hours after elution from the Ni-NTA column. This was followed by separation of excess DTT 
by gel filtration chromatography. The SOCS-box monomer sample from the sizing exclusion 
column was collected and incubated with either the diamagnetic (1-acetyl-2,2,5,5-tetramethyl-
Δ3-pyrroline-3-methyl) methanethiosulphonate or the paramagnetic (1-oxyl-2,2,5,5-
tetramethyl-Δ3-pyrroline-methyl) methanethiosulphonate (Toronto Research Chemicals) 
overnight at 4 ℃. The modified SOCS-box sample was dialyzed against NMR buffer and 
mixed with 15N-labelled EloBC in NMR buffer at a 1.1:1 ratio. The mixed sample was then 
transferred to an NMR tube for NMR data acquisition. A 1H-15N HSQC spectrum was recorded 
for each 50 μM sample with three-hour acquisition. Intensity ratios were converted to distances 
according to an established model optimized from the Solomon–Bloembergen equation 
(Battiste and Wagner 2000). 
 
 
2.7 Solution structure calculation and analysis 
 
2.7.1 Fundamentals of structure calculation 
 
As is detailed in the NMR theory part, each spin, i.e. 1H, 15N and 13C in this work, has its 
particular physical character such as spin state, angular momentum, coupling frequency, 
resonance, etc, affected by the spin type and the surrounding micro-environment. These unique 
characteristics of a spin are displayed as chemical shifts and peak intensity in the spectra, and 
thus distances between 1H spins are able to be acquired, from which the orders of a group of 
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residues in the solution can be calculated. As for the protein, by similar protocols, the orders of 
amino acid residues in a sequence are able to be determined. 
Currently several tools are developed to determine NMR solution structures. The most 
common and typical way for a single macro-molecule to be solved is by using distance restraints 
from NOESY spectra, which has been widely used in the past decades of years (Banks, Hare et 
al. 1989, Nerdal, Hare et al. 1989). Briefly, under a NOESY pulse-program, there is a nuclear 
Overhauser effect (NOE) (Overhauser 1953) between two protons that are closer to each other 
in space within 5 Å. In a 3D spectrum, the resonance from one spin can be observed on the 
other spin and its strength is decreased according to the real distance between these two spins 
according to the principle that the strength is proportional to the inverse sixth power of the 
distance (Anderson and Freeman 1962). Each distance matches a pair of assigned protons 
between which a NOE transfer takes place through space rather than through bonds and is used 
as a distance restraint in structural calculations. Therefore, NMR solution structures can be 
determined from hundreds of these distance restraints. 
Residual dipolar coupling (RDC) data is another common restraint in studies of 
biomolecular structures (Deloche and Samulski 1981, Tjandra, Garrett et al. 1997, Tjandra, 
Omichinski et al. 1997). This type of experiments is based on the idea that a molecule 
surrounded by liquid crystals such as lipid bicelles is aligned to an external magnetic field at a 
particular orientation, which provides a unique angle vector θ of each bond such as N-H or C-
H relative to the external magnetic field. This angle can be derived from the following formula: 
2






   

                     (2.10) 
where DIS represents the residual coupling observed from spectra and r represents the distance 
between two spins. γI and γS are the gyromagnetic ratios of spin I and S respectively (Tolman, 
Flanagan et al. 1995). Differing from NOE distance restraints, RDCs provide global long-
distance restraints considering that they provide relative orientations of some regions of a 
protein that are far apart in space. For example, in α-helix the angles of N-H bonds towards the 
external magnetic field are in theory the same whereas in an anti-parallel β-sheet angles on one 
sheet are opposite to those on the other sheet. One advantage of this technique is that it is less 
time-consuming compared to NOESY methods. The other advantage is that it does not require 
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the side-chain assignments, which prevents the errors from ambiguous NOESY data and poor-
quality distance measurements. By this technique the relative orientations among long-distance 
separated residues can be acquired, thus determining the structures. 
Site-specific labelling with paramagnetic tags is a newly-developed method providing 
greater distance restraints in recent years (Battiste and Wagner 2000). Briefly, the cysteine-
connected chemical label, known as paramagnetic chemical, broadens peaks from residues 
closest to the label, which is called a paramagnetic relaxation enhancement effect. Its 
diamagnetic analogue, the control, does not generate such an effect. Similar to the NOE effect, 
the intensity is proportional to the inverse sixth power of the distance (Battiste and Wagner 
2000). This phenomenon is observed between two spins up to 25 Å away. Another characteristic 
of this method is that only one cysteine is allowed in a protein sequence, which means that the 
observed effect happens exactly between an assigned residue and the labeled cysteine site. Due 
to these advantages, PRE is useful in studies of complexes (Korotkova, Yang et al. 2008). All 
these methods used to acquire long-distance restraints, including various pseudo-contact shift 
methods, have been well reviewed (Saio, Yokochi et al. 2010, Su and Otting 2010). 
Besides the experimental-data-dependent structure calculations, structural modelling or 
prediction is becoming more advanced and reliable with the development of algorithms and 
computer clusters. One of the robust modelling software is the Chemical-Shift-ROSETTA (CS-
Rosetta) (Shen, Lange et al. 2008, Shen, Vernon et al. 2009). This approach requires the input 
of the backbone assignments (NH, Hα, CA, CB, CO, N). In the first step, it performs data 
mining in the structural database where protein chemical shifts are deposited according to the 
assignment so as to acquire hundreds of fragments. These fragment candidates are used to 
assemble all-atom models by a Rosetta Monte Carlo protocol in the second step. The generated 
models are evaluated against the initial chemical shifts by SPARTA (Shifts Predicted from 
Analogy in Residue type and Torsion Angle) (Shen and Bax 2007). In the final step, all models 
are re-scored and aligned to the model with the lowest energy. If clustering around the lowest 
energy structure is converged, this run of calculations is regarded as ‘successful’. It is of note 
that distance restraints and RDC data are now combined with CS-Rosetta, which improves the 
accuracy of the modelling. However, the disadvantage of this method is that it requires large 
calculation capability, i.e. computer clusters and storage space. For a single processer, it takes 
71 
 




2.7.2 Protein structure calculation 
 
In this study, the SOCS-box peptide structure was generated by CS-Rosetta on the 
Biological Magnetic Resonance Bank (BMRB) CS-ROSETTA server 
(condor.bmrb.wisc.edu/bbee/rosetta/) and accepted according to the principles of CS-Rosetta 
(Shen, Vernon et al. 2009). The structure with the lowest energy was further refined according 
to the Rosetta refinement protocol (Ramelot, Raman et al. 2009). EloB and EloC structures 
were generated de novo as well on the server and accepted when the r.m.s.d. was less than 0.5 Å 
against the published crystal structure (PDB ID: 3DCG). 
Vif SOCS-box was docked onto the EloBC dimer by a High Ambiguity Driven 
biomolecular DOCKing (HADDOCK) approach (Dominguez, Boelens et al. 2003, de Vries, 
van Dijk et al. 2007) on the WeNMR web server (de Vries, van Dijk et al. 2010). In the process 
of docking, 5 residues in SOCS-box (Gln-146, Ala-149, Leu-163, Pro-164, Ser-165), 4 residues 
in EloB (Asp-101, Val-102, Met-103, Lys-104) and 2 residues in EloC (Ala-82, Leu-86) were 
selected as active residues. The interfacial residues sitting between the SOCS-box proline-rich 
motif and the C-terminus of EloB were allowed to move fully at all stages. A file with distance 
restraints from PRE and the published crystal structure (PDB ID: 3DCG) are provided with 
coordinate files and the restraints were always enforced during the calculation. Two thousand 
initial structures of the complex were generated and the best two hundred structures were 
chosen for explicit solvent refinement. The cutoff of the cluster is 5 Å, 5 structures per cluster. 
Default parameters excluding the settings above were taken. 
 
2.7.3 Structural refinement and analysis 
 
The best structure of the complex from the top cluster generated by the HADDOCK 
modelling interface was used for the further refinement through the refinement interface on the 
72 
 
server. 20 structures with the lowest energy were chosen as the final structures. Pymol was used 
to analyze the structures and to generate structural figures (Schrodinger 2010). The quality of 
structure coordinates was determined by PROCHECK (Laskowski, Rullmannn et al. 1996) and 
iCing (Doreleijers, Sousa da Silva et al. 2012). Assignments vs coordinate validation was 





2.8.1 Overview of X-ray crystallography 
 
X-ray crystallography is the most widely used method to obtain structures of biological 
macromolecules. Recent developments enable X-ray crystallography to solve various sizes of 
small molecules as well as proteins ranging from less than 10 kDa to over hundreds of kDa. 
The first protein structure solved by X-ray crystallography was completed in 1958 (Kendrew, 
Bodo et al. 1958) and the biological molecular structure best known to the public is the DNA 
double-helix, published in 1953 (Watson and Crick 1953). Conclusively, compared to NMR 
spectrometry and cryo transmission electron microcopy, X-ray crystallography has several 
advantages: 
1) Almost all sizes of proteins are able to be investigated by X-ray crystallography. 
2) X-ray crystallography is the only technique that provides structural information at 
atomic resolution. 
3) Crystal data obtained from a single solid state can be more accurate, whereas NMR 













Figure 2.4: X-ray generation. Electron beams with high energy hit a copper anode, knocking out 





X-ray radiation is a form of very short wavelength radiation (0.01-10 nm) generated from 
electron falling from a higher state to lower state. In order to produce X-rays, a high energy 
electron beam is accelerated using a high voltage to knock out electrons from inner orbitals of 
the atoms of the anode which is made of metals like zinc or copper. Electrons in higher orbitals, 
i.e. with higher energy, subsequently fall into the low-energy shells, releasing energy in the 
form of radiation. The radiation generated has a certain amount of X-ray quanta whose 
wavelength is dependent on the anode material (figure 2.4). Currently more X-ray sources from 
synchrotron radiation sources (SRS) are more used instead of in-house equipment because SRS 
is able to generate rays with less than 1 Å wavelength, which gives higher resolution data and 
improves the possibility of studying small crystals. 
 
2.8.2 Fundamentals of crystallization 
 
It is no doubt that in crystallography the first step, also one of the most critical and 
challenging steps, is to obtain a crystal of a high-quality in terms of its X-ray diffraction. The 
basic idea of growing crystals is to mix protein samples with a precipitant which is used for 
moving the protein sample to a supersaturated state in solution. In a certain kind of solution 
condition, there are three phases associated with increasing concentration of protein and 
precipitant respectively, which can be simply plotted on a phase diagram (figure 2.5). In the 
first phase, i.e. low amount of proteins and precipitants, proteins are undersaturated. After 
improving the concentration of proteins and precipitants, proteins go into the second phase 
called the metastable zone where crystals usually grow. In the third phase where there is a high 
concentration of proteins and precipitants, proteins aggregated and start precipitating. It is 
worth mentioning that in order to form a crystal, proteins generally enter phase III to nucleate 
before re-entering to phase II (figure 2.5). The nucleation state in phase III is therefore 
specifically termed the nucleation zone. The full path of crystal formation and growth is 








Figure 2.5: Protein phase diagram. The dotted line and arrow represent the pathway of forming 





Figure 2.6: Vapour-diffusion equipment. Equilibration is established by vapouration in the room 




To achieve crystallization, two methods are widely used based on vapour-diffusion 
principle. The first method is named ‘hanging drop’ (figure 2.6A), in which the mixture of 
protein and solution is added and hung on a siliconised coverslip. The other one is named 
‘sitting drop’, in which the mixture is loaded into a well in a small sealed space (figure 2.6B). 
In both methods, the precipitating solution is equilibrated against a large amount of that in the 
reservoir through evaporation, during which the phase of the solution changes slowly. 
A crystal can be described as a three-dimensional array where molecules are assembled in 
a very strict geometrical order. A crystal cell, or a unit cell, is viewed as the basic component 
of a crystal which has internal symmetry to other cells. The symmetry of a unit cell, or a space 
group, is revealed at a diffraction level as equal intensities of reflections in rotational symmetry 
and systematic absences in translational symmetry. There are six parameters to describe a 
crystal cell, a, b and c standing for three axes, and α, β and γ corresponding to angles between 
each axe (figure 2.7). Depending on the values of each parameter, a crystal lattice is classified 
as: 
i. Cubic (a = b = c, α = β = γ = 90) 
ii. Trigonal (a = b ≠ c, α = β = 90,γ = 120) 
iii. Tetragonal (a = b ≠ c, α = β = γ = 90) 
iv. Rhombohedral (a = b = c, α = β = γ ≠ 90) 
v. Orthorhombic (a ≠ b ≠ c, α = β = γ = 90) 
vi. Monoclinic (a ≠ b ≠ c, α = β = 90,γ ≠ 90) 
vii. Triclinic (a ≠ b ≠ c, α ≠ β ≠ γ ≠ 90) 
 
2.8.3 Fundamentals of X-ray diffraction and structure determination 
 
Once a crystal is obtained and placed in the X-ray beam, it diffracts X-rays and thus 
generates diffraction according to the Bragg’s law (figure 2.8): 
2 sin( )d n                              (2.11) 
where θ is the angle of incidence and d is the distance between two planes of crystals. 
 Miller indices (h, k, l) are used to describe a crystal which is regarded as a series of 
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molecular planes. The three coordinates in Miller indices are defined as h = a/aˊ, k = b/bˊ, l = 
c/cˊ, where aˊ, bˊ, cˊ are the coordinates at which the plane (h, k, l) intersects axes a, b and c 
respectively. By this, the reciprocal lattice vector for a certain plane is defined as: 
* * *
hklG ha kb lc                              (2.12) 













                    (2.13) 
Therefore, when atom j within a unit cell is observed by X-ray beams and the phase defined 
as sr of an electron of the atom is an integer, the phase differences between atoms are 2nπ and 
the scattering vector s of atom j is defined as: 
2 ( )j j j j j j jr s asx bsy csz hx ky lz                     (2.14) 
where rj is the coordinate of individual electrons, s is the vector of scattering wave and xj, yj, zj 
are the fractional coordinates of atom j. If the electron density is continuous throughout a unit 




F r ir s dv                           (2.15) 
in which ρ(r) is the electron density in the space at position r. Subsequently, the electron density 
can be calculated from the structure factor by an inverse Fourier transformation: 
1( ) exp( 2 )hkl
h k l
r F ir s
V
                       (2.16) 
where V is the volume of a unit cell. By applying the Friedel’s law that intensity of a reflection 
is equal to that of its centro symmetric related reflection, i.e. I(h, k, l) = I(-h, -k, -l) 
mathematically and replacing r*s with the equation (14), equation (16) can be substituted to: 
1( ) | | cos(2 ( ) )hkl j j j hkl
h k l
r F hx ky lz
V
                (2.17) 
In the equation (17) the new parameter Фhkl is the phase for the structure factor |F|(hkl) amplitude 
and cannot be acquired directly from experiments, which is known as the phase problem in 
crystallography. After the phase is determined, equation (17) is finally applied to calculate an 
electron density map, where the electron density indicates positions of atoms and the height of 
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density is proportional to the number of electrons in an atom. 
In order to address the phase problem and thus to solve the structure, there are several 
methods available. Experimentally, if a crystal is co-crystallized with some heavy atoms that 
occupy specific positions within the unit cell without disturbing original structures, the structure 
factor differences between data sets collected from native or derivative samples can be used to 
establish the positions of the heavy atoms by using known heavy atom positions (Green, Ingram 
et al. 1954). Similarly, the single anomalous diffraction method is another alternative to localize 
some specific atoms (Rice, Earnest et al. 2000). This idea is based on the fact that at certain 
wavelengths some atoms diffract X-rays anomalously. Positions of these atoms are acquired 
from the collected data sets are thus used to restore the phases. 
Besides the experimental methods, Molecular Replacement method (MR) is a widely-used 
way to address the phase problem using only the originally collected data sets. Briefly, 
previously-solved structures of homologous macromolecules are used as starting models. In the 
first step, the starting model is used to calculate structure factors and phases during each 
replacement, which are then compared with experimental structure factors. In the second step, 
structure factors, including observed and calculated factors, and the model phases are applied 
in mapping the electron density that, in turn, is used to correct the generated model. This process 
of correcting models is called refinement which is repeated until calculated structure factors 
have a satisfactory agreement with experimental structural factors. Detailed information on MR 
has been reviewed by Delarue (Delarue 2008). 
The resolution of a model is an important criterion that decides what kind of information 
can be obtained from crystals and diffraction. Usually a larger and more ordered crystal is able 
to provide higher resolution, and as a result the composition of a unit cell can be observed more 
clearly. Basically, around 6 Å resolution only suggests the arrangement of α-helices. Positions 
of side-chains are resolved at 3 Å resolutions whereas the position of each atom can only be 















Figure 2.8: The diagram of Bragg's law. The incident angle is θ and the distance between two crystal 




2.8.4 Vif/EloBC/CBFβ complex crystallization 
 
The sample of Vif/EloBC/CBFβ complex was concentrated to 4 mg/ml. As for high-
throughput condition screening (HTS) in  Hauptman Woodward Medical Research Institute 
(HWI) (Buffalo, New York, U.S.A.), 700 μl sample was prepared each time and shipped in a 
thermos covered by ice bags to the lab, which usually took four days to arrive. Various types of 
crystallization kits were tested in 96-well sitting-drop MRC plates (Molecular Dimensions) set 
by Mosquito® in-house. A 0.6 μl protein sample was mixed with 0.6 μl and 0.3 μl crystallization 
solution respectively. As for hanging-drop scanning, 500 μl solution was added in the reservoir 
of a 24-well Linbro-style vapour diffusion plate (Molecular Dimensions). Protein and solution 
was mixed on a siliconized cover slide (Jena Bioscience) which was sealed onto the reservoir. 
All plates set up in-house were placed in a cold room (4 ℃). Crystals were checked for 
diffraction by using a PX-scanner manufactured by Agilent. 
 
 
2.9 Biological assays 
 
2.9.1 Immunoblot analysis 
 
To test the Vif expression and purification from E. coli, 2 μl of 10-fold diluted samples in 
each purification step was added onto a 15% acrylamide gel. For the western blotting from 
cellular assays, 15 μl of each sample was loaded onto 15% acrylamide gel. Gel was run at 
120 volts for 2 hours. Afterwards proteins were transferred onto a nitrocellulose membrane at 
16 V overnight in transfer buffer (20% methanol, 0.2 M glycine, 0.1% SDS, 27.6 mM Tris). 
The membrane was blocked in blocking buffer (2.7 mM KCl, 137 mM NaCl, 2 mM KH2PO4, 
10 mM Na2HPO4, pH 7.4, 0.5% Tween-20, 2% milk) for one hour, and then incubated with 
appropriate primary antibodies diluted to the acquired concentration in PBST buffer (2.7 mM 
KCl, 137 mM NaCl, 2 mM KH2PO4, 10 mM Na2HPO4, pH 7.4, 0.5% Tween 20) for one hour 
or overnight. After washing with PBST buffer three times, three minutes each, membranes were 
incubated with appropriate HRP-conjugated secondary antibodies for one hour. After three 
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washes of 5 min each in PBST buffer, proteins were detected by Thermo Scientific® Pierce* 
ECL Plus western blotting substrate and visualized using the Odyssey® imaging system (LI-
COR). 
 
2.9.2 Cell culture and transfection 
 
293T cells derived from human embryonic kidney fibroblasts were cultured in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 1% penicillin and 10% fetal bovine at 
37 ℃ in 5% CO2. Cells are dealt with TripLETM and split every two days. 
To transfect DNA into 293T cells, the appropriate amount of DNA was mixed with 4 ug of 
polyethylenimine (PEI, working stock concentration 1 mg/ml) per ug of DNA diluted in 500 μl 
Opti-MEM, and mixed by vortexing. After 20 minutes, the mix was added gently drop-by-drop 
to cells seeded at approximately 1x105 in 6-well plates 24 hours before. Transfected cells were 
incubated at 37 ℃ in 5% CO2 for 20 hours, after which the medium was changed. Transfected 
cells were usually harvested 48 h post transfection. All chemicals above were provided by 
GIBCO. 
 
2.9.3 Infectivity assay 
 
To produce infectious HIV-1 virions, 0.4 μg p8.91 (HIV-1 Gag-Pol), 0.4 μg pCSGW, 0.6 μg 
pMDG (G protein of vesicular stomatitis virus), 0.5 μg pA3G-hemagglutinin epitope (HA) or 
pCMV-HA (as a negative control for APOBEC3G) and 0.12 μg pVif from NL4.3 or mutants 
were co-transfected into 293T cells. The total amount of DNA was kept constant by adding 
plasmid pcDNA3.1, an empty parental vector. The virus-containing media was harvested 24 
hours later, and filtered using a 0.45 μm filter (Milipore). Virus-producing cells were 
resuspended in 200 μl RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 2% NP40, 0.5% sodium 
deoxychloride) and then sonicated for 10 seconds. 10 μl of the sonicated cell lysis was taken 
and mixed with gel loading buffer for western blot analysis. 
Viral infectivity was measured by challenging 293T cells seeded at around 1x105 per well 
the day before infection in 24-well plates with 100 μl of a three-fold dilution series of the viral 
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stock. 105 cells per well were plated in 24-well plates 24 hours before infection. After 72-hour 
infection at 37 ℃ the media was removed and the cells were trypsinised and resuspended in 
PBST buffer with 2% formic acid. Green fluorescent protein (GFP)+ expression cells were 
quantified by flow cytometry using a Calibur FACS machine (B&D). 
 
2.9.4 Co-immunoprecipitation assay 
 
293T cells were co-transfected with 2 μg pCul5-HA or pCMV-HA as a negative control, 
and 2 μg pVif or mutants. 2 μg pcDNA3.1 was used to replace pVif in Vif- groups. Transfected 
cells were incubated as described above, after which the medium was changed. Another 24 
hours later cells were resuspended in 250 μl Co-IP buffer (150 mM NaCl, 50 mM Tris pH 7.0, 
0.5% Triton X-100, Roche protease inhibitor tablet) and debris was removed by centrifugation 
at 6,000g for 1 min. 25 μl of the supernatant was mixed with 25 μl gel loading buffer and boiled 
for 5 min for western blot. The remaining supernatant was incubated with 30 μl buffer-balanced 
protein G-conjugated agarose beads (Invitrogen) for 3 hours at 4 ℃. The beads were collected 
by centrifugation at 10,000 g for 30 sec, and the supernatant was removed. After four washes 
with 1 ml co-immunoprecipitation (Co-IP) buffer for 5 min at 4 ℃, samples were separated 
from beads by elution with 30 μl Co-IP buffer containing HA peptides. Fractions were mixed 
with 30 μl loading buffer and boiled for 5 min. Both cell lysates and elutions were analysed by 
western blot.  
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CHAPTER 3: NMR STUDY OF HIV-1 VIF SOCS-BOX 
 
As described in Chapter 1, the structure of Vif is still undetermined due to the problems of 
expressing soluble folded Vif. Our previous work (Bergeron, Huthoff et al. 2010) succeeded in 
acquiring a soluble Vif fragment including the critical BC-box and the proline-rich motif, which 
allows us to determine the function of Vif SOCS-box from a structural biological standpoint. 




3.1 NMR spectra of Vif SOCS-box peptide 
 
3.1.1 HSQC spectra of the SOCS-box 
 
The expressed protein is composed of two portions, a solubility-enhancement-tag (SET-
tag) and the target Vif SOCS-box domain fused with a hexa-histidine tag at the C-terminus 
(figure 3.1A, residues 63-95 are corresponding to residues 143-175 in the Vif sequence). The 
1H-15N HSQC recorded on free SOCS-box peptide reveals that the SET-tag is folded properly 
in the solution with a very good peak distribution whereas SOCS-box is unstructured (figure 
3.1B). During the binding to EloBC, the peaks from residues 143-153 that are known to lie on 
the binding surface start broadening in the HSQC spectrum due to the decreased exchange rate 
(figure 3.1B, red spectrum). It implies that a conformational change of this domain undergoes. 
This perturbation provides important information in structural determination and whereas 
difficulties in assigning the SOCS-box peptide in bound state. 
 
3.1.2 Towards the re-appearance of missing peaks in the bound state 
 
In order to observe and assign more peaks for the bound SOCS-box peptide, 15N-labeled 







Figure 3.1: (A) The full sequence of the SOCS-box peptide fused with a SET-tag sequence coloured 
in violet. The BC-box in Vif is presented in green and the proline-rich motif is highlighted in red. 
Residues 63-95 in the expression peptide are corresponding to residues 143-175 in the full-
length Vif sequence (B) Two 1H-15N HSQC spectra of the free SOCS-box (blue) and the bound 
SOCS-box peptide are overlaid. Missing peaks corresponding to SOCS active residues are indicated. 
These peaks were missing during the binding in NMR perturbation experiments. Reproduced from 
the reference: The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit 

















Figure 3.2: 1H-15N HSQC spectra of bound SOCS-box peptide was run at different temperatures: 




from 25 ℃ to 37 ℃ (figure 3.2). More peaks in the central region of the spectrum are broadened 
with increasing of temperature. At 37 ℃ only a few peaks from the SOCS-box can be observed. 
Providing that Vif naturally functions at body temperature, and that EloBC spectra were 
recorded at 30 ℃, lower temperatures were not further tried. A small scale pH study (from pH 
6.5 to pH 8.0) was performed, which did not induce any reappearance of peaks (data not shown). 
 
 
3.2 SOCS-box assignment 
 
3.2.1 Side-chain assignments 
 
In normal assignment strategies, side-chains are able to be assigned after backbone 
assignments (CO, Cα, Cβ, NH and N) are confirmed. 3D spectra such as HCCH-COSY and 
HCCH-TOCSYs with a range of mixing time are usually applied to fully assign the side-chains, 
followed by 15N-TOCSY-HSQC and HCC(CO)NH for validation. In this study we first ran a 
15N-TOCSY-HSQC, HCCH-TOCSY with 8 ms mixing time and HCCH-TOCSY with 17 ms 
mixing time. Usually 15N-TOCSY-HSQC does not give enough side-chain information due to 
the large-distance connection between detected scalar coupled spins (figure 3.3A). A HCCH-
TOCSY with a shorter mixing time usually provides unambiguous and secure information on 
neighbouring protons (figure 3.3B), and a longer mixing time offers more information on 
distinct protons for long side-chain groups (figure 3.3C). For each spectrum peaks were picked 
and assigned manually, using the software CcpNmr suite. 
In the next step we applied HCC(CO)NH pulse program not only for the validation but 
also for the proline assignment in our case. Due to the cyclized side-chain proline cannot be 
observed in 15N spectra. Therefore, before assigning the peaks from prolines in 13C spectra, one 
starts with a limited number of proline assignments. Through a HCC(CO)NH experiment, some 
proton chemical shifts of a proline (i) were observed and determined from the next residue (i+1). 
By this procedure, most of the residues were assigned regardless of their presence in a proline-
rich motif, improving the percentage of assigned backbone to 83.7% and that of assigned proton 
to 78%. Over 90% of resides were either fully or partially assigned. All the assignments 
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excluding the assignments on SET-tag are listed in Appendix III 
 
3.2.2  Nuclear Overhauser effect spectrometry assignment 
 
After side-chains had been assigned, the next step was to run 3D NOESY spectra (figure 
3.3 D, E) to obtain NOEs and hence distance restraints for structural calculation. Peaks were 
picked and assigned manually using CcpNmr suite. However, instead of having peaks from the 
SOCS-box, most of the cross peaks were from the well-structured SET-tag, and some changes 
in the intensities of resonances were from two spins in the tag and the SOCS-box respectively. 
This is because of the fact that in a structured region a spin, i.e. a proton, has a large population 
of neighbouring spins through space and changes in the intensities of two resonances take place 
more possibly, thus more distance restraints can be obtained. On the contrary, in a flexible 
region most NOEs are from an observed residue (i) and its neighbour residues (i±1), which 
means that the number of NOEs is usually limited.  
 
3.2.3 An approach to assigning the bound SOCS-box 
 
Considering that SOCS-box experiences a structural change during the binding to EloBC, 
we chose to use backbone assignments from bound SOCS-box for CS-Rosetta structural 
calculation. 15N-HSQC, 13C-HSQC, 15N-TOCSY-HSQC and HCCH-TOCSY spectra were run 
and processed. In the first step all peaks from SOCS-box in these spectra were picked. In the 
next step our assignments from free SOCS to the bound SOCS-box peptide were taken, which 
was able to provide assignments on HN, N, Cα, Cβ and Hα for CS-Rosetta calculation. In the 
final step 15N-editted NOESY and 13C-editted NOESY spectra were collected in order to 
measure more NOEs for distance restraints. It should be noted that as the structure of Vif BC-
box in bound state had been solved by X-ray crystallography (Stanley, Ehrlich et al. 2008), it 
facilitated NOE assignment and improved the accuracy in spite of missing peaks from BC-helix 
domain. But due to the reasons elaborated above, only 78 unambiguous intra-molecular NOEs 














Figure 3.3: Explanation of various 3D spectra of the SOCS-box. For all spectra, the spin system and 
magnetization transfer coloured in red is presented on the left. Red arrows stands for ‘through space’. 
A strip from the relative spectrum is selected and presented on the right. The assigned peaks are 
indicated. (A) 15N-TOCSY-HSQC. (B) HCCH-TOCSY with 8 ms mixing time. (C) HCCH-TOCSY 
with 17 ms mixing time, which gives more information on sidechains. (D) 15N-NOESY-HSQC with 
120 ms mixing time. (E) 13C-NOESY-HSQC. NOESY spectra provide information from other 




3.3 Bioinformatic analysis 
 
3.3.1 Flexibility analysis 
 
Although using flexibility predication software cannot provide much accurate structural 
information compared to other bioinformatic analysis, it gives a direct and general view on the 
behaviour of a protein in solution. In this study chemical shifts were required to identify flexible 
loops according to the protocol of CS-Rosetta (Shen, Vernon et al. 2009). 
Our RCI analysis obtained for the SET-tag domain agrees with the published structure of 
the tag (Gronenborn, Filpula et al. 1991), showing that SET-tag (residue No. 1-58 in this 
construct) is completely structured in (figure 3.4A,B). The low RCI value of SOCS-box α-helix 
is caused by missing chemical shifts, which means the result for this domain may not be correct. 
Interestingly, RCI predicts that sequence 76-83 which includes residues 81PPL83 and sequence 
87-91 is less disordered both in bound and unbound state (S2 > 0.7) as Dr Julien Burgeron 
previously did (Dr Julien Burgeron’s thesis, 2010). This result, combined with a previous 
mutational study (Simon, Sheehy et al. 1999), may imply an important loop formed by 84PS85 
in Vif function. 
 
3.3.2 Torsion angle prediction 
 
Being a part of the preparation of input data for CS-Rosetta, the role of TALOS+ is to 
identify the disordered tails and loops, which is similar to what RCI does. Following the result 
from RCI, TALOS+ also nicely predicts the angles of SET-tag (figure 3.4C). As for the SOCS-
box, owing to the lack of sufficient chemical shifts TALOS+ fails to perform a prediction on 
the α-helical domain, the PPLPS motif and the carboxyl trail. The rest of the SOCS region is 
predicted well. The predicted angles by TALOS+ may imply a β-strand-like structure. At this 
point, according to the results from RCI and TALOS+, the C-terminus of SOCS-box (residue 
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3.4 Solution structure calculation of Vif SOCS-box 
 
Although most of the assignments from the α-helical motif of SOCS-box are unavailable 
due to peak broadening caused by the exchange rate, it is still reasonable to generate solution 
structures by CS-Rosetta (figure 3.5A). This is because the structure of sequence 163-173 has 
been determined by X-ray crystallography (PDB ID: 3DCG) and this published structure could 
be referred to in data mining stage of CS-Rosetta (Stanley, Ehrlich et al. 2008). 
Superimposition of the refined ten lowest-energy models shows that a loop between two β-
sheet is disordered and flexible (figure 3.5B) as it is predicted by RCI, and that the rest of 
sequences are structured and stable in the complex. The coordinates with the lowest-energy are 
aligned to the crystal structure, giving an r.m.s.d. at 0.411 Ǻ (figure 3.5C), which means the 
structures slightly differ between the solid and solution states. The structural statistics for 
SOCS-box is given in table 3.1. It is worth mentioning that the chemical shifts from the β-sheet 
are not disturbed by the exchange rate, which may indicate the β-sheet does not exist on the 
interface of the interaction. 
 
Table 3.1. Structural statistics for the SOCS-box in bound state 
 




Average RMSDs from the mean structure 
Backbone average (Å) 0.54 ± 0.19 
Heavy atom average (Å) 0.65 ± 0.22 
Ramachandran plot 
Most favoured region (%)  96.7 
Allowed region (%)  3.3 
Generously allowed region (%)  0 






















Figure 3.5: The solution structure of bound Vif SOCS-box (34 residues). (A) The RMS vs relative 
energy plot figure from CS-Rosetta calculation. (B) The alignment of ten models with the lowest 
energy after refinement. (C) The alignment to the α-helix of the crystal structure (PDB ID: 3DCG, 
chain E). The crystal structure is shown in violet. (D) The solution structure of Vif SOCS-box. 
Prolines on the PPLPS motif are coloured in orange. Leucine and serine are coloured in red and blue 
respectively. (E) The surface of the SOCS-box. The second proline in the PPLPS motif is coloured 




Our group has demonstrated that the PPLPS motif lying after the Lys157-Lys160 β-sheet 
binds to the C-terminus of EloB, and the peaks of Leu163, Ser165 and Val 166 fade away with 
the increasing ratio of EloBC (Bergeron, Huthoff et al. 2010). The solution structure reveals 
that the target short loop is composed of residues Pro164 and Ser165, and that residue Leu163 
is sitting closer to the loop (figure 3.5D), suggesting the importance of these three residues. 
Specifically, these two β-sheets in the structure push Pro164 and Ser165 outwards so that they 
can easily interact with other surrounding molecules in solution to perform biological functions. 
A careful inspection of the surface of the SOCS-box structure can infer that the side-chains of 
the first and the third proline and the leucine are responsible for the interaction (figure 3.5E). 





In this chapter the structure of SOCS-box bound state with EloBC is described. The main 
challenge in this study was the lack of chemical shifts and subsequently NOE assignment, 
which hindered the structure calculation by conventional methods. Various conditions were 
tested, and they failed to restore the broadened peaks. Due to this, CS-Rosetta provided an 
alternative method to generate structures. In theory, CS-Rosetta does a data-mining in fragment 
selection stage, by which a published structure might be referred to if the amino acid sequences 
are the same or homologous. In our case, the generated coordinates nicely agree with the crystal 
structure 3DCG, which demonstrates that the method provides reasonable results. More details 





CHAPTER 4: NMR STUDY OF ELONGIN BC COMPLEX 
 
This chapter describes the solution structure of Elongin BC. The structure was calculated 
and reported by the same methods used in Chapter 3. Besides, NMR spectrometry was applied 
to study EloB mutants in order to identify the characteristics of EloB DVMK stretch at the C-
terminal tail in the binding to SOCS-box. 
 
 
4.1 15N-HSQC spectra of Elongin BC 
 
EloB and EloC are an insoluble proteins if expressed in E. coli independently. Until now 
there have not been reports on the biophysical or biochemical studies of EloB or EloC 
individually. Thus the EloB-EloC complex has to be co-expressed and co-purified as described 
in Chapter 2. The 15N-HSQC spectrum displayed in figure 4.1A reveals a partially-structured 
behaviour of the EloB-EloC dimer in solution. However, due to the large molecular weight (26 
kDa) and exchange rates, peaks in the central region of the spectrum cannot be distinguished 
clearly, except those from flexible domains. Deuteration was used to replace a proportion of the 
non-exchangeable protons with deuterous. Briefly, in order to obtain deuterated sample, 
bacteria were grown in 100% D2O instead of H2O supplemented other normal chemicals for 
minimal media. Normal H2O buffer was used during purification. Figure 4.1B confirms that the 
deuteration gives a much improved 15N-HSQC spectrum compared to the regular one, showing 
good peak distribution and providing evidence for a good fold. 
 
 
4.2 Elongin BC assignments 
 
The original assignments of EloBC bound to the SOCS3 fragment (BMRB ID: 15606) 
were completed by Jeffrey Babon’s group in 2008 (Babon, Sabo et al. 2008). Dr. Julien 






Figure 4.1: 1H-15N HSQC spectra of EloBC. (A) HSQC spectrum run on normal 15N-labeled EloBC. 
Peaks in the red circle are from the EloB C terminus. Partial assignments of these peaks have been 




obtain side-chain assignments, HCCH-COSY, HCCH-TOCSY and 13C-NOESY-HSQC spectra 
were recorded. However, on account of the molecular weight of the complex (38 kDa.), 3D 
spectra recorded on regular EloBC sample in the complex gave only sharp peaks assigned to 
the mobile and unstructured C-terminus of EloB, residues 98 to 118 which could be assigned 
(figure 4.2). The absence of peaks for the less mobile regions meant that it was impossible to 
assign the side-chains for the rest of the dimer. 
As for the EloC component, due to the same limitation affecting the assignment of EloB, 
the side-chains of EloC were not assigned. Considering that CS-Rosetta generates structures 
based on backbone assignment and that the EloBC structure has been solved, this disadvantage 
did not affect the de novo structural generation. Regardless of all the difficulties, the limited 
data still enabled one to identify the interaction mechanism between the PPLPS motif and EloB 
101-104 DVMK stretch. The sequences of EloB and EloC are given in figure 4.4 with 
bioinformatic analysis. 
In order to assign more EloBC resides and to confirm that there were no peaks 
corresponding to structural regions overlapped with other peaks, a selective labelling strategy 
was tried. 1-13C-labeled amino acids were added into the M9 minimal media supplemented with 
15N-labeled ammonium chloride. Two different amino acids, proline and glutamine, were used 
due to the residual percentages in the sequences. A HNCO spectrum was recorded and the 
processed H-N plane of the spectrum is displayed in figure 4.3. This result reveals that there 
are no extra peaks appearing except for those from the carboxyl tail of EloB and a flexible 
element of EloC, proving that peaks corresponding to unassigned residues are absent from 
spectra due to line broadening. 
 
 
4.3 Solution structure calculation of Elongin BC 
 
4.3.1 Bioinformatic analysis 
 
Similarly, we performed a hydrophobic analysis, a random coil index analysis and torsion 
















4.3: The 1H-15N plane of HNCO collected for 1-13C glutamine and proline-labeled EloBC. Assigned 
labeled residues are indicated. Due to the pulse-program, residues at the C-terminus to the 13C-
labeled amino acids can be observed on the 1H-15N plane. Peaks are assigned on the spectrum. B 




structure generation. The hydrophobicity analysis reveals that EloB and EloC contain many 
hydrophobic residues distributed throughout their sequences (figure 4.4A). EloC, especially, 
has a hydrophobic C-terminal tail, which is known to bind members of the SOCS-box family 
(figure 4.4C). The hydrophobic characters of the residues in these two proteins may make it 
difficult to express EloB or EloC independently in E. coli. 
The RCI predication suggests that the Ubiquitin (Ub)-like-domain of EloB (residues 1-80) 
is structured and stable in solution (figure 4.4B). The predication on the C-terminal tail after 
residue 98, however, shows that the C-terminal tail is very disordered as demonstrated by the 
15N-1H HSQC spectrum (figure 4.1A). Meanwhile the feedback from TALOS+ provides a good 
prediction for torsion angles except for the last 10 amino acids (figure 4.4E). These results 
indicate that the flexible C-terminal tail will not be considered during the alignment to the 
published structures after structure generation. 
Although the assignments for EloC were not as complete as for EloB, both RCI predication 
and torsion angle prediction display that the full-length EloC is less disordered. The last two 
residues LD were removed because of the flexibility during the structural generation (figure 
4.4D, F). The blank entries between each column are caused by the lack of chemical shifts. All 
chemical shifts were adjusted by RCI automatically for CS-Rosetta calculation in the next step. 
 
4.3.2 The structures of EloBC 
 
As detailed above, the EloB structure contains a folded Ub-like domain whose second β-
sheet (residue 11-16) forms an interaction surface to the EloC (figure 4.5A). Loop 68RPQA71 
is another strand to hold the long α-helix of EloC (figure 4.5B). The modelling gives an 
unstructured flexible C-terminal tail as we expected. EloC, the component that is thought to 
have the only binding site of EloBC dimer to Vif SOCS-box, has three important domains. The 
second β-sheet and long α-helix 11-15 are involved in the binding to EloB. The C-terminus of 
EloC experiences a structural change to a hydrophobic α-helix that interacts with Vif BC-box 
(Stanley, Ehrlich et al. 2008, Bergeron, Huthoff et al. 2010). The structure of the dimer agrees 
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Figure 4.5: The solution structure of bound EloBC. (A) The interface between EloB and EloC. 
Residues 11-16 on EloB are coloured in green and residues 62-67 on EloC are coloured in blue. (B) 
The loop (residues 68-72) on EloB is another domain that binds EloC. (C) The alignment with the 




200 residues (figure 4.5C). The structure with the lowest energy was then used in the stage of 
docking the complex. 
 
 
4.4 The character of EloB C-terminus in binding to Vif SOCS-box 
 
It was found in our previous studies that residues 101 to 104 of EloB participate in SOCS-
EloBC binding as well besides the C-terminus of EloC (Bergeron, Huthoff et al. 2010). We then 
enquired how these two domains interact and which residues may be critical for the binding. In 
order to observe the changes, we made four EloB mutants, each of which has a mutation site in 
the 101-104 stretch (figure 4.6A). 15N-labeled sample was split into two sample fractions. 
Fraction I was mixed with unlabeled SOCS-box at 1:1 ratio and fraction II was diluted with 
NMR buffer to the same concentration. Briefly, if an alanine peak keeps changing during 
binding as well as the other three residual peaks, it suggests that this residual site does not 
determine the interaction, and that the interaction is not driven by side-chain interaction. 
CcpNmr suite was used to detect peaks and to calculate peak heights. Some peaks that had 
been known not to be affected by the binding were chosen as references and normalized to the 
same height in two individual spectra. The final percentages were calculated from the height in 
the bound state relative to that in unbound state for each mutant. 
 Mutant EloB101 has a slightly different profile compared to WT. Only peaks from residues 
101 and 102 have significantly decreasing intensities by 70% whereas residues 103 and 104 
retain the same intensity (figure 4.6B). The 15N-HSQC spectrum of this mutant displays two 
positions of those peaks from C-terminus which change when it is referred to the WT, 
confirming that this site mutation, to some extent, affects the rest of the sequence. Importantly, 
the decreasing intensity of 101A peak reveals that the interaction to the 101 site still exists. 
Interestingly, the other three mutants, provide the same profile of intensity changes as what we 
observed for WT (Bergeron, Huthoff et al. 2010). It shows that none of these residues are crucial, 







Figure 4.6: Peak analysis for the C-terminal element of EloB. (A) Schematic representation of the 
EloB construct (including the His-tag in the cyan box) used in this assay. The domain of interest is 
coloured in red and each mutation site is shown in blue. (B) Relative strength of the peaks assigned 
to residues 101 to 108. The percentage is given by the ratio of peak intensities in the spectra of the 






 In this Chapter I analyzed the characteristics of the EloBC amino acid sequences, assigned 
the side-chains of EloBC and calculated the structure of EloBC from our assignments. The 
structure generated from CS-Rosetta is in agreement with the crystal structure. This structure 
was used in later structural calculation of the SOCS-EloBC complex by HADDOCK. Results 
from NMR mutational study reveal that although the 101-104 stretch is critical for the EloB-
SOCS binding, a single site mutation does not affect the binding. Moreover, it also implies that 
the interaction may not be related to any side-chain effect, because peak intensities from 
mutated alanine sites were decreased as well. The mechanisms under pinning these results are 






CHAPTER 5: STUDIES ON THE SOCS-ELOBC COMPLEX 
 
In previous two Chapters the structures of Vif SOCS-box and Elongin BC were presented 
respectively. This Chapter describes the entire structure of SOCS-Elongin BC complex and 
their interfaces. Meanwhile, biophysical methods were applied to quantify and characterize this 
interaction. The results suggested that the PPLPS motif did not bind to EloB carboxyl tail as 
tightly as we had expected. 
 
 
5.1 Paramagnetic relaxation enhancement study 
 
The binding between HIV-1 Vif SOCS-box domain and EloBC forms a stable heterotrimer 
with a 1:1:1 stoichiometric ratio determined by gel filtration analysis and SDS-PAGE (figure 
5.1). In order to gain the distance information between these three components, NOESY spectra 
of the complex were recorded. However, due to several reasons mentioned in Chapters 3 and 4, 
a large number of inter-molecular NOEs were not observable using routine 15N and 13C-edited 
NOESY experiments, meaning that without sufficient distance restraints, the generated 
structure will not be accurate.  
Considering that there are no cysteines in the SOCS-box peptide, and that the complex 
structure has a 1:1:1 ratio, it is an advantage to generate single-point mutations in this peptide 
so that the distances by PRE between the substituted amino acid in question and amino acids 
from other components of the complex, namely within EloBC, can be measured. Basically, in 
each molecule of the complex, a SOCS-box peptide was engineered with only one cysteine 
substitution, therefore the observed relaxation enhancement effect arose from the PRE molecule 
bound to the introduced cysteine. A paramagnetic relaxation enhancement procedure was 
applied to acquire more intermolecular restraints. Point mutations were placed at three widely 










Figure 5.1: A purification profile of SOCS-EloBC complex. The SDS-PAGE gel (inset) shows the 




As was expected from other assays, peaks from residues 101DVMK104 were significantly 
weakened or invisible in the presence of each paramagnetic-labeled SOCS-box. This 
phenomenon was caused by both NMR perturbation effects and paramagnetic relaxation effects. 
Individually, the C-terminus of EloB was less impacted by the G143C mutant compared to the 
others (figure 5.2B). Paramagnetic-labeled Q158C mutant displays a clear clue to the possible 
positions of these EloB carboxyl residues in space (figure 5.2C). Moreover, the peak-intensity 
ratios from EloB carboxyl terminus reveal that the DVMK stretch was closer to the third labeled 
cysteine (R167C) of the SOCS-box (figure 5.2D). These intensity ratios were calculated and 
transformed into distance restraints by the method described in Chapter 2. 
 
 
5.2 Overview of SOCS-Elongin BC Complex 
 
The overlay of 20-solution-structures after applying the HADDOCK refinement protocol 
is displayed in figure 5.3A. The N-terminus of SOCS-box is indicated. EloB and EloC are 
coloured in blue and grey respectively. The structural statistics are collated in table 5.1. It is 
worth mentioning that the structural validation by CING (Common Interface for NMR structure 
Generation, for NMR data and structure validation) gave an over 75% reasonable structure 
score (ROG coding) (Doreleijers, Sousa da Silva et al. 2012), which was even higher than that 
of the validation on Jeffrey Babon’s structures based on NOEs. Besides, PROCHECK reported 
that over 95% of residues were folded in the allowed regions. Considering these validation 
reports, since the solution structures are quite closer to the crystal structure, our structures are 










Figure 5.2: Long distance restraint measurements. (A) The three mutated sites in SOCS-box peptide 
which were distributed at widely separated positions in the peptide. G143C, Q158C and R167C are 
highlighted in white and the sulphur of the cysteine to be modified by label is coloured in yellow. 
Each predicted mutant structure is generated by Pymol in order to determine that the side chain of 
cysteine is not buried inside the molecule. (B) Intensity ratio of EloB C-terminus for G143C mutant. 
(C) Intensity ratio of EloB C-terminus for Q158C mutant. (D) A portion of the 1H-15N HSQC spectra 
of EloBC in the presence of the paramagnetic-molecule-labeled SOCS-box R167C peptide (red) or 
the diamagnetic-molecule-labeled R167C peptide (blue). Peaks assigned to the EloB C-terminal tail 
are indicated in green (significantly broadened) or in black (not affected). (E) Intensity ratio of EloB 
C-terminus for R167C mutant. The intensity of peaks from residues 101-104 are broadened due to 









Figure 5.3: General view on the structure of the complex. (A) The alignment of twenty coordinates 
with the lowest energy after refinement. (B) The backbone cartoon of the final structure with the 
lowest energy. (C) The molecular surface of the complex. The proline-rich motif is displayed in 




Table 5.1. Structural statistics for the SOCS-EloBC complex 
 
Average RMSDs from the mean structure 
Backbone average (Å) 0.26 ± 0.03 
Heavy atom average (Å) 0.52 ± 0.04 
HADDOCK statistics  
van der Waals energy (kcal mol-1) -63.5 ± 2.4 
Electrostatic energy (kcal mol-1) -574.5 ± 15.9 
Desolvation energy (kcal mol-1) 3.1 ± 3.3 
Restraints violation energy (kcal mol-1) 0.3 ± 0.16 
Buried Surface Area (Å2) 2438.6 ± 46.0 
Experimental PRE distance restraints 
Number 58 
Distance violation (Å) 2.76 ± 1.90 
Ramachandran plot 
Most favoured region (%)  82.3 
Allowed region (%)  15.2 
Generously allowed region (%)  1.4 
Disallowed region (%)  1.1 
Deviations from Ideal Geometry 
Angles (degree) 0.6 





The backbone cartoon of the structure with the lowest energy is presented in figure 5.3B. 
SOCS-box domain sits across the carboxyl tail of EloC. The remaining part of the SOCS-box 
is in a random coil structure. The small loop (163LPSV166) is close in space to the DVMK 
stretch of EloB, whose broadened peaks as observed in 15N-HSQC spectra. Figure 5.3C presents 
the molecular surface of the complex. Three important residues on the PPLPS motif are 
highlighted in various colours. The side-chains of these three residues are clearly exposed on 
the interface co-formed by the PPLPS motif and the DVMK stretch of EloB, whereas the second 
proline is found buried inside the complex, implying that this residue is less important. 
 
 
5.3 Binding sites between SOCS-box and Elongin BC 
 
5.3.1 Interface between SOCS BC-box and the Elongin C carboxyl terminus 
 
The structural model reveals that the SOCS-box crosses the EloC carboxyl α-helix and 
binds to the flexible EloB carboxyl terminus. Residues L145, A149, L150 of Vif SOCS-box 
and A99, L103 of EloC form hydrophobic interfaces respectively which drive the SOCS-EloC 
interactions (figure 5.4A, C), typical of protein-protein high-affinity binding (Schreiber 2002, 
Wolfe, Stanley et al. 2010). This tight hydrophobic interaction is the main driving force of 
SOCS-EloBC complex formation. This portion of the structure of the complex matches that of 
the crystal structure 3DCG very closely (0.41 Å). 
 
5.3.2 Interface between proline-rich motif and Elongin B carboxyl terminus 
 
Further investigations on the PPLPS motif shows that it is 164PS165 which interacts with 
the EloB DVMK stretch rather than the whole PPLPS motif (figure 5.4B). This 164PS165 loop is 
stabilized by an anti-parallel β-sheet-like structure (shown in figure 3.5D). As for the EloB 
component, the C terminus was quite flexible in solution as shown by the line widths within 
the NMR spectrum (Bergeron, Huthoff et al. 2010), whereas in the presence of SOCS-box, the 
DVMK stretch experiences a conformational change and becomes partly structured by the 
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PPLPS motif (figure 5.4D). The distance measurement between these two domains suggests 
that the interface between 164PS165 and the DVMK stretch is formed by closer spatial 
positioning (around 5.5 Å) instead of bond connection or hydrophobic interaction. It indicates 
that this interaction is not as significant as observed in NMR perturbation experiments 
(Bergeron, Huthoff et al. 2010), and that the interaction observed by NMR may be driven by 
weak van der Waals forces. 
 
 
5.4 Biophysical tests on the SOCS-Elongin BC Complex 
 
The structure described above does not show any specific interaction mode between the 
PPLPS motif of the SOCS-box and the DVMK stretch of EloB. In order to confirm that there 
is no strong binding existing at the interface, ITC was applied to address this question and to 
quantify the interaction for different mutants. 
Several constructs with single mutations in the PPLPS motif were made. The reason for 
replacing proline with a serine rather than an alanine is that serine, which is a hydrophilic acid 
with a small side-chain group, helped improve the solubility of SOCS-box (figure 5.5A). 
Meanwhile, this substitution also changed the character of the molecular surface to a 
hydrophilic surface, which provided more significant difference in this biophysical study. Each 
sample for ITC was purified through a gel filtration column to remove self-associated polymers 
of SOCS-box peptide. The concentration of SOCS-peptide was determined by Nanodrop 
spectrometer whereas that of EloBC was determined by BioRad due to its low extinction 
coefficient at 280 nm. 
Figure 5.5B shows that the thermal changes could be measured calorimetrically by the 
binding reaction upon the titration of the SOCS-box with EloBC. Titration points were fitted to 
Daniel Koshland's theory of enzyme-substrate binding model to obtain thermodynamic 
parameters. The plotted single-binding curve appears that the middle point (half-maximum 
binding) of each curve is around 1.0, confirming that protein A, namely SOCS-box or its 





Figure 5.4: Interaction between the SOCS-box and EloBC. (A) The binding surface of the BC-box 
of the SOCS-box. L145, A149 and L150 form a hydrophobic surface which interacts with EloC C-
terminus. (B) The proline-rich motif downstream from the SOCS-box is coloured. Residues are 
highlighted in various colours. The second proline (residue 162) in yellow is buried in the complex.  
(C) The binding surface of EloC C-terminal α-helix. Resides on the interface are coloured in blue. 
(D) The interface of EloB DVMK stretch and the Vif proline-rich motif. The distance between two 





the gel filtration column (figure 5.5A).  
The dissociation constant describes the binding affinity between molecules. The higher its 
value, the lower the binding affinity. Interestingly, the dissociation constants are not changed 
significantly by a single mutation with a maximum difference of 0.5 μM (table 5.1). This 
difference is usually regarded that the values of the binding constants of all target molecules 
are at the same level. In this case it means that a change on a single point does not affect the 
binding. 
The ITC data also reveal that calculated –TΔS derived from free energy and enthalpy 
differs among mutants (table 5.1). However, to be critical, it cannot be simply concluded that 
residue substitution influences the interaction for two reasons: 
1) Hydration or dehydration property is another factor that should be addressed carefully 
in the conclusion on ITC data. This factor is usually used to describe a hydrophobic or 
hydrophilic force. Also it is used to explain interactions in charged conditions (Bjelic 
and Jelesarov 2008). This may be the case for the proline-serine replacement. 
2) Generally, ITC is a method that sensitively detects the thermodynamic change of a 
whole target system, namely the SOCS-EloBC binding system in this work. It detects 
macroscopic changes rather than microscopic details on a system. It was found in the 
recent studies that slight modification on a site away from an active site can increase 
or decrease the binding affinity (Tzeng and Kalodimos 2012). This long-distance effect 
is thought to be led by conformational entropy. Similarly, the thermodynamic change 
observed in this case may be caused by the difference of internal conformational 
entropy rather than the direct binding energy. That could be why the dissociation 















Figure 5.5: (A) Schematic representation of the SOCS-box constructs used in this assay. Mutated 
residues are coloured in red. (B) The data of ITC binding assay. Top, plotted curves according to the 
single-bind model. Bottom, raw data.  
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WT 1.23 0.82 ± 0.06 -10.2 ± 1.6 -7.9 2.3 
SPLPS 2.14 0.52 ± 0.18 -8.3 ± 2.3 -7.6 0.7 
PSLPS 1.24 0.86 ± 0.24 -8.8 ± 2.0 -7.9 0.9 
PPLSS 1.36 0.77 ± 0.19 -10.7 ± 2.8 -7.8 2.9 
PPLPA 1.18 0.89 ± 0.24 -8.6 ± 0.3 -7.9 0.7 
APLAS 1.10 0.97 ± 0.28 -8.8 ± 0.2 -8.0 0.8 





Here the first solved structure of the Vif SOCS-EloBC complex including the proline-rich 
motif on Vif component has been presented. SOCS-box primarily binds to EloC by a 
hydrophobic interaction in the BC-box and EloC binding surface. The proline-rich motif on 
SOCS mediates another weak interaction with the EloB DVMK (residues 101-104) stretch, 
suggesting that it is the α-helix of EloC that first drives the induced-folding binding of Vif, 
followed by the interaction between the PPLPS motif and EloB. The side-chains of the first and 
third prolines (residues 161 and 164) are exposed in the solution whereas the side-chain of the 
second proline is buried in the protein. The structure of the complex provides a detailed insight 
into the function of the Vif proline-rich motif. In the next stage biological assays were used to 
verify the structural model and to identify the function of each residue in cells, which will be 




CHAPTER 6: FUNCTIONAL STUDIES OF THE VIF 
PROLINE-RICH MOTIF 
 
In previous chapters biophysical, biochemical and structural biological methods were 
applied to investigate the mechanisms behind the Vif SOCS-Elongin BC interaction. In 
particular, the solution structure of the complex was revealed. In this Chapter, biological assays 
were used to further identify the details of this interaction. 
 
6.1 The role of each residue in the PPLPS motif 
 
6.1.1 Expression of APOBEC3G and Vif plasmids in mammalian cells 
 
HIV-1 vectors have been proven useful tools to study the early events in HIV-1 infected 
cells (Lee, Malim et al. 2008). The assay consists of a VSV-G pseudotyped HIV-1 based GFP 
reporter vector that expresses GFP upon completing the early replication steps in infected cells 
in a single round. Using flow cytometry it is possible to determine the infectious titer of the 
vector in the presence or absence of A3G. With help of this system it is possible to compare the 
anti-A3G activities of wild type Vif or Vif mutants that are produced along with the vector in 
presence of A3G.  
In this system, pseudovirus that packages A3G protein along with a RNA sequence 
containing GFP cDNA and a packaging signal sequence were generated from 293T cells, and 
used to challenge 293T cells instead of TZM cells. In infectious cells A3G from the virus binds 
onto the promoter of GFP mRNA, thus blocking the expression of GFP in cells, from which the 
infectivity of a virus can be deduced, i.e. the more intensive the fluorescent signals are, the 
higher the infectivity. This method is therefore different from the method our group used before 
(Bergeron, Huthoff et al. 2010),  
Considering the amount of DNA for the transforming efficiency and the toxicity of PEI to 
cells, we first asked how much A3G was required to significantly suppress the infectivity of 
HIV-1 GFP vector in this assay. The amount of HA-tagged A3G was co-transfected with a 
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gradient of the pseudovirus/GFP-expression plasmids in 293T cells. Virus-containing 
supernatant was collected and used to infect 293T cells. pHA-CMV, the parental vector of pHA-
A3G, was used as negative control. As shown in figure 6.1A & B, increasing the amount of 
A3G plasmids to 0.5 μg could significantly suppress the infectivity to approximately 3%, 
corresponding to around 50-fold drop in infectious titer as compared to the negative control. 
Titration of A3G in this system caused only a weak decrease in virus production at high A3G 
concentration as judged by western blotting against p24 in the viral supernatant, suggesting that 
the observed antiviral effect predominantly is exerted by the activity of A3G in newly infected 
target cells, as described before (Lee, Malim et al. 2008). Similarly, by the titration with WT 
Vif plasmids, approximately 0.12 μg of NL4.3 Vif plasmids was enough to counteract the 
function of A3G (figure 6.1 C & D).  
In order to study the function of each residue in the PPLPS motif later, a series of Vif 
mutants were constructed by a Stratagene Quick Change strategy. Vif plasmids were extracted 
using the QIAGEN Maxiprep kits. At the same DNA concentration read from Nanodrop 
spectrophotometer, DNA agarose gel confirms that the total amount of DNA for each mutant 























Figure 6.1: Expression of APOBEC3G in mammalian cells. (A) Infectivity of ΔVif HIV-1 
pseudovirus with a titration of A3G. (B) Western blot of the virus supernatant used to challenge 
293T cells. Gag p24 was used as a control of viral amount and as a loading control. (C) 
Infectivity of HIV-1 pseudovirus with a titration of Vif WT. (D) Western blot of the virus 
supernatant used to challenge 293T cells. Hsp90 was used as a control of cell amount and as a 
loading control. The second sample from the right is corresponding to the titration of 0.11 μl in 
C. (E) According to the reading from the Nanodrop spectrophotometer, same amounts of DNA 






6.1.2 Effects of Vif mutations in A3G restriction 
 
The function of different Vif mutants were then assessed by generating VSV-G 
pseudotyped HIV-1 GFP reporter vectors in 293T cells co-transfected with a plasmid encoding 
for A3G or control and a plasmid encoding NL4.3 Vif or Vif mutants. In one data set each 
condition was tested in triplicate. Three data sets were collected independently and a typical 
profile was presented. 
The results, displayed in figure 6.2A, reveal that the first proline on the PPLPS motif and 
the valine downstream the motif are less important than other residues in the motif for Vif 
function. Changing the second proline to serine (P162S) does not decrease viral infectivity, 
which is in agreement with the structural information that the buried side-chain of this proline 
actually does not participate in functional interactions. Interestingly, the L163S and P164S 
mutants considerably lost their ability to rescue viral infectivity, suggesting a critical role in Vif 
function. However, the western blot on virus-producing cells shows that compared with WT 
Vif, L163S mutant had a slightly lower expression level compared to NL4.3 wild type Vif 
whereas P164S mutant was close to the limit of detection by immunoblotting (figure 6.2B). 
Now that original plasmids were checked before biological assays (figure 6.1C), this 
phenomenon may be caused by two reasons: 1) The transfected P164S plasmid has a very low 
expression yield in cells. 2) Vif mutant P164S is very unstable, and thus digested by proteases. 
Therefore, it cannot be simply concluded that P164 is critical for viral infectivity regardless of 
the fact that P164 is essential for Vif stability. Interestingly, L163S mutant Vif expression levels 
were only slightly reduced compared with wild type Vif (figure 6.2B), yet its anti-A3G activity 
was reduced by ~10-fold, suggesting that L163 is a critical residue for anti-A3G function. 
Residue L163 was of interest given that substitution with serine caused a substantial defect 
in anti-A3G activity but not in Vif expression. To investigate the conservation of this residue in 
natural HIV-1 isolates we interrogated the Los Alamos HIV-1 sequence database 
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). The majority of sequences 
have preserved a leucine at position 163, however, there were two isolate, 
B.JP.1995.PT6_i.AB034473 and B.US.1996.USPI90770EI197y96011pcWG2B4.JN024500, 
which had S163, suggesting that there may be variations in anti-A3G activities of natural 
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occurring Vif variants in circulating HIV-1 strains. The alignment of Vif sequence is attached 
in the appendix III (presented in an electronic version). We therefore tested a variant that 
appeared to a higher percentage in the database, F163. From a biochemical viewpoint, 
phenylalanine has a side-chain whose hydrophobicity and size are similar to those of leucine 
(although phenylalanine is aromatic). The same biological assays were applied again. It shows 
that even though the amount of transfected plasmid of L163S mutant was raised five fold to a 
level where the detected expression yield was similar to that of WT, viral infectivity still 
declined because of the presence of A3G (figure 6.3A & B). The L163F mutant, however, 
preserved Vif function and rescued the virus. These results confirm that the side-chain of 
residue 163 is critical for Vif function, and the loss of the side-chain prevents Vif from 
counteracting A3G. 
As for the P164S, a titration on the mutant plasmids was performed. Figure 6.3C & D 
reveals that an increasing amount of the mutant did not affect the viral infectivity. Although 
from group 4 (10*P164S) it might be argued that this proline is important for Vif function on 
neutralization of A3G, it is not very reasonable or meaningful to draw such a conclusion 
because this Vif mutant was very unstable in cells, which means in nature it seldom exists. 
Interrogation of the Los Alamos HIV-1 sequence database revealed that P164 is very conserved, 
however, there are some sequences (B.CA.1998.CANB4FULL.AY779554, 
B.CA.1998.CANB5FULL.AY779555) with S164, again suggesting that natural circulating 
HIV-1 strains may have variations in their anti-A3G activity or stability of Vif. One would 
predict that HIV-1 strains with Vif S164 would express an unstable Vif, however, secondary 








Figure 6.2: 163Leu and 164Pro are important for Vif function. (A) The function of Vif and its 
mutants was measured by the capacity to rescue virus in the presence of the anti-virus protein, 
A3G, in a single-cycle infectivity assay. The data are represented as relative infectivity 
normalized to WT Vif. The mean of three measurements was used, with error bars showing the 
standard deviation. (B) Immunoblot the virus supernatant and whole cell lysates from the 
producer cells. Gag p24 from virus was used for the control of viral amount. Hsp90 is shown 










Figure 6.3 Single residue studies. (A) L163 is crucial for Vif function. The infectivity of HIV-
1 pseudovirus with different amounts of Vif L163S plasmids or L163F plasmids. Plasmids 
pcDNA3.1 was used to keep the total amount of DNA same during transfaction. (B) 
Immunoblot whole cell lysates from the 293T producer cell lysis. (C) The plausible role of the 
third proline in the PPLPS motif. The infectivity of HIV-1 pseudovirus against the increasing 





6.2 Roles of each residue in the PPLPS motif in forming the ubiquitination complex 
 
The previous results suggested that L163 and P164 are more important than the first and 
second prolines. Now we were interested in whether these mutations would impact on the 
binding to the ubiquitination complex. Thus, co-IP of Cul5 with Vif and its mutants was used 
to study the mechanism and structure-function correlations. 
The results (figure 6.4) firstly show that the P164S mutant experienced a low expression 
in this assay as well as in the infectivity assay, demonstrating its instability. Interestingly, the 
three single-mutation proteins, P161S, P162S and L163S, retained the ability to recruit the 
ubiquitination complex as did NL4.3 wild type Vif. It is worth noting that in our previous work 
(Bergeron, Huthoff et al. 2010), the ΔPPL triple-mutation construct had a significantly deceased 
ability to recruit the ubiquitination complex. Taking this comparison and previous biophysical 
studies (Simon, Sheehy et al. 1999) into consideration, we argue that 161PPL163 is essential 
for Vif function whereas a single amino acid change does not undermine Vif functions 
significantly. 
As for the P164S mutant, no Vif protein was detected in the elution, indicating that the 
third proline plays an important role in forming the ubiquitination complex. In Dr. Julien 
Bergeron’s work, the construct APLA, a double-point mutant, lost its ability to bind to the 
complex, and had a lower expression yield as well. Since the first proline does not affect the 
binding as we observed in figure 6.4, it is likely that the third proline is essential for forming 














Figure 6.4: Co-immunoprecipitation study on the recruitment of ubiquitination complex. 293T 
cells were transfected with plasmids expressing WT Vif or Vif mutants and HA-tagged Cul5. 
HA-Cul5 was isolated by elution from anti-HA beads with HA peptides. Cell lysis and elution 






In previous work the PPLPS motif of Vif had been studied, but it was largely still unclear 
how each residue contributes to the functions of the motif (Donahue, Vetter et al. 2008, 
Bergeron, Huthoff et al. 2010, Walker, Khan et al. 2010). In previous chapters I presented the 
structure of SOCS-box in the complex with EloBC and found that a single residual mutation 
did not affect the binding to EloBC by biophysical techniques. Here, the importance of residues 
L163 and P164 was confirmed whereas P161 and P162 do not seem to have crucial functions, 
at least not in the assays performed in the thesis. 
Further experiments are required to understand the interface between the PPLPS motif and 
Cul5. Actually, the function of L163 is different from the function of P164 according to our 
biological assays. Mutation of the leucine decreased viral infectivity but did not disable Vif’s 
ability to recruit the ubiquitination complex, which also implies that this leucine (L163) may 
be related to the interaction with A3G, whereas the mutation on the third proline removed Vif 
from the complex. Therefore, it is worth knowing whether the PPLPS motif of Vif, and the 
DVMK stretch of EloB will form a common interface for the recruitment of Cul5 by the 
interaction between Vif and EloB before further binding to A3G. It is possible that the PPLPS 
motif of Vif is the hub within the final Vif-A3G-Cul5-EloB complex. 
Our results also imply that circulating HIV-1 strains may express Vif proteins with different 
anti-A3G activities as judged by performing single point mutations in the Vif from NL4.3. 
However, these results have to be interpreted very carefully and there are a couple of reasons 
why point mutants in NL4.3 Vif would lose anti-A3G activity or become instable, while these 
Vif changes may exist in circulating HIV-1 strains. It is possible that unidentified secondary 
compensating mutations are present in these strains and that Vif has kept stability and anti-A3G 
activity. Alternatively, polymorphisms may be present in Cul5 which may exert a selective 
pressure on HIV-1 Vif to change critical residues such as L163 or P164. Further studies should 
combine these ideas and look at the possibly flexible interplay between the host protein Cul5 




CHAPTER 7: TOWARDS A PROTOCOL FOR SOLUBLE VIF 
 
Chapter 1 discussed that Vif and Vif-related interactions are potential targets for the 
development of new anti-HIV drugs. Attempting to purify and crystallize Vif is the final 
objective of this Vif project. Until now, due to the insolubility of Vif, only the structure of Vif 
BC-box was achieved. The discovery of a chaperone in A3G degradation pathway, named 
CBFβ (isoform I), highlighted the possibility of obtaining soluble Vif from a prokaryotic system, 
e.g. from E. coli. In this Chapter efforts were made to search for a condition of expressing and 
purifying Vif from E. coli, and the entire process of obtaining a soluble Vif is described. 
 
 
7.1 Vif sequential analysis 
 
Initially, a bioinformatic analysis to characterize the Vif amino acid sequence was 
performed. The secondary structure predication by PsiPred shows that Vif is composed of an 
N-terminal β-strand, four short β-strands in the middle of sequence, four α-helices and a C-
terminal coil tail (figure 7.1A). Interestingly, hydrophobic analysis indicates that most of the 
amino acid residues in the Vif sequence are hydrophilic (figure 7.1B), giving the value of the 
‘grand average of hydropathicity index’ (Kyte and Doolittle 1982) as -0.734 which indicates a 
hydrophilic character. The value of the ‘instability index II’ (Guruprasad, Reddy et al. 1990) is 
37.35 which means the protein is stable, whereas in experimental practice Vif is insoluble and 
easily aggregates. These conflicting results from theoretical predictions and practical 
experiments suggest that those hydrophobic residues may be exposed on the protein surface in 
structured Vif, or that the folding process of Vif during expression needs extra factors to help 
its folding. Therefore, we managed to co-express Vif with the chaperone CBFβ in E. coli since 
the chaperone was found to be critical in the folding and stabilization of Vif and Vif-mediated 







Figure 7.1: Vif protein sequence analysis. (A) The secondary structure prediction on Vif was 




7.2 Expression test of Vif 
 
7.2.1 Co-expression of Vif with core binding factor β 
 
In the first step, we used a truncated CBFβ (tCBFβ) construct (residues 1-140) rather than 
a full-length construct for three reasons. First, there are two isoforms of CBFβ, sharing over 
three-quarters identity of the N-terminal amino acid sequences. On the other hand, the 
molecular weight of full-length CBFβ is very close to that of Vif (22 and 24 kDa. respectively), 
which means they may not be separated completely on a gel, which may influence the 
quantitative analysis and judgment just by Coomassie blue. Besides, the structure of the core 
body of CBFβ (residues 1-140) has been solved (Goger, Gupta et al. 1999), confirming the 
importance of the N-terminus. Therefore, a tCBFβ construct was used as a starting construct as 
this facilitated the preliminary studies from which we might know whether tCBFβ was able to 
help Vif fold properly in bacteria or a full-length construct was required. 
Vif and tCBFβ were co-expressed in LB media at 37 ℃ or 18 ℃, followed by re-
suspending, sonication and spinning cell debris down in Tris buffer with different pH and a 
gradient concentration of NaCl. The SDS-PAGE gel shows that if proteins were expressed at 
37 ℃, Vif protein remained in the pellet, termed inclusion bodies, after a hard spin regardless 
of buffer conditions. Besides, at 37 ℃ tCBFβ was expressed in larger amounts than Vif (figure 
7.2A, B), which was probably caused by the high solubility of CBFβ. Noticeably, if proteins 
were expressed at low temperature, the Vif band was still visible in the supernatant lane on the 
SDS-PAGE gel after a hard spin (figure 7.2C), showing that Vif only folded properly at low 
temperature, and that salt concentration and pH impacted on the stability of Vif in solution 
(figure 7.2D). Meanwhile, this result acquired from tCBFβ construct suggests that the N-
terminal 140 residues are sufficient for Vif folding in the presence of CBFβ, which was also 









Figure 7.2: Expression test of Vif co-expressed with truncated CBFβ. (A) Cell lysis of samples at 
37 ℃. (B) Supernatant of cell lysis from 37 ℃. (C) Cell lysis from 18 ℃. (D) Supernatant of 
samples from 18 ℃. NE and T stands for non-expression control and Tris buffer. 6, 7 and 8 stands 
for the pH. 1, 2, 3 indicates NaCl concentration 50, 250 and 500 mM respectively. 
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7.2.2 Co-expression of Vif, Elongin B, Elongin C and core binding factor β 
 
In the next step we managed to co-express Vif His6-fused EloB, EloC, with CBFβ isoform 
I, the isoform that other groups have used in their published work (Jager, Kim et al. 2012, Zhang, 
Du et al. 2012). In order to achieve that Vif and CBFβ sequences were cloned into a pRSFDuet 
vector with a kanamycin antibiotic manner, and EloB and EloC sequences onto a pETDuet 
vector (constructed by Dr. Julien Bergeron) with an ampicillin antibiotic manner. The two 
plasmids were co-transformed into E. coli BL21 (DE3) pLysS competent cells selected for 
resistance to the antibiotics (figure 7.3A). 
Similarly, the proteins were expressed at 18 ℃ or 37 ℃ but also with a gradient of IPTG 
concentration. Cells were dealt with in the same way as in the previous experiments in Tris 
buffer, pH 7.0, 250 mM NaCl. Supernatants were loaded onto Tricine gels for analysis. Figure 
7.3B reveals that at lower temperature with lower IPTG induction concentration Vif was more 
soluble and stable in solution. This is because low temperature and less IPTG decreased the rate 
of protein production, providing more time for the protein to fold. Besides, the yield of 
individual protein was very closer to a 1:1:1 stoichiometry whereas at higher temperature more 
EloBC dimer was expressed. Therefore, it is now known that soluble Vif in the presence of 
CBFβ, EloB and EloC can be obtained by co-expression in LB media supplemented with low 
IPTG concentration at low temperature. 
 
 
7.3 Solubility test for Vif 
 
7.3.1 Solubility test for Vif in the tetramer 
 
In order to further confirm that Vif remains in the supernatant and to find the best buffer 
condition for extracting Vif from cells, we co-expressed the four proteins and re-suspended 
them in different buffers as in previous experiments. Because of the similar molecular weight 
of CBFβ and Vif, these two proteins could not be separated completely on a SDS-PAGE gel, 





Figure 7.3: Expression test of Vif co-expressed with CBFβ/EloBC. (A) Schematic representation of 
co-expression strategy of the tetramer. EloB and EloC CDs were cloned onto pETDuet Vector. Vif 
and CBFβ CDs were constructed onto pRSFDuet Vector. Two vectors were co-transformed into E. 
coli. (B) Expression test of the tetramer at body temperature or at cold temperature with various 





gel (figure 7.4A). Thus we used western blotting to detect Vif protein in each sample using anti-
Vif primary antibody. As was expected, the immunoblotting demonstrated that the target protein 
was present in the supernatant. It also reveals that Vif is more soluble at a low salt concentration 
at pH 7.0-8.0 in the sonication and spinning steps (figure 7.4B). 
Then we managed to compare various types of buffer by the same method. The 
immunoblot provided the same trend for the decreasing amount of Vif in the supernatant along 
with the rising salt concentration at pH 7.0 (figure 7.4B). Interestingly, Vif in the supernatant 
with sodium-phosphate buffer was not affected by salt concentration (figure 7.4C), suggesting 
that phosphate buffer is the best choice to keep Vif stable when Vif was separated from cells.  
 
7.3.2 A study on Elongin BC and core binding factor β interaction 
 
Now it is possible to purify Vif together with His6-EloBC and CBFβ from supernatant on 
a Ni-NTA column according to the previous results. However, considering that there was only 
one His6 tag on EloB component, we first asked whether or not CBFβ interacts with EloBC. As 
it is known that Vif binds to EloBC and CBFβ respectively, if CBFβ does not bind to EloBC, 
and meanwhile if four bands from the elution fractions are observed on the gel, it will be 
undoubtedly that soluble Vif is purified successfully by this co-expression and purification 
strategy. 
Following this assumption we prepared purified CBFβ and EloBC individually and mixed 
them together (figure 7.5A). This mixture was then loaded on to a sizing column (Superdex 75 
10/300 GL). Fractions were collected and loaded onto gels for analysis. Figure 7.5B and C 
appears that there is no binding between EloBC and CBFβ. These two proteins were separated 
completely according to the gel filtration analysis. This result indicates that untagged CBFβ 
cannot be acquired by Ni-NTA purification in the presence of His-EloBC whereas in the 











Figure 7.4: Solubility test for Vif in the tetramer. (A) SDS-PAGE analysis of pH & salt test in Tris 
buffer. 6, 7, 8 stands for the pH and 50, 250, 500 indicates 50, 250, 500 mM of NaCl. (B) Western 
blot of pH and salt tests. (C) Western blot of buffer tests. Anti-Vif antibody is used to detect Vif in 










Figure 7.5: EloBC and CBFβ interaction study. (A) Schematic representation of this assay. (B) 
The EloBC-CBFβ mixture was loaded onto a sizing column and detected by UV280. Two peaks 
were observed. (C) SDS-PAGE gel analysis of fractions 19-24. 
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7.4 Stability test for Vif after purification 
 
7.4.1 Detergent test 
 
In order to continue the search for the best buffer conditions for Vif in the 
Vif/CBFβ/EloB/EloC tetramer, several detergents were tested. Briefly, after sonication, the cell 
lysis was distributed into several tubes. Appropriate detergents were added to each tube, 
followed by high-speed centrifugation and purification from Ni-NTA columns. Water was used 
as a negative control, i.e. no detergent (figure 7.6A). The Tricine gel shows that Tween 20, 
NP40 and CHAPS improves the final yield of the target proteins compared to the negative 
control whereas Triton, a widely used detergent in protein preparation, is harmful to Vif in 
solution (figure 7.6B). The protein concentration in the final fractions was measured 
immediately after elution or after three days. It suggests that 90% of the proteins stayed in 
solution with CHAPS, and that all the proteins came out of the solution with Triton after three 
days. The rest of conditions kept between 80% to 88% of proteins in their individual condition 
(figure 7.6C), indicating that CHAPS can improve the amount of soluble Vif and keep Vif stable 
under artificial buffer conditions. 
 
7.4.2 Hunting for conditions to enhance stability 
  
Finally the Thermal Shift Assay (TSA) was applied to optimize conditions accurately for 
the stability of purified Vif. Basically, in each well of a 96-well PCR plate there is a mixture of 
fluorescent dye, testing buffer and approximately 0.02 mg/ml of protein. At the beginning the 
dye is quenched in a hydrophilic environment, i.e. buffer. The protein then starts denaturing 
with increasing temperature by qPCR machine, thus exposing its hydrophobic residues which 
will take and activate the dye. The machine records the signals at each temperature level 
quantitatively. Under favourable conditions protein denatures at a higher temperature whereas 
under poor conditions signals can be detected at a lower temperature. The temperature at which 






Figure 7.6: Detergent hunting for Vif stability. (A) Schematic representation of this test strategy. In 
this case 20 mM Tris buffer, pH 7.0 with 250 mM NaCl was used as a basic buffer. (B) Tricine gel 
analysis of purification with different detergents. Left, supernatant. Right, elution from Ni-NTA 
column. (C) The yield of protein was measured by BioRad kits immediately after elution and on the 
third day. Percentage stands for the amount of protein left in supernatant after a hard spin. CL, -, Tri, 
Tw, NP, CH stands for cell lysis, no detergent, Triton-20, Tween, NP40 and CHAPS respectively.
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Figure 7.7A shows that in HEPES buffer protein samples prefer acidic conditions with an 
ionic strength in the mild range. Similarly figure 7.7B reveals that in phosphate buffer protein 
samples prefer alkaline conditions with a mild ionic strength. It is of note that in this assay the 
mild ionic strength is the best option for Vif whereas in the solubility test low salt concentration 
is the best (figure 7.4B). This is because the solubility test was performed within cell lysis and 
supernatant, which means endogenous ions from cells actually improved the ionic strength in 
the conditions regardless of external 50 mM salt. On the other hand, this TSA assay was 
performed on purified proteins and the ionic strength was only provided by the salts in the 
buffer. Thus these two results provide clear information that Vif prefers mild salt concentration. 
Meanwhile it is observed that the Tm in all phosphate buffer conditions are comprehensively 
higher than that in HEPES conditions, which agrees with the previous result from 
immunoblotting described above (figure 7.4C), confirming that phosphate buffer is the best one 
for Vif. In addition, we compared the effect of NaCl and KCl by the same technique. Figure 
7.7C reveals that NaCl is better than KCl at pH 7.0. Therefore, it now can be concluded that the 
best buffer for Vif when in the tetramer is 20 mM phosphate buffer, pH 7.0 containing around 
250 mM NaCl and 8 mM CHAPS. 
 
 
7.5 Understanding the characteristics of CBFβ 
 
7.5.1 Vif/CBFβ and EloBC pull-down assay 
 
As soluble Vif can be obtained by the methods detailed above, it is interesting to know 
whether CBFβ helps Vif fold properly in order to obtain biological functions with or without 
EloBC. A pull-down assay was then performed to address this question. Briefly, untagged Vif 
and untagged CBFβ were co-expressed. The cell lysis after sonication was spun down and the 
supernatant was loaded onto a Ni-NTA column on which His6-tagged EloBC was bound (figure 
7.8A). Proteins were eluted by approximately 400 mM imidazole after intensive wash. Cell 
lysis, supernatant, flowthrough and elution fractions were taken and mixed with loading buffer 










Figure 7.7: Hunting for conditions for Vif stability by thermal shift assay. (A) Salt and pH 
optimization in HEPES buffer. (B) Salt and pH optimization in phosphate buffer. (C) The effect of 




Figure 7.8B reveals that Vif and CBFβ bands disappear in the flowthrough lane compared 
with the cell lysis and supernatant lanes, whereas in the elution lane two bands are clearly 
visible besides the EloBC bands. As it is known that CBFβ does not bind to EloBC, these two 
new bands are definitely from Vif and CBFβ respectively, confirming that in our study CBFβ 
is the only crucial factor that is required to help Vif fold in E. coli so that it attains its functional 
structure.  
 
7.5.2 A study on CBFβ isoform II 
 
In the previous studies we focused on CBFβ isoform I. Now we want to understand 
whether CBFβ isoform II has the same function as isoform I does. Sequential alignment shows 
that these two isoforms share a 90% identity of amino acid sequences. Only the carboxyl 
terminal residues are different (figure 7.8C). The published solution structure (PDB ID: 1CL3) 
reveals that the core body of CBFβ (residues 1-140) is a stable barrel-like structure composed 
of 6 β-sheets (Goger, Gupta et al. 1999) whereas the structure of full-length CBFβ has not been 
reported. Therefore, if the behaviour of isoform I and isoform II is found the same, it will 
indicate that this core body is the only region that is crucial for Vif folding as well as genetic 
regulation, its original function. 
Similarly, Vif, CBFβ isoform II and EloBC were co-expressed with low ITPG 
concentration (0.2~0.25 mM) at low temperature (16~18 ℃), followed by purification on a Ni-
NTA column and a sizing column. Interestingly, the Tricine gel displays that the yield of EloBC 
was much higher than the yield of Vif and CBFβ isoform II (figure 7.8D). It also shows that in 
the first step some of Vif was lost in the inclusion bodies due to the unfolded aggregation and 
in the flowthrough due to incorrect folding that disables the binding to EloBC. The functional 
difference between two CBFβ isoforms intimates that the carboxyl terminus on isoform I 



























Figure 7.8: The characteristics of CBFβ during Vif expression process. (A) Schematic 
representation of the pull-down assay. (B) Tricine gel analysis of the pull-down assay. The red 
square indicates that Vif and CBFβ were not left in flowthrough. M, CL, ↑, FT and E stands for 
marker, cell lysis, supernatant, flowthrough and elution respectively. (C) The sequences of two 
CBFβ isoforms. The carboxyl tail is presented in different colours. (D) Vif was co-expressed with 
EloBC and CBFβ isoform 2. Tricine gel analysis was used to check Vif behaviour. M, CL, P, ↑, 







In this chapter the attempts which were made to acquire purified soluble Vif protein for 
biochemical and structural studies are described. In a prokaryotic expression system, Vif protein 
is able to be extracted from cells in the presence of a chaperone CBFβ isoform I. Owing to the 
solubility and stability of Vif, it must be expressed at low temperature with low levels of IPTG 
induction. The purification process must be conducted at low temperature as well. Zwitterionic 
detergent CHAPS is essential for Vif stability under the artificial conditions. The intensive 
studies made it possible to set up the crystallization screen, which will be discussed in the next 
Chapter. 
On the other hand, CBFβ isoform II was investigated. Differing from isoform I, isoform II 
contains a weak capability to help Vif fold in cells, because of which more EloBC was 
expressed rather than the tetramer of interest. This result implies that the C-terminus of isoform 







CHAPTER 8: CRYSTALLIZATION OF VIF 
 
In the previous Chapter 1 discussed how soluble Vif in the Vif/CBFβ/EloB/EloC hetero-
tetramer was acquired after employing many biochemical and biophysical assays in order to 
find a suitable expression and purification strategy. This Chapter continues to describe the 
complete protocol for acquiring purified Vif. Subsequently efforts were made to crystallize the 
hetero-tetramer (tetramer) for structural studies by X-ray crystallography. 
 
 
8.1 The preparation of Vif/CBFβ/EloBC complex 
 
The four components of the complex were co-expressed and co-purified in the manner 
detailed in Chapter 2 and Chapter 7. The Tricine gel (figure 8.1A) shows how an affinity 
chromatographic purification followed by intensive washing achieves a sample of a very high 
purity level (figure 8.1A). It is worth mentioning that sometimes there is another band or a small 
region of smear just below the second band (the CBFβ band). In order to identify the bands, the 
first band, the second band and the unclear third band were cut out respectively for mass 
spectrometry analysis. The results from MS confirmed the presence of Vif in the first band and 
the constituent present of molecules in the second band and the third small band (raw data are 
included in the electronic version). In addition, CBFβ monomer and EloBC dimer were 
prepared and checked by Tricine gel respectively. The gel reveals that the smear or the other 
small band below the second band might be only caused by a strange or aberrant mobility of 
CBFβ in gels. The gel also demonstrates that the first clear band at the top is clearly a Vif band 
(figure 8.1B).  
In the next step the elute from the nickel column was loaded onto a gel filtration column 
washed with the final buffer (10 mM Na-phosphate buffer, pH 7.0, 0.02% NaN3, 8 mM CHAPS, 
250 mM NaCl) to remove the excessive EloBC dimer. Figure 8.1C is a typical profile from the 
gel filtration column. Usually there are three clearly visible peaks in each run. The first peak 




















Figure 8.1: The profile of the tetramer purification. (A) Tricine gel analysis of the purification on 
Ni-NTA column. (B) Complex, EloBC and two CBFβ isoforms were loaded in one gel to validate 
Vif band. CL, ↑, E, Tet, EBC, I2, I1 stands for cell lysis, supernatant, elution, tetramer, EloBC, 
isoform 2, and isoform 1 respectively. (C) The protein samples eluted from Ni-NTA were loaded 
onto a gel filtration column for further purification. Tricine gel analysis was performed to see 
proteins from each peak. S, 1, 2, 3 stands for samples before loading, peak 1, 2 and 3 respectively. 




impurities. The target protein complex was eluted in the second peak after approximately 14 ml 
of washing volume. Extra EloBC (26 kDa.) and disassociated CBFβ (22 kDa.) from Vif 
aggregate were separated from the tetramer and came out in peak 3. Figure 8.1D shows that the 
changing of composition within each fraction during the sizing column purification. The 
positions of each peak and the corresponding molecular weights match those from a group of 
protein ladders used for column calibration (table 2.2). It confirms that the protein in peak 2 is 
the tetramer of interest with approximately 71 kDa molecular weight. 
 
 
8.2 High-throughput screening from Hauptman Woodward Institute 
 
Hauptman Woodward Medical Research Institute (HWI) at Buffalo, New York is a famous 
institute renowned for its structural biological studies (http://www.hwi.buffalo.edu). The high-
throughput screening laboratory (HTS lab) at HWI is equipped with a robust crystallization trial 
that tests 1536 conditions in one set of experiments with standard screen kits (Luft, Collins et 
al. 2003) or membrane screen kits (Koszelak-Rosenblum, Krol et al. 2009). These kits were 
constructed based on the results from a large number of trials performed at the HTS lab. These 
data are integrated into a crystallization database that is used to produce crystallization recipes. 
Photographs for each well, i.e. condition, are taken on day 0, day 1, week 1, 2, 4 and 6, which 
can be used for the analysis when crystals grow. 
The final tetramer sample sitting in the final buffer was concentrated to 4 mg/ml in 700 μl 
volume as measured by BioRad protein assay kit and was sealed in a falcon tube placed in a 
thermos. A styrofoam box containing the sample in a thermos with ice bags was shipped to the 
HTS lab in four days. Samples were set up immediately at 14 ℃ when they arrived. 
Unfortunately, the protein precipitated in the majority of the conditions in less than one 
week. However, in several conditions there was something special that could be observed after 
two weeks as shown in figure 8.2. Basically, tree-like crystals grew in conditions containing 
over 0.1 M MgCl2. These kinds of crystals are possibly salt crystals according to their 







Figure 8.2: Crystallization results from the high-throughput screening lab. The changes of interest 
are circled. The up photographs were taken one day after setting. The lower photographs were taken 




PEG400 and 0.2 M CaCl2, 0.1 M Tris pH 5.5, 45% (+/-)-2-Methyl-2,4-pentanediol), some 
interesting particles were found, but they cannot be confirmed in the screening system because 
of technical limitations. Therefore, these conditions were repeated further and modified by 
hanging drop methods in-house, which will be discussed in the next section. 
 
 
8.3 In-house screening for crystallization conditions 
 
8.3.1 High-throughput screening using a Mosquito crystallization robot 
 
The in-house crystallization trials were conducted using hanging or sitting drop methods. 
As it was described in Chapter 2, a Mosquito® robot was used to set 96-well plates for 
crystallization kit screening. In order to prevent the protein precipitating at high temperature in 
the middle of setting up, sample containers and plates with solutions were cooled down on ice 
for 15 min before placing on the machine. Plates were sealed and placed in a 4-℃ cold room 
immediately after setting up. Because the complex of interest consists of proteins, several kits 
that were developed for complex screening were tested in the past months. All kits which were 
tried are listed in table 8.1 below: 
 
Table 8.1 The manufacturer’s kits used for crystallization condition screening 




Derived from a database Precipitation, S.C. b 
Memsys For transmembrane proteins Precipitation 
ProPlex For protein complexes Precipitation 
JCSG-Plus A highly effective strategy Precipitation 
Cryo I, II Emerald Biosystems Cryoprotectant conditions Precipitation, S.C. 
a. The main character of each kit is listed. The full details can be found on the manufacture 
website. 
b. S.C. stands for salt crystals that were observed in some conditions from the kit. 
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The Morpheus kits were derived from an extensive data mining of over 33,000 PDB 
records, covering a range of pH, salt additives and PEGs. All the conditions in this set of kits 
are cryo-protected. After several days of setting up the trials, crystals were found in a few 
conditions. Figure 8.3A shows two conditions containing 0.09 M salt (NaNO3, Na2HPO4, 
(NH4)2SO4), pH 7.5 0.1 M Na-HEPES buffer with 4-Morpholinepropanesulfonic acid, 12.5% 
v/v 2-Methyl-2,4-pentanediol, 12.5% w/v PEG1000, 12.5% w/v PEG3350 and 0.09 M salt 
(NaNO3, Na2HPO4, (NH4)2SO4),  pH 8.5 0.1 M Tris-Bicine, 20% v/v Ethylene glycerol, 
10% w/v PEG8000 respectively. In order to test whether these were protein or salt crystals, the 
crystals were tested using the PX-scanner. The salt-detect method was chosen to shot the crystal. 
In theory, protein crystals give well-distributed, dense and small spots in the diffraction image, 
whereas salt crystals give only several strong spots in the image. Figure 8.3B shows the 
diffraction image acquired from the crystals displayed in figure 8.3A, suggesting that they were 
salt crystals rather than protein crystals. Because of the limited clear and strong spots in the 
image, the crystals were possibly from the sodium salts as Na+ concentration in the solution 
was approximately 200 mM. Crystals from the other conditions were also checked and 
confirmed as salt crystals. 
In the other kits from Molecular Dimensions only precipitation was observed. As for cryo 
kits from Emerald Biosystems, some crystals were obtained in conditions with a high 
concentration of salts and all of them finally were identified as salt crystals. These results imply 
that to crystallize Vif is still a tough challenge although it can be purified. 
 
8.3.2 Screening by the hanging drop method 
 
Samples of the complex were prepared and set up using the hanging drop method in-house 
as well as by the sitting drop method to mimic the conditions from HTS lab and to test for new 
conditions. The designed screening conditions were based on the phase diagram theory as 
elaborated in Chapter 2. Basically, a moderate concentration of precipitant was tested against 
pH gradients first. If the condition is still clear after several days, it means that higher 
concentration of the precipitants is required to push the complex into a nucleation zone (figure 





8.3: Results from the screening in house. (A) Photographs on the salt crystals. (B) The diffraction 
images from the salt crystals. Left panel, 0.09 M salt (NaNO3, Na2HPO4, (NH4)2SO4), pH 8.5 0.1 
M Tris-Bicine, 20% v/v Ethylene glycerol, 10% w/v PEG8000. Right panel, 0.09 M salt (NaNO3, 
Na2HPO4, (NH4)2SO4), pH 7.5 0.1 M Na-HEPES buffer with 4-Morpholinepropanesulfonic acid, 




grow. The tested conditions and results of each condition are collated in table 8.2 (Presented in 
an electronic version).  
To start with, four different kinds of precipitants were tried, ammonium sulphate, methanol, 
PEG400 and PEG6000 respectively. The starting point for ammonium sulphate was set at 50%, 
which gave precipitation immediately. In later trials the concentration was decreased to 25% 
and 10%. The complex precipitated at a condition of 25% ammonium sulphate after 
approximately one week whereas interestingly conditions with 10% ammonium sulphate 
remained clear for quite a long time (more than four weeks), suggesting that 15% to 20% 
ammonium sulphate can be tried further. It should be noted that the pH did not affect the protein 
behaviour in these conditions. 
Similarly, the complex precipitated in a short time in 50% methanol as a beginning point. 
Then the concentration was again decreased to 25% and 10%. Being an organic solvent, 25% 
methanol still denatured the complex after one day. However, until the end of recording after 
four months, conditions with 10% methanol were still clear. These results indicate that the 
metastable zone provided by methanol is very narrow and more effort needs to be taken to 
optimize these conditions. 
As for PEG and its derivatives, 40% PEG400 and 10% PEG6000 was used at the start of 
screening. Interestingly, there was a significant difference between acidic and alkaline 
conditions with 40% PEG400. In acidic buffer, PEG400 denatured the complex immediately 
after setting the plates, whereas in alkaline buffer it took approximately two weeks to precipitate. 
Thus the amount of precipitant in acidic buffer was decreased from 40% to 20% and 10%, and 
raised the amount in alkaline buffer to 60% and 80%. It showed that the acidic conditions with 
PEG400 were dangerous to the complex, because it precipitated even at low PEG400 
concentration. It is worth mentioning that 60% and 80% PEG400 in alkaline buffer denatured 
protein in a short time, showing that concentrations ranging from 40% to 60% can be tested 
further. The amount of PEG6000 was decreased to 5% and 2.5% because of precipitation at 10% 
PEG6000. The complex precipitated again at 5% PEG6000 regardless of the pH and a slow rate 
of precipitation was found at 2.5% PEG6000. It was observed that the complex was more stable 
in acidic conditions rather than alkaline conditions with 2.5% PEG6000, in contrast to those 
with PEG400. This suggests that as for PEG6000, the combination of pH, salt and precipitants 
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need screening further. (All the information has been summarized in sheets 1218 a, b and 1219 
a–d, table 8.2) 
In addition, we also set up crystals in-house according to the conditions obtained from 
HTS lab as described in the previous section. However, on the contrary to what happened from 
the high-throughput assays with sitting drop methods, proteins precipitated directly or several 
days later after hanging drop plates were set up (Information can be found in sheets 0125 a-g 
and 0222 a-f, table 8.2). In order to optimize the conditions, we increased the drop volume and 
decreased the concentration of precipitants. Despite the tree-like salt crystals, as observed in 
photographs from HTS lab, when this condition was reproduced, the complex still precipitated 
under most conditions (sheets 0306 a-d and sheets 0327 a-e, table 8.2). These results first 
confirm that crystals in figure 8.2 B, C & E are actually salt crystals. Besides, it also indicates 
that crystallization solution kits made in-house are, to some extent, different from those in HTS 






In this Chapter efforts to crystallize the Vif/CBFβ/EloB/EloC complex are described and 
results from the trials are concluded. The high-throughput experiments in the HTS lab, HWI, 
did not provide as encouraging results as we had expected, suggesting crystallizing the complex 
is still one of the difficult problems in viral protein structural studies. The results from screening 
conditions in-house that were similar to those obtained from the HTS lab were discussed, i.e. 
salt crystals were observed in some conditions. Although the tetramer was soluble in its final 
buffer for over one week, when mixing with crystallization solution, for the majority of the 
conditions, this leaded to protein precipitation in a short time. This means that there is still a 
solubility problem for this complex. As a consequence, crystallization of the tetramer was 
unsuccessful, and the structure of the complex was not pursued further.  
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CHAPTER 9: DISCUSSION 
 
 
9.1 SOCS-Elongin BC interaction 
 
9.1.1 Comparison of the structures of the SOCS-box family 
 
The SOCS-box family (SOCS1-7) proteins are indispensable regulators, functioning in 
many aspects including ubiquitination and transcription, and having high sequence similarity. 
Published structures show that they all share a common α-helical structure. It is worth noting, 
however, that the downstream sequences have a different spatial portfolio depending on the 
structural family. Domains from SOCS2 and SOCS4 (PDB ID: 2C9W, 2IZV) contains three 
small α-helixes that are known to interact with the EloB C-terminus as well (figure 9.1A, B) 
(Bullock, Debreczeni et al. 2006, Bullock, Rodriguez et al. 2007), whereas SOCS6 (PDB ID: 
2VIF) adopts a partially folded sequence (figure 9.1C) and the SOCS3 (PDB ID: 3DCG) 
downstream sequence cannot be resolved in the X-ray crystallographical analysis (figure 9.1D) 
(Stanley, Ehrlich et al. 2008, Zadjali, Pike et al. 2011), which implies that the downstream 
structure is flexible in the solution and can be only observed by NMR. Our results for the first 
time report the whole SOCS3 domain including a BC-Box and the proline-rich motif in the 
presence of EloBC and show its conformational changes when interacting with EloBC. 
 
9.1.2 Does the proline-rich motif perform other functions? 
 
It has been demonstrated in our previous published work (Bergeron, Huthoff et al. 2010) 
and in Chapter 6 that mutations in the PPLPS motif impact the binding of Vif to the 
ubiquitination complex as assessed using co-IP assay. In theory, it is not rigorous to conclude 
from these kind of experiments, namely co-IP, that some residues on component A are crucial 
for the binding to component B because protein A and B may connect to other cellular factors 








Figure 9.1: Structures of SOCS-box family proteins. Close up of the SOCS domains from published 
structures of different SOCS-box family. The C-terminus of each SOCS α-helical domain is labeled. 
(A) SOCS2 domain (2C9W). (B) SOCS4 domain (2IZV). (C) SOCS6 domain (2VIF). (D) SOCS3 
domain (3DCG). The unobserved downstream sequence of SOCS3 is presented by a dotted line. 




what we observe in experiments. In this case, since it was proved that the PPLPS motif is not 
critical for the binding to EloBC, it can be inferred that this motif interacts with Cul5 although 
it is possible that there is an unknown factor existing in this complex. Therefore, further 
experiments are required to investigate this. 
 In previous studies it has been described that in the absence of SOCS-box the carboxyl 
terminus of EloB is very flexible in solution, and that the binding to SOCS-box induces the 
disordered DVMK stretch to gain structure. Considering the weak binding between these two 
domains which is not essential for SOCS-EloBC binding, we further suggest that it is the α-
helix of EloC that first drives the induced-folding binding of Vif, followed by the interaction 
between the PPLPS motif and EloB C-terminal tail. The final common interface formed by the 
PPLPS motif and the induced-folding DVMK region in space is required to form an E3 
ubiquitin ligase complex, properly specifically to recruit Cul5 (figure 9.2). 
 Some research studies report that the PPLPS motif also participates in forming Vif 
homomultimers (Yang, Sun et al. 2001, Yang, Gao et al. 2003), arguing that Vif multimerization 
is required for Vif function. Although Vif multimerization was observed both by in vivo or in 
vitro experiments, evidence in those studies, however, is not sufficient to prove that the 
multimerization of Vif is crucial in Vif-induced degradation on APOBEC3G. First, it is shown 
that the HCCH zinc-finger-like motif and BC-box play an important role in the pathway. From 
a structural biological viewpoint, the multimerization driven by the PPLPS motif may hide 
important functional domains. Moreover, in early studies (Yang, Sun et al. 2001) a 35S-lableled 
Vif generated from in vitro translation was utilized for binding assays. It is doubtful that this 
produced Vif folded properly and that it kept its natural function, because the problems of 
expressing and purifying full-length Vif are still not solved until now. Techtmann and co-
workers’ work in 2012 showed that the PPLPS motif was not essential for Vif oligomerization 
and that the multimerization mechanism was more complicated and involved the HCCH 
domain, BC-box and downstream residues of Vif (Techtmann, Ghirlando et al. 2012). Therefore, 








Figure 9.2: Schematic of the proposed induced-folding mechanism. The SOCS-box includes an α-
helix domain (represented as 144SLQ146) and a proline-rich domain (represented as PPLPS). The 
formation of the Vif SOCS-EloBC complex is mainly driven by hydrophobic interactions between 
Vif BC-box and EloC C-terminus via a conformational change process. Then the proline-rich motif 
induces the EloB C-terminal tail folded to form a common interface to recruit cellular factors, 
perhaps Cul5. The various interaction events are presented in succession. The C-terminus of each 
subunit is indicated.  
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9.1.3 A dynamic model of SOCS-Elongin BC-Cullin5 interaction 
 
It is commonly known that Vif hijacks APOBEC3G and recruits cellular factors Rbx, Cul5, 
EloB, EloC and CBFβ to stimulate the ubiquitination pathway on APOBEC3G. Figure 9.3 
summarizes current knowledge on the complex. There is no report on the interaction between 
Rbx and Vif, and it has been shown in our studies that the PPLPS motif is not important for 
SOCS-EloBC binding. Many studies have confirmed that a zinc-finger-like motif, H108x5Cx17-
18Cx5H139, binds to Cul5 even in the absence of EloC (Luo, Xiao et al. 2005, Mehle, Thomas et 
al. 2006, Paul, Cui et al. 2006). Then a question arose why mutations in 144SLQ146 or in the 
PPLPS motif are also able to eliminate the ability of Vif to bind to the ubiquitination complex?  
There is no doubt the static graphic picture displayed in figure 9.3 fails to answer this 
question. In order to explain all the results obtained from the experiments clearly, a dynamic 
analysis must be taken, i.e. the final Vif-APOBEC3G-cellular factor complex that is supposed 
to be true is assembled in a strict and concerted fashion. Any interference may stop the 
ubiquitination pathway. Therefore, here we further propose the following mechanism of the 
formation of this E3 ligase. As shown in figure 9.4, Vif is firstly translated and folds with the 
help of CBFβ in cells. After Vif detects APOBEC3G, it binds to the EloBC heterodimer by a 
hydrophobic interaction between Vif BC-box and EloC carboxyl domain. Then the PPLPS 
motif induces the folding of the EloB DVMK stretch at the C-terminal tail, forming a common 
interface. This Vif-EloBC interaction perhaps enables Vif to change the conformation of its 
HCCH and PPLP domain to acquire the successful positioning. Then these two domains, along 
with EloC, function together to recruit Cul5, stimulating the degradation on APOBEC3G. In 
this step, the two sites on Vif except for EloC are required to stabilize the Vif-ligase complex. 
This hypothesis explains why mutations in the zinc-finger-like motif, BC-box or the proline-













Figure 9.3: Vif forms an E3 complex to promote the degradation on A3G in a strict and concerted 
fashion. CBFβ helps Vif fold first in cells, followed by recognizing APOBEC3G. The Vif-A3G 





9.2 Problems within NMR studies on SOCS-Elongin BC complex 
 
9.2.1 Unobserved peaks resulting from binding 
 
Although the NMR solution structure of the complex was successfully solved by 
alternative NMR techniques, the occurrence of missing peaks from the spectra of the proteins 
of interest is still worth mentioning. As has been illustrated in previous Chapters, this problem 
is the main issue that hindered the progress of this project. Interestingly, the reason for the 
inability to observe peaks from SOCS-box and EloBC are different.  
As for the SOCS-box, peaks from BC-box are observable in the free state, i.e. in the 
monomeric state. During the binding to EloBC, these peaks started disappearing rather than 
shifting or re-appearing at other positions. This is because of the exchange between two or more 
conformations in different micro-environments, which has a profound effect on the appearance 
and the chemical shifts of a resonance spin system. Basically, in two conditions, a spin may 
experience a conformation change. If the relaxation properties of each conformation are various 
under different conditions, the spectral properties will change. Figure 9.5 shows a brief example 
of exchange in two chemical environments. In conformation II, the methyl group may 
experience a ring current shift due to its proximity to the aromatic ring. Since the exchange 
phenomenon usually involves a change of the chemical environment of a spin, it is generally 
referred to as chemical exchange. 
Mathematically, the exchange rate is defined and derived from a series of parameters 
involving rate constants of a chemical reaction and frequencies of spin states. Consider an 
exchange reaction given by the following scheme: 
 
where k1 and k2 are the kinetic rate constants for the conversion of A to B and B to A respectively, 
giving an overall equilibrium constant Keq = k1/k2. Then the fraction of each conformation found 

















                           (9.2) 
Now we define an apparent exchange rate, kex = k1 + k2 and a frequency difference between two 
conformational states, Δω = ωA – ωB. Basically, at a fast exchange rate (kex >> Δω), in the 
midway of a spin precessing, the conformation of the molecule is detected and changed to 
environment B. Consequently the precessional frequency changes to ωB and meanwhile the 
rotation changes to the opposite direction. Finally the magnetization is along the original 
orientation. On the other hand, one slow exchange rate will give a spin sufficient time to precess 
irrespectively of a spin state before the molecular conformation changes. At the end signals 
from these two states are able to be acquired respectively, giving two peaks in the spectrum. 
Besides, there is a simple way to distinguish fast from slow exchange. We define a 
parameter that represents the contribution of exchange to the overall spin-spin relaxation rate:  





k                            (9.3) 
Here, another dimensionless parameter is used to characterize the time scale of chemical 





                               (9.4) 
Substituting Rex in equations 9.4 with 9.3, it can be derived that: 
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                            (9.5) 
Therefore it is clear that α varies from 0 for very slow exchange (kex << Δω) to 2 for very fast 
exchange (kex >> Δω). To summarize, in the fast exchange condition, the exchange process is 
capable of averaging the chemical shifts when the spins are precessing. Table 9.1 and figure 9.6 

















Figure 9.5: The effect of chemical exchange on lineshape. (A) The peak height changes alone with 
conformational exchange (http://triton.iqfr.csic.es/guide/eNMR/restraints/exchange.html) (B) 






Table 9.1, Summary of the effects of exchange on NMR spectra 
 
Exchange rate kex/Δω α Observed spectrum 
Very slow kex << Δω 0 Two resonances 
Slow kex < Δω <1 Two broadened resonances 
Intermediate kex ≈ Δω 1 Broad lineshape 
Fast kex > Δω >1 One broadened resonance 
Very fast kex >> Δω 2 One sharp resonance 
 
As for the EloBC dimer, besides the exchange rate, a slow correlation time due to a high 
molecular weight is the other reason that causes the disappearance of peaks. As was described 
in Chapter 2, NMR has two relaxation rates, T1 and T2. During T2 relaxation, the proton T2 of 
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where 2 2 2 2 6/H Nd r    and r is the inter-proton distance. Δσ represents the anisotropic 
chemical shift. Because large proteins tumble slower in solution, the rotational correlation time 
τc is mathematically proportional to the molecular weight. Thus for T2, according to equations 
9.6 and 9.7, it is inversely proportional to the molecular weight. Therefore, for large proteins 
the magnetization between spins relaxes much faster, resulting in less time to fully detect the 
signals. This in turn produces broader or weaker peaks, and ultimately lower signal-to-noise in 
NMR spectra. That is why in an EloBC spectrum only approximately 60% of the amino acids 






9.2.2 The problem of Elongin B and Elongin C solubility 
 
Since the complex of interest is a hetero-trimer, ideally it would be better to label each 
component independently, which may provide clearer spectra and allow assignment and ability 
to follow peak changes on binding. Therefore attempts to achieve preparations of soluble EloB 
and EloC were made. Expression at low temperature, in minimal media or low IPTG induction 
still failed to permit extraction of EloB or EloC from the inclusion bodies. Considering that the 
peaks from SOCS-box were clear, we tried to co-express SOCS-EloB and SOCS-EloC, thus 
extracting EloB and EloC peaks from the combined spectra. This alternative also failed due to 
the solubility problem.  
There are several factors that affect the expression of a soluble protein in prokaryotic 
systems, e.g. E. coli. First, E. coli lacks chaperones that are required for protein translation and 
folding in eukaryotic cells, especially in mammalian cells. In order to address this problem, 
some companies engineered E. coli to express a group of human chaperones within these 
prokaryotic cells. Besides, some proteins are toxic to E. coli, and hence suppress the growth of 
cells or the expression of the proteins. The third factor is the characteristics of a protein 
sequence. Until now there are no general ways to solve the later two problems in protein studies. 
One alternative is to engineer the protein sequences, thus improving the solubility and 
decreasing the impact on host cells. The work on APOBEC3G is a typical case suggesting that 
engineering a sequence can dramatically facilitate protein preparation and structural calculation 
(Chen, Harjes et al. 2008).  
 
 
9.3 Structural studies on Vif 
 
Vif is a small accessory protein in HIV-1 rather than a viral structural protein. However, in 
the past dozens of years there have been great advances in the knowledge of the virus structure 
and the process of cell fusion. Owing to the discovery of CBFβ, it is possible to express and 
purify Vif from prokaryotic systems from which the yield of protein is promising for further 
biological studies. Considering that the Vif sample precipitated in most of the crystallization 
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conditions, there are still several problems that hinder the progress of structural studies of Vif. 
First, the behaviour of Vif in the solution is not as stable as it should be regardless of the 
presence of the detergent. The solution is only clear at 4 ℃ whereas at room temperature it 
becomes cloudy within a short time. The purified sample was re-loaded onto a sizing column 
after one week, and only a small amount of protein was found to form the large aggregations 
observed after elution, suggesting that it may be kept at lower temperature for approximately 
10 days. In addition, co-expressing Vif, CBFβ, EloC with a truncated EloB, M1-98 (residue 
number) and M1-106 respectively was tried in order to crystallize the complex without the 
flexible C-terminal tail of EloB. Interestingly, it is noticed that in the complex with EloB M1-
106, the rate of precipitation after purification was faster than that of the wild type, whereas in 
the presence of M1-98 the complex precipitated directly after the elution from a Ni-NTA 
column. This phenomenon indicated that a strong self-association exists among Vif molecules 
in solution although they can be purified successfully, which can be seen from the sample of 
early elution fractions of gel filtration column (figure 8.1). The flexible C-terminal tail of EloB 
actually improves the solubility of the complex and, to some extent, decreases the self-
interaction caused by Vif, thus stabilizing the complex in solution. 
Moreover, in the complex of Vif-CBFβ-EloB-EloC, there are two known flexible elements, 
the hexa-histidine tag at the N terminus of EloB and the flexible C-terminus of EloB. In 
crystallography, flexible elements in a protein may prevent the formation of crystals by 
disturbing the nucleation because of their flexibility and dynamic nature. This is the reason why 
in many studies the His-tag is cut off before crystallization. In our case, it is possible that the 
retained His6-tag and the C-terminus of EloB affects the formation of crystals. Now that the C-
terminus of EloB has been shown to be crucial for the stability of the complex, removing the 
His-tag may be worth trying. 
Another point is that CHAPS detergent is required in current protocol. In crystallography, 
because of special characteristics of a detergent, the behaviour of proteins in a system and the 
saturation of buffer are changed. Therefore, high salt concentration (usually over 0.5 M) is 
sometimes used to replace detergents, based on the idea that a strong solution background by 
salts can force protein to fold and to be stable.  
This problem exists in analytical ultracentrifugation (AUC) field as well. The analysis on 
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proteins with detergents is actually a complex field for AUC. We used to run an AUC on our 
protein in the final buffer in order to confirm the molecular weight of the complex. However, 
the centrifugation data could not be used to calculate the molecular weight because the detergent 
that bound to the protein changed the hydrophobicity and molecular mass. It indicates that there 
may be more than one form of protein plus detergent existing in the solution, which may impair 
crystallization. 
In summary, crystallization will only occur under very specific conditions. Any trace of 
ions and slight differences of protein concentrations, detergents or pH will impact on the 
characteristics of solution, especially free energy of solution and water activity. The problems 
described above prevent us from preparing crystals. More buffer condition optimizations are 
needed in the future. 
 
 
9.4 Future work on HIV-1 Vif and relative factors 
 
Since the discovery of CBFβ, the characteristics of Vif-CBFβ interaction and the binding  
regions in the complex of CBFβ-Vif-Cul5-EloBC have been reported (Zhou, Evans et al. 2012, 
Du, Zhao et al. 2013, Kim, Kwon et al. 2013), structural biologists and virologists have more 
understanding on how CBFβ helps Vif fold and keep stable and soluble in vitro. However, 
regardless of the huge progress in this field, there are no further studies reported on full-length 
Vif structure until now, suggesting that it is still difficult to crystallize and solve the structure 
of Vif. Combining our experience in the studies, there are other alternatives worth trying to 
crystallize Vif in the presence of some cellular factors. 
As discussed above, the His-tag can be removed to produce an untagged tetramer. In order 
to achieve this, a protease cleavage site should be engineered between the His-tag and EloB. 
Before proteins of interests are eluted from a Ni-NTA column, a protease aliquot is loaded on 
to the column, thus eluting target proteins automatically. It prevents using high-concentration 
imidazole. Imidazole is known to be toxic to proteins in some cases, e.g. decreasing the activity 
(Lu, Chen et al. 2010). It is unclear whether high-concentration imidazole impacts the stability 
of the tetramer. In addition, in a typical affinity chromatography protocol, target proteins are 
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usually eluted with high-concentration imidazole (more than 200 mM), which may elute 
strongly bind impurities along with the proteins. Therefore, this method could improve the 
purity after a Ni-NTA column purification, thus raising the efficiency of gel filtration separation. 
Another way is to co-crystallize the tetramer with more cellular factors, namely Cul5 or 
A3G. It has been reported that by small-angle X-ray scattering the complex of CBFβ-Vif-Cul5-
EloBC is stable in solution with the molecular size that agrees with the theoretical value (Kim, 
Kwon et al. 2013). In experience, a protein with solubility problem can be very hard to be 
crystallized because it is easily precipitated out of the solution in crystallization kits in the 
presence of precipitants. Cul5, CBFβ and EloBC are thought to increase the solubility of Vif by 
sheltering the hydrophobic residues on the surface of Vif, which means that the large complex 
may stack to form crystals more easily than the Vif-EloBC-CBFβ complex. As for A3G, there 
is no report on the structure of N-terminus because of its insolubility. If this binding has a high 
affinity, it indicates that the generated product may be stable enough for crystallization. In order 
to achieve this, N-terminal A3G can be co-expressed with Vif and CBFβ, followed by pull-
down assay with purified EloBC on a Ni-NTA column. This way would provide more 
interesting information on the Vif-APOBEC3G interaction. 
In a recent report Kim’s experiments demonstrated that Vif and CBFβ bind to each other 
mainly by the N-terminal 140 residues (Kim, Kwon et al. 2013). Our work has solved the 
structure of downstream SOCS-box. Therefore, it is also worth trying to study the small dimer, 
i.e. Vif140-CBFβ140, instead of an entire large complex by structural biological methods. It is 
of note that the molecular weight of this 280-residue dimer is around 30 kDa, which is still 
suitable for NMR studies. Encouragingly, now that the assignment of N-terminal region of 
CBFβ (residues 1-138) and the NMR solution structure has been published (Goger, Gupta et al. 
1999), it would dramatically facilitate the NMR work on the dimer. In this case, the advantage 
of NMR that it does not require crystals can be used to identify the structure of the dimer and 





9.5 Concluding remarks 
 
The work have strengthened the current knowledge on the interaction of Vif SOCS-box 
and EloBC heterodimer by calculating the structure of the trimer and studying the specific 
motifs or elements. The results obtained in this work and our previous studies (Bergeron, 
Huthoff et al. 2010) have clearly uncovered that SOCS-box, EloB and EloC all experience 
structural changes, and that the binding between SOCS-EloC and SOCS-EloB happens 
successively. Now that a significant biological meaning of the SOCS-EloB interaction was not 
observed in our biophysical and biochemical experiments, an important question emerges that 
what the particular role of this interaction is in cells. We deduce that the common interface is 
formed to bind Cul5. Regarding that EloBC and Cul5 are endogenous and crucial for cell 
survival, in the next step it is worth testing the interaction between the purified trimer and 
purified Cul5 using biophysical and biochemical assays in vitro. 
Another interesting aspect is the comparison among different SOCS-box-containing 
proteins. As has been discussed above, the structures of SOCS family can be classified into two 
groups, namely a completely-structured group and a partially-structured group. However, the 
biological meanings of the structural differences are still unclear. In the future a systematic 
comparison may be required to investigate the functions of different regions, which will provide 
a more comprehensive understanding of Vif SOCS-box. 
Finally in this work we present a protocol of expression and purification of high-yield 
folded and soluble Vif from E. coli in the presence of EloBC and CBFβ, which facilitates the 
structural studies of Vif and its binding partners. Efforts have been made to crystallize the 
tetramer whereas there were no positive results from HTS assays and in-house screening. In the 
future more conditions need exploring and some new constructs mentioned above are worth 
trying due to their individual advantages. In addition, our studies also suggest that the C-
terminus of CBFβ is important for Vif folding as well as the N-terminal 140 resides (Kim, Kwon 
et al. 2013). The dynamics mechanism of CBFβ-induced Vif folding is another important topic 
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1. Primer used for PCR 
 
Name Sequence Ter Gene Comments 
N_SET_VIF GGCCATGGGCCAGTACAAACTGATCCTG 5' Vif For SET-Vif cloning 
C_SET_VIF  GGGTCGACGAATTCTTAGTGGTGGTGGTG 3' Vif For SET-Vif cloning 
SET_Vif_Cstop  GGAAGCTTGTCGACTTAGTCGACCTAGTG 3' Vif For SET-Vif cloning 
SET_Vif_NHis_SET GGCTCTAGCCATGGGCCACCATCACCATCACCACCATATGCAGTACAAACTG 5' His-SET For His-SET-Vif cloning 
N_EcoRI-SacI-SET GGGAATTCGAGCTCGATGCAGTACAAAC 5' SET  
C_CBFb1t_XhoI GGctcgagCTAGGGTCTTGTTGTCTTCTT 3' CBFb-II For CBFb isoform  I (shorter Isoform) 
N_His_CBFb GGcatatgCATCACCATCACCACACATGCCGCGCGTCGTGCCCGACCAG 5' CBFb For His-CBFb cloning 
C_CBFb2o_XhoI GGctcgagTTAACGCAGTTTCAGGTC 3' CBFb-I For CBFb isoform  II (longer Isoform) 
SET_Vif_Mut_N GCCATACAATGAATGAATGGACACTAG 5' Vif A mutation on original tempalte 
SET_Vif_Mut_C CTAGTGTCCATTCATTCATTGTATGGC 3' Vif A mutation on original tempalte 
NcoI-EloB GGCCATGGACGTGTTCCTCATGATCCG 5' EloB  
DuetDOWN1_Primer GGGATTATGCGGCCGTGTACAA 3' - Duet Vector 3' primer 
N_His_CBFb GGcatatgCATCACCATCACCACCACATGCCGCGCGTCGTG 5' CBFb High pure 
XhoI_T7_promoter GGACCCTCGAGGAAATTAATACGACTCAC 5' - general T7 primer 
T7-term primer CCGCTAGTTATTGCTCAGCGGT 3' - general T7 terminal primer 
N_Pep5_L165A GCCACCTGCCCCTAGTGTTAGGAAACTG 5' Vif L163A mutation, failed 
C_Pep5_L165A CCTAACACTAGGGGCAGGTGGCTTTATC 3' Vif L163A mutation, failed 
N_Pep5_S168A GCCACCTTTGCCTGCTGTTAGGAAACTG 5' Vif S165A mutation for ITC studies 
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C_Pep5_S168A CCTAACAGCAGGCAAAGGTGGCTTTATC 3' Vif S165A mutation for ITC studies 
SPLP AAAACCAAAACAGATAAAGAGCCCTTTGCCTAGTGTTAGGA  5' Vif P161S mutation for ITC studies 
SPLP TCCTAACACTAGGCAAAGGGCTCTTTATCTGTTTTGGTTTT 3' Vif P161S mutation for ITC studies 
PSLP ACCAAAACAGATAAAGCCAAGCTTGCCTAGTGTTAGGAAAC 5' Vif P162S mutation for ITC studies 
PSLP GTTTCCTAACACTAGGCAAGCTTGGCTTTATCTGTTTTGGT 3' Vif P162S mutation for ITC studies 
PPLS ACAGATAAAGCCACCTTTGAGCAGTGTTAGGAAACTGACAG 5' Vif P164S mutation for ITC studies 
PPLS CTGTCAGTTTCCTAACACTGCTCAAAGGTGGCTTTATCTGT 3' Vif P164S mutation for ITC studies 
SET_Vif_Mut_N  GCCATACAATGAATGGACACTAGGTCG 5' Vif  
SET_Vif_Mut_C CCTAGTGTCCATTCATTGTATGGCTCC 3' Vif  
Vif_C-term_stop CCCAAGCTTGTCGACTCAGTGTCCATTC 3' Vif  
NcoI_HIV2Vif GGGAAACCATGGAGGAAGACAAGAGATG 5' HIV-2 Vif  
HIV2Vif_stop_C CCGCAAGCTTGTCGACTCATGCCAGTATC 3' HIV-2 Vif  
N_BamHI_SOCS GGGGAAAGGATCCCAGGTACCGTCACTTC 5' Vif  
Vif_His_end_C CCAAGCTTGTCGACGAATTCTTAGTGGTGGTGGTGGTGTGCCAGTATCTCCAGGAC 3' Vif For Vif-His 
SOCS_His_end_C CCAAGCTTGTCGACGAATTCTTAGTGGTGGTGGTGGTGTCTCCGATAGTCTCTTCGCC 3' Vif For SOCS-His 
N_Pep5_G143C CATAACAAGGTATGTTCTCTACAGTAC 5' Vif PRE studies 
C_Pep5_G143C TGTAGAGAACATACCTTGTTATGGGATCC 3' Vif PRE studies 
N_Pep5_Q158C CCAAAATGTATAAAGCCACCTTTG 5' Vif PRE studies 
C_Pep5_Q158C GGCTTTATACATTTTGGTTTTATTAATG 3' Vif PRE studies 
N_Pep5_R167C CCTAGTGTTTGTAAACTGACAGAGGAC 5' Vif PRE studies 
C_Pep5_R167C CTGTCAGTTTACAAACACTAGGCAAAGG 3' Vif PRE studies 
N_Vif_L163F GATAAAGCCACCTTTTCCTAGTGTTAGGAAACTG 5' Vif For biological studies 
C_Vif_L163F CAGTTTCCTAACACTAGGAAAAGGTGGCTTTATC 3' Vif For biological studies 
N_EloB_D101A CCCGCCAGAGCTGCCCGCTGTGATGAAGCCCCAGG 5' EloB NMR Perturbation studies 
C_EloB_D101A CTGGGGCTTCATCACAGCGGGCAGCTCTGGCGGGC 3' EloB NMR Perturbation studies 
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N_EloB_V102A  CCAGAGCTGCCCGATGCGATGAAGCCCCAGGACTC 5' EloB NMR Perturbation studies 
C_EloB_V102A GTCCTGGGGCTTCATCGCATCGGGCAGCTCTGGC 3' EloB NMR Perturbation studies 
N_EloB_M103A GAGCTGCCCGATGTGGCGAAGCCCCAGGACTCGGG 5' EloB NMR Perturbation studies 
C_EloB_M103A CCCGAGTCCTGGGGCTTCGCCACATCGGGCAGCTC 3' EloB NMR Perturbation studies 
N_EloB_K104A CTGCCCGATGTGATGGCGCCCCAGGACTCGGGAAG 5' EloB NMR Perturbation studies 
C_EloB_K104A CTTCCCGAGTCCTGGGGCGCCATCACATCGGGCAG 3' EloB NMR Perturbation studies 
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2. Scripts for amino acid statistics 
 
#! /usr/bin/perl -w 
 
"<$ARGV[0]"; 
print "Reading file: $ARGV[0] ... \n"; 
sleep 1; 





























 if ($l == 0){ 
  $name=substr($line, 1, 100); 
#  $name_length=length($name);  
#  print "$name, $name_length\n"; 
  $l++; 




  chomp($line); 
  $wholeseq=$wholeseq . "$line"; 
  @aa=split(//,$line); 
  foreach $aa(@aa){ 
   use 5.010; 
   given ($aa){ 
    when ($aa eq A) {$A++;$n++;push (@water,"~");$weight=$weight+ 71.05} 
    when ($aa eq C) {$C++;$n++;push (@water,"n");$weight=$weight+103.07} 
    when ($aa eq D) {$D++;$n++;push (@water,"p");$weight=$weight+115.06} 
    when ($aa eq E) {$E++;$n++;push (@water,"p");$weight=$weight+129.08} 
    when ($aa eq F) {$F++;$n++;push (@water,"~");$weight=$weight+147.12} 
    when ($aa eq G) {$G++;$n++;push (@water,"n");$weight=$weight+ 57.03} 
    when ($aa eq H) {$H++;$n++;push (@water,"p");$weight=$weight+137.10} 
    when ($aa eq I) {$I++;$n++;push (@water,"~");$weight=$weight+113.12} 
    when ($aa eq K) {$K++;$n++;push (@water,"p");$weight=$weight+128.13} 
    when ($aa eq L) {$L++;$n++;push (@water,"~");$weight=$weight+113.12} 
    when ($aa eq M) {$M++;$n++;push (@water,"~");$weight=$weight+131.12} 
    when ($aa eq N) {$N++;$n++;push (@water,"n");$weight=$weight+114.07} 
    when ($aa eq P) {$P++;$n++;push (@water,"~");$weight=$weight+ 97.08} 
    when ($aa eq Q) {$Q++;$n++;push (@water,"n");$weight=$weight+128.09} 
    when ($aa eq R) {$R++;$n++;push (@water,"p");$weight=$weight+156.14} 
    when ($aa eq S) {$S++;$n++;push (@water,"n");$weight=$weight+ 87.05} 
    when ($aa eq T) {$T++;$n++;push (@water,"n");$weight=$weight+101.07} 
    when ($aa eq V) {$V++;$n++;push (@water,"~");$weight=$weight+ 99.10} 
    when ($aa eq W) {$W++;$n++;push (@water,"~");$weight=$weight+186.15} 
    when ($aa eq Y) {$Y++;$n++;push (@water,"n");$weight=$weight+163.12} 
    } 
   } 
   $l++; 



























if ($n == $all){ 
 print " Protein $name has $all residues. The molecular weight is $weight Da.\n"; 
 my @allres = sort by_number keys %aminoacid; 
 sub by_number {$aminoacid{$b} <=> $aminoacid{$a}} 
 print " \n The descending order of frequency of each amino acid is: \n   @allres 
\n\n The details are: \n"; 
 while (($res, $value) = each %aminoacid){ 
  printf "   %-2s residues in protein $name are %1s.\n", $value, $res; 
 } 
 print "\n The hydrophobic / hydrophilic characters of the sequence is: \n";  
 foreach $water(@water){ 
  print "$water"; 
 } 
 print "\n *'p' stands for polor hydrophilic.\n  'n' stands for non-polor 
hydrophilic.\n  '~' stands for hydrophobic.\n "; 
 $_=$wholeseq; 
 use 5.010; 
 given($_){ 
  when(/LVPRGS/i)  {print "\n Warning! There is a thrombin cleavage site in this 
sequence!\n"; continue} 
  when(/ENLYFQG/i) {print "\n Warning! There is a TEV cleavage site in this 
sequence!\n"; continue} 
  when(/LEVLFQGP/i){print "\n Warning! There is a PreScission cleavage site in 




 print "\nWrong! Please check the file!\n"; 
} 
print "\n-> p stands for polar residue, n stands for non-polar hydrophilic residue and 





3. The assignments of Vif SOCS-box and EloBC 
 
The assignments of Vif SOCS-box and EloBC are completed by Dr. Julien Bergeron and 
me, and deposited to BMRB database, ID: 19333. The full list of assignments is attached in the 
electronic version of this thesis. 
 
 
4. Vif amino acid sequence alignment 
 
 Vif sequences selected from Los Alamos HIV-1 sequence database are aligned and 
attached in the electronic version of this thesis. 
 
 
5. The files of mass spectrometry 
 
The detail of the experiment is described in Chapter 2. Two raw data files and a reported 
offered by KCL Proteomics Facility, Institute of Psychiatry are attached in the electronic version 









s/p salt crystals and precipitation
X drops were demaged
Date 20121218
Protein Vif-EloBC-CBFb
[con] 4 mgs/ml Method BioRed
Salt 250 mM Nacl
Buffer 50 mM Tris
Drop1 condition 1 ul sample 1 ul
Drop2 condition 1 ul sample 2 ul
Prep.
Cell: pH gradient
1 2 3 4 5 6
A 3 5.5 7.5 4 6 8
B 3.5 6 8 4.5 6.5 8.5
C 4 6.5 8.5 5 7 9
D 4.5 7 9 5.5 7.5 9.5
Check 1 20121219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130104
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130117
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 5 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
50% Ammonium sulphate 50% Methonal
Date 20121218
Protein Vif-EloBC-CBFb
[con] 4 mgs/ml Method BioRed
Salt 250 mM Nacl
Buffer 50 mM Tris
Drop1 condition 1 ul sample 1 ul
Drop2 condition 1 ul sample 2 ul
Prep.
Cell: pH gradient
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20121219
1 2 3 4 5 6
A p p c p p p
B p p c p p p
C p c c p p p
D p c c p p p
Check 2 20130104
1 2 3 4 5 6
A p p mp p p p
B p p mp p p p
C p mp c p p p
D p mp c p p p
Check 3 20130117
1 2 3 4 5 6
A p p mp p p p
B p p mp p p p
C p p c p p p
D p mp c p p p
Check 4 20130202
1 2 3 4 5 6
A p p mp p p p
B p p mp p p p
C p p ? p p p
D p p c p p p
Check 5 20130219
1 2 3 4 5 6
A p p mp p p p
B p p mp p p p
C p p ? p p p
D p p c p p p
Check 5 20130307
1 2 3 4 5 6
A p p mp p p p
40% PEG 400 10% PEG 6000
B p p mp p p p
C p p ? p p p
D p p c p p p
Check 6 20130314
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p c p p p
D p p c p p p
Check 7 20130409
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p X p p p
D p p X p p p
Date 20121219
Protein Vif-EloBC-CBFb
[con] 3.5 mg/ml Method BioRed
Salt 250 mM Nacl
Buffer 50 mM Tris
Drop1 condition 1 ul sample 1 ul
Drop2 condition 1 ul sample 2 ul
Prep.
Cell: pH gradient
1 2 3 4 5 6
A 3 5.5 7.5 3 5.5 7.5
B 3.5 6 8 3.5 6 8
C 4 6.5 8.5 4 6.5 8.5
D 4.5 7 9 4.5 7 9
Check 1 20130104
1 2 3 4 5 6
A mp c c mp c c
B mp mp c c c c
C mp c c c c c
D mp c c c c c
Check 2 20130117
1 2 3 4 5 6
A p mp p mp c c
B p p p c c c
C p p p c c c
D mp p p c c c
Check 3 20130202
1 2 3 4 5 6
A p p p mp c c
B p p p mp c ?
C p p p c c c
D p p p c c c
Check 4 20130219
1 2 3 4 5 6
A p p p p p c
B p p p p c ?
C p p p mp c c
D p p p mp c mp
Check 5 20130307
1 2 3 4 5 6
A p p p p p c
B p p p p c ?
C p p p mp c c
D p p p mp c mp
Check 6 20130314
1 2 3 4 5 6
A p p p p p p
25% Ammonium sulphate 10% Ammonium sulphate
B p p p p p p
C p p p mp mp p
D p p p mp mp p
Date 20121219
Protein Vif-EloBC-CBFb
[con] 3.5 mg/ml Method BioRed
Salt 250 mM Nacl
Buffer 50 mM Tris
Drop1 condition 1 ul sample 1 ul
Drop2 condition 1 ul sample 2 ul
Prep.
Cell: pH gradient
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130104
1 2 3 4 5 6
A p p p c c c
B p p p c c c
C mp mp p c c c
D p p p c c c
Check 2 20130117
1 2 3 4 5 6
A p p p c c c
B p p p c c c
C p p p c c c
D p p p c c c
Check 3 20130202
1 2 3 4 5 6
A p p p c c c
B p p p c c c
C p p p c c c
D p p p c c c
Check 4 20130219
1 2 3 4 5 6
A p p p c c c
B p p p c c c
C p p p c c c
D p p p c c c
Check 5 20130307
1 2 3 4 5 6
A p p p c c c
B p p p c c c
C p p p c c c
D p p p c c c
Check 6 20130314
1 2 3 4 5 6
A p p p c c c
25% Methonal 10% Methonal
B p p p c c c
C p p p c c c
D p p p c c c
Check 6 20130409
1 2 3 4 5 6
A p p p c c c
B p p p c c c
C p p p c c c
D p p p c c c
Date 20121219
Protein Vif-EloBC-CBFb
[con] 3.5 mg/ml Method BioRed
Salt 250 mM Nacl
Buffer 50 mM Tris
Drop1 condition 1 ul sample 1 ul
Drop2 condition 1 ul sample 2 ul
Prep.
Cell: pH gradient
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130104
1 2 3 4 5 6
A mp c p c c c
B c c p c c c
C c p p c mp c
D c p p c c c
Check 2 20130117
1 2 3 4 5 6
A mp mp p p p mp
B mp c p p p c
C mp p p p p c
D c p p p mp c
Check 3
1 2 3 4 5 6
A p p p p p mp
B p c p p p c
C p p p p p c
D mp p p p p c
Check 4 20130219
1 2 3 4 5 6
A p p p p p mp
B p c p p p mp
C p p p p p mp
D p p p p p mp
Check 5 20130307
1 2 3 4 5 6
A p p p p p mp
B p c p p p mp
C p p p p p mp
D p p p p p mp
Check 5 20130314
1 2 3 4 5 6
A p p p p p mp
20%, 60%  PEG 400 10%, 80%  PEG 400
B p c p p p mp
C p p p p p mp
D p p p p p mp
Check 6 20130409
1 2 3 4 5 6
A p p p p p mp
B p p p p p mp
C p p p p p p
D p p p p p p
Date 20121219
Protein Vif-EloBC-CBFb
[con] 3.5 mg/ml Method BioRed
Salt 250 mM Nacl
Buffer 50 mM Tris
Drop1 condition 1 ul sample 1 ul
Drop2 condition 1 ul sample 2 ul
Prep.
Cell: pH gradient
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130104
1 2 3 4 5 6
A p p p c c c
B p p p c X c
C p p p c c c
D p p p c c c
Check 2 20130117
1 2 3 4 5 6
A p p p c mp mp
B p p p c X c
C p p p c mp mp
D p p p c c c
Check 3
1 2 3 4 5 6
A p p p mp mp mp
B p p p mp X mp
C p p p mp mp mp
D p p p mp mp mp
Check 4 20130219
1 2 3 4 5 6
A p p p mp mp p
B p p p mp X X
C p p p mp p p
D p p p mp p p
Check 5





5% PEG 6000 2.5% PEG 6000
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 0.2 M CaCl
Buffer 0.1 M HEPES
Prep. 40% PEG 400
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130125
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4











no Zn  1 mM Zn
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 0.1 M MgCl2
Buffer 0.1 M Tris
Prep. 8% PEG 8000
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130125
1 2 3 4 5 6
A mp mp mp p p p
B mp mp mp p p p
C mp mp mp p p p
D mp mp mp p p p
Check 2 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4











no Zn  1 mM Zn
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 0.2 M MgCl2
Buffer 0.1 M Tris
Prep. 20% PEG8000
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130125
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4











no Zn  1 mM Zn
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 50 mM MgCl2
Buffer 0.1 M MES
Prep. 20% PEG6000
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 5 5.5 6 6.5 7 7.5 + Mg
B 5 5.5 6 6.5 7 7.5 + Mg +Zn
C 5 5.5 6 6.5 7 7.5
D 5 5.5 6 6.5 7 7.5 +Zn
Check 1 20130125
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4













[con] 6 mg/ml Method BioRed
Salt 0.2 M MgCl2
Buffer 0.1 M Tris
Prep. 36% PEG3350
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130125
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4











no Zn  1 mM Zn
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 0.2 M CaCl
Buffer 0.1 M Tris
Prep. 45% 2-Methyl-2,4 pentadiol
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130125
1 2 3 4 5 6
A p mp p mp mp p
B p p c c mp c
C mp c mp mp c c
D mp c p c c p
Check 2 201202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p c p
D p mp p p c p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p c p
D p p p p c p
Check 4 20130307
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p c p
D p p p p c p
Check 5 20130314
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p mp p
D p p p p mp p
Check 6 20130409
1 2 3 4 5 6
no Zn  1 mM Zn
A p p p p p p
B p p p p p p
C p p p p mp p
D p p p p mp p
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 50 mM CaCl
Buffer 0.1 M Tris
Prep. 20% 2-Methyl-2,4 pentadiol
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1
1 2 3 4 5 6 Destroyed!
A c p mp c p c
B p mp mp p mmp c
C p mp mp p mp mp
D mp mp mp mp mp mp
Check 2 20130202
1 2 3 4 5 6
A p p X X X ?
B X p p p X mp
C p p p p p X
D X X p X X X
Check 3 20130219
1 2 3 4 5 6
A p p X X X X
B X p p p X X
C p p p p p X
D X X p X X X
Check 4











no Zn  1 mM Zn
Date 20130124
Protein Vif-EloBC-CBFb
[con] 6 mg/ml Method BioRed
Salt 0.25 M NaCl
Buffer 50 mM Tris
Prep. 30% PEG3350
Drop1 condition 0.75 ul sample 0.75 ul
Drop2 condition 0.75 ul sample 1.5 ul
Cat.
Cell:
1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130125
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130202
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 4











no Zn  1 mM Zn
Date 20130222
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 0.2 M CaCl
Buffer 0.1 M HEPES
Prep. 40% PEG 400




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130307
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3

















 1 mM Zn
Date 20130222
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 0.1 M MgCl2
Buffer 0.1 M Tris
Prep. 8% PEG 8000




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130307
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3

















 1 mM Zn
Date 20130222
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 0.1 M MgCl2
Buffer 0.1 M Tris
Prep. 8% PEG 8000




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130307
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3

















 1 mM Zn
Date 20130222
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 50 mM MgCl2
Buffer 0.1 M MES
Prep. 20% PEG6000




1 2 3 4 5 6
A 5 5.5 6 5 5.5 6
B 6.5 7 7.5 6.5 7 7.5
C 5 5.5 6 5 5.5 6
D 6.5 7 7.5 6.5 7 7.5
Check 1 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130307
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3





















[con] 4 mg/ml Method BioRed
Salt 0.2 M MgCl2
Buffer 0.1 M Tris
Prep. 40% PEG3350




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130219
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130307
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3

















 1 mM Zn
Date 20130222
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 0.2 M CaCl
Buffer 0.1 M Tris
Prep. 45% 2-Methyl-2,4 pentadiol




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130219
1 2 3 4 5 6
A rubbish rubbish mp rubbish rubbish p
B rubbish rubbish mp rubbish c rubbish
C rubbish mp p rubbish c mp
D rubbish mp p rubbish c c
Check 2 20130307
1 2 3 4 5 6
A rub/c ? rubbish p rub/c ? rub/c ? p
B rub/c ? rubbish p rub/c ? c rubbish
C rubbish p p rub/c ? p p
D rubbish p p rub/c ? p c
Check 3 20130314
1 2 3 4 5 6
A r/p r/p p rub/c ? rub/c ? p
B r/p r/p p r/p c r/p
C r/p p p rub/c ? p p
D r/p p p r/p p c
Check 4 20120409
1 2 3 4 5 6
A r/p r/p p r r p
B r/p r/p p r c r/p
C r/p p p r p p
D r/p p p r/p p c
Check 5





 1 mM Zn
Date 20130306
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 0.2 CaCl2
Buffer 0.1 M HEPES




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130307
1 2 3 4 5 6
A s, mp s, mp p s, mp p p
B s, mp s, mp p s, mp p p
C s, mp p p p p p
D s, mp p p p p p
Check 2 20130314
1 2 3 4 5 6
A s/p s/p p s, mp p p
B s/p s/p p s, mp p p
C s/p p p p p p
D s/p p p p p p
Check 3 20130322
1 2 3 4 5 6
A s/p s/p p s, mp p p
B s/p s/p p s, p p p
C s/p p p p p p
D s/p p p p p p
Check 4 20130409
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 5





40% PEG 400 20% PEG 400
Date 20130306
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt
Buffer 0.1 M Tris




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130307
1 2 3 4 5 6
A c c c p p p
B c c c p p p
C c c salt? p p p
D c c salt? p p p
Check 2 20130314
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p salt? p p p
D p p salt? p p p
Check 3 20130322
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p salt? p p p
D p p salt? p p p
Check 4 20130409
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p s p p p
D p p s p p p
Check 5





0.1 M MgCl2 4% PEG 8k 0.2 M CaCl2 45% 2-Me-2,4-Pen
Date 20130306
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt 0.2 MgCl2
Buffer 0.1 Tris




1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130307
1 2 3 4 5 6
A p p p p p salt?
B p p salt? p p salt?
C p p p salt? p p
D p p p p p p
Check 2 20130314
1 2 3 4 5 6
A p p p p p s/p
B p p salt? p p s/p
C p p p p, middle? p p
D p p p p p p
Check 3 20130322
1 2 3 4 5 6
A p p p p p s/p
B p p salt? p p s/p
C p p p p, middle? p p
D p p p p p p
Check 4 20130409
1 2 3 4 5 6
A p p p p p s/p
B p p s/p p p s/p
C p p p p p p
D p p p p p p
Check 5





20% PEG 8000 10% PEG 8000
Date 20130306
Protein Vif-EloBC-CBFb
[con] 4 mg/ml Method BioRed
Salt
Buffer





1 2 3 4 5 6
A 5 5.5 6 4 6 8
B 6.5 7 7.5 4.5 6.5 8.5
C 5 5.5 6 5 7 9
D 6.5 7 7.5 5.5 7.5 9.5
Check 1 20130307
1 2 3 4 5 6
A p p p p p salt?
B p p p p p salt?
C p p p p p p
D mp mp mp p p salt?
Check 2 20130314
1 2 3 4 5 6
A p p p p p s/p
B p p p p p s/p
C p p p p p p
D p p p p p salt?
Check 3 20130322
1 2 3 4 5 6
A p p p p p s/p
B p p p p p s/p
C p p p p p p
D p p p p p s/mp
Check 4 20130409
1 2 3 4 5 6
A p p p p p s/p
B p p p p p s/p
C p p p p p p
D p p p p p s/mp
Check 5





20% & 10% PEG6000 20% PEG3350
50 mM MgCl2 0.1 MES 0.2 M MgCl2 0.1 M Tris
Date 20130327
Protein Vif-EloBC-CBFb
[con] 3.6 mg/ml Method BioRed






1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130328
1 2 3 4 5 6
A mp mp mp p p p
B mp mp mp p p p
C mp mp p p p p
D mp mp p p p p
Check 2 20130409
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3

















10% PEG400 10% PEG3350
0.2 M MgCl2 0.2 MgCl2
0.1 M HEPES 0.1 M Tris
Date 20130327
Protein Vif-EloBC-CBFb
[con] 3.6 mg/ml Method BioRed






1 2 3 4 5 6
A 5 5.5 6 4 6 8
B 6.5 7 7.5 4.5 6.5 8.5
C 5 (Zn+) 5.5 6 5 7 9
D 6.5 7 7.5 5.5 7.5 9.5
Check 1 20130328
1 2 3 4 5 6
A p p p mp mp mp
B p mp mp mp mp mp
C p p p mp mp p
D p p p mp mp p
Check 2 20130409
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 3

















5% PEG6000 4% PEG8000
50 mM MgCl2 0.1 M MgCl2
0.1 M MES 0.1 M Tris
Date 20130327
Protein Vif-EloBC-CBFb
[con] 3.6 mg/ml Method BioRed






1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130328
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130409























22.5% 2-Methyl-2,4 pentantal 12% 2-Methyl-2,4 pentantal
0.2 M CaCl2 0.2 M CaCl2
0.1 M Tris 0.1 M Tris
Date 20130327
Protein Vif-EloBC-CBFb
[con] 3.6 mg/ml Method BioRed






1 2 3 4 5 6
A 4 6 8 4 6 8
B 4.5 6.5 8.5 4.5 6.5 8.5
C 5 7 9 5 7 9
D 5.5 7.5 9.5 5.5 7.5 9.5
Check 1 20130328
1 2 3 4 5 6
A p p p p p p
B p p p p p p
C p p p p p p
D p p p p p p
Check 2 20130409























10% PEG3350 10% PEG3350
0.25 M NaCl 0.25 M NaCl + 1 mM ZnCl2
50 mM Tris 50 mM Tris
Date 20130327
Protein Vif-EloBC-CBFb







1 2 3 4 5 6
A 4 4.5 5 5.5 6 6.5




1 2 3 4 5 6
A p p p p p p





































































1 2 3 4 5 6
A
B
C
D
